WO2018104279A1 - Liquid crystal medium and liquid crystal device - Google Patents
Liquid crystal medium and liquid crystal device Download PDFInfo
- Publication number
- WO2018104279A1 WO2018104279A1 PCT/EP2017/081471 EP2017081471W WO2018104279A1 WO 2018104279 A1 WO2018104279 A1 WO 2018104279A1 EP 2017081471 W EP2017081471 W EP 2017081471W WO 2018104279 A1 WO2018104279 A1 WO 2018104279A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phe
- phel
- compounds
- formula
- independently
- Prior art date
Links
- 239000004973 liquid crystal related substance Substances 0.000 title description 72
- 150000001875 compounds Chemical class 0.000 claims abstract description 245
- 238000000034 method Methods 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 229910052731 fluorine Inorganic materials 0.000 claims description 60
- -1 alkoxy radical Chemical class 0.000 claims description 39
- 229910052801 chlorine Inorganic materials 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 230000003287 optical effect Effects 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 239000002019 doping agent Substances 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 125000002723 alicyclic group Chemical group 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 229910052710 silicon Inorganic materials 0.000 claims description 4
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 84
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 35
- 239000000463 material Substances 0.000 description 29
- 239000012071 phase Substances 0.000 description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 18
- 230000007704 transition Effects 0.000 description 18
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 16
- 125000003545 alkoxy group Chemical group 0.000 description 16
- 230000005684 electric field Effects 0.000 description 16
- 238000005259 measurement Methods 0.000 description 16
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- 230000003098 cholesteric effect Effects 0.000 description 10
- 230000002349 favourable effect Effects 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000010626 work up procedure Methods 0.000 description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 6
- 125000005407 trans-1,4-cyclohexylene group Chemical group [H]C1([H])C([H])([H])[C@]([H])([*:2])C([H])([H])C([H])([H])[C@@]1([H])[*:1] 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000004955 1,4-cyclohexylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])C1([H])[*:2] 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 239000002178 crystalline material Substances 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 239000004986 Cholesteric liquid crystals (ChLC) Substances 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- IKGLACJFEHSFNN-UHFFFAOYSA-N hydron;triethylazanium;trifluoride Chemical compound F.F.F.CCN(CC)CC IKGLACJFEHSFNN-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 2
- BTTUMVHWIAXYPJ-UHFFFAOYSA-N 1,3-dithian-2-yl(trimethyl)silane Chemical compound C[Si](C)(C)C1SCCCS1 BTTUMVHWIAXYPJ-UHFFFAOYSA-N 0.000 description 2
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 239000004990 Smectic liquid crystal Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 125000006193 alkinyl group Chemical group 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000002858 crystal cell Anatomy 0.000 description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 2
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000005262 ferroelectric liquid crystals (FLCs) Substances 0.000 description 2
- 239000011737 fluorine Chemical group 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006038 hexenyl group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 2
- 125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000004381 surface treatment Methods 0.000 description 2
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ICPSWZFVWAPUKF-UHFFFAOYSA-N 1,1'-spirobi[fluorene] Chemical compound C1=CC=C2C=C3C4(C=5C(C6=CC=CC=C6C=5)=CC=C4)C=CC=C3C2=C1 ICPSWZFVWAPUKF-UHFFFAOYSA-N 0.000 description 1
- ZFXBERJDEUDDMX-UHFFFAOYSA-N 1,2,3,5-tetrazine Chemical compound C1=NC=NN=N1 ZFXBERJDEUDDMX-UHFFFAOYSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- HTJMXYRLEDBSLT-UHFFFAOYSA-N 1,2,4,5-tetrazine Chemical compound C1=NN=CN=N1 HTJMXYRLEDBSLT-UHFFFAOYSA-N 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- UDGKZGLPXCRRAM-UHFFFAOYSA-N 1,2,5-thiadiazole Chemical compound C=1C=NSN=1 UDGKZGLPXCRRAM-UHFFFAOYSA-N 0.000 description 1
- UUSUFQUCLACDTA-UHFFFAOYSA-N 1,2-dihydropyrene Chemical compound C1=CC=C2C=CC3=CCCC4=CC=C1C2=C43 UUSUFQUCLACDTA-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- ALVZNPYWJMLXKV-UHFFFAOYSA-N 1,9-Nonanediol Chemical compound OCCCCCCCCCO ALVZNPYWJMLXKV-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- USYCQABRSUEURP-UHFFFAOYSA-N 1h-benzo[f]benzimidazole Chemical compound C1=CC=C2C=C(NC=N3)C3=CC2=C1 USYCQABRSUEURP-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- LYTMVABTDYMBQK-UHFFFAOYSA-N 2-benzothiophene Chemical compound C1=CC=CC2=CSC=C21 LYTMVABTDYMBQK-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000001331 3-methylbutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005828 4,4′-bicyclohexylene group Chemical group [H]C1([H])C([H])([H])C([H])(C([H])([H])C([H])([H])C1([H])[*:1])C1([H])C([H])([H])C([H])([H])C([H])([*:2])C([H])([H])C1([H])[H] 0.000 description 1
- XRMZKCQCINEBEI-UHFFFAOYSA-N 4-bromo-2-fluoro-1-iodobenzene Chemical compound FC1=CC(Br)=CC=C1I XRMZKCQCINEBEI-UHFFFAOYSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 description 1
- 125000003627 8 membered carbocyclic group Chemical group 0.000 description 1
- BPMFPOGUJAAYHL-UHFFFAOYSA-N 9H-Pyrido[2,3-b]indole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=N1 BPMFPOGUJAAYHL-UHFFFAOYSA-N 0.000 description 1
- 101001053395 Arabidopsis thaliana Acid beta-fructofuranosidase 4, vacuolar Proteins 0.000 description 1
- 101000767534 Arabidopsis thaliana Chorismate mutase 2 Proteins 0.000 description 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
- LONSOADHAKERFD-UHFFFAOYSA-N CC(C)C1SCCCS1 Chemical compound CC(C)C1SCCCS1 LONSOADHAKERFD-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 239000004890 Hydrophobing Agent Substances 0.000 description 1
- YHBTXTFFTYXOFV-UHFFFAOYSA-N Liquid thiophthene Chemical compound C1=CSC2=C1C=CS2 YHBTXTFFTYXOFV-UHFFFAOYSA-N 0.000 description 1
- QVBIYURCDPRLIG-UHFFFAOYSA-N N#Cc(c(F)cc(-c(cc1)ccc1OC(CCCCCCCCCC(Oc(cc1)ccc1-c(cc1F)cc(F)c1C#N)(F)F)(F)F)c1)c1F Chemical compound N#Cc(c(F)cc(-c(cc1)ccc1OC(CCCCCCCCCC(Oc(cc1)ccc1-c(cc1F)cc(F)c1C#N)(F)F)(F)F)c1)c1F QVBIYURCDPRLIG-UHFFFAOYSA-N 0.000 description 1
- 101000986989 Naja kaouthia Acidic phospholipase A2 CM-II Proteins 0.000 description 1
- 239000004988 Nematic liquid crystal Substances 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- XBDYBAVJXHJMNQ-UHFFFAOYSA-N Tetrahydroanthracene Natural products C1=CC=C2C=C(CCCC3)C3=CC2=C1 XBDYBAVJXHJMNQ-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- WMUIZUWOEIQJEH-UHFFFAOYSA-N benzo[e][1,3]benzoxazole Chemical compound C1=CC=C2C(N=CO3)=C3C=CC2=C1 WMUIZUWOEIQJEH-UHFFFAOYSA-N 0.000 description 1
- FZICDBOJOMQACG-UHFFFAOYSA-N benzo[h]isoquinoline Chemical compound C1=NC=C2C3=CC=CC=C3C=CC2=C1 FZICDBOJOMQACG-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- ZDZHCHYQNPQSGG-UHFFFAOYSA-N binaphthyl group Chemical group C1(=CC=CC2=CC=CC=C12)C1=CC=CC2=CC=CC=C12 ZDZHCHYQNPQSGG-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- JHAYEQICABJSTP-UHFFFAOYSA-N decoquinate Chemical group N1C=C(C(=O)OCC)C(=O)C2=C1C=C(OCC)C(OCCCCCCCCCC)=C2 JHAYEQICABJSTP-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- HKNRNTYTYUWGLN-UHFFFAOYSA-N dithieno[3,2-a:2',3'-d]thiophene Chemical compound C1=CSC2=C1SC1=C2C=CS1 HKNRNTYTYUWGLN-UHFFFAOYSA-N 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- PJULCNAVAGQLAT-UHFFFAOYSA-N indeno[2,1-a]fluorene Chemical compound C1=CC=C2C=C3C4=CC5=CC=CC=C5C4=CC=C3C2=C1 PJULCNAVAGQLAT-UHFFFAOYSA-N 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- AMGQUBHHOARCQH-UHFFFAOYSA-N indium;oxotin Chemical compound [In].[Sn]=O AMGQUBHHOARCQH-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- MQUPWTBHHPUUMC-UHFFFAOYSA-N isoindole Chemical compound C1=CC=C[C]2C=NC=C21 MQUPWTBHHPUUMC-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000005693 optoelectronics Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- UJMWVICAENGCRF-UHFFFAOYSA-N oxygen difluoride Chemical compound FOF UJMWVICAENGCRF-UHFFFAOYSA-N 0.000 description 1
- SLIUAWYAILUBJU-UHFFFAOYSA-N pentacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C21 SLIUAWYAILUBJU-UHFFFAOYSA-N 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 125000005005 perfluorohexyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 description 1
- 125000005007 perfluorooctyl group Chemical group FC(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)* 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- MABNMNVCOAICNO-UHFFFAOYSA-N selenophene Chemical compound C=1C=C[se]C=1 MABNMNVCOAICNO-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- VMNDCBPWBMKDBI-UHFFFAOYSA-N silinane Chemical compound C1CC[SiH2]CC1 VMNDCBPWBMKDBI-UHFFFAOYSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- JAKYJVJWXKRTSJ-UHFFFAOYSA-N sodium;oxido(oxo)borane;tetrahydrate Chemical compound O.O.O.O.[Na+].[O-]B=O JAKYJVJWXKRTSJ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- IFLREYGFSNHWGE-UHFFFAOYSA-N tetracene Chemical compound C1=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C21 IFLREYGFSNHWGE-UHFFFAOYSA-N 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- NMFKEMBATXKZSP-UHFFFAOYSA-N thieno[3,2-b]thiophene Chemical compound S1C=CC2=C1C=CS2.S1C=CC2=C1C=CS2 NMFKEMBATXKZSP-UHFFFAOYSA-N 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/02—Liquid crystal materials characterised by optical, electrical or physical properties of the components, in general
- C09K19/0258—Flexoelectric
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K19/06—Non-steroidal liquid crystal compounds
- C09K19/062—Non-steroidal liquid crystal compounds containing one non-condensed benzene ring
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K19/06—Non-steroidal liquid crystal compounds
- C09K19/08—Non-steroidal liquid crystal compounds containing at least two non-condensed rings
- C09K19/10—Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings
- C09K19/20—Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings linked by a chain containing carbon and oxygen atoms as chain links, e.g. esters or ethers
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K2019/0444—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit characterized by a linking chain between rings or ring systems, a bridging chain between extensive mesogenic moieties or an end chain group
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K2019/0444—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit characterized by a linking chain between rings or ring systems, a bridging chain between extensive mesogenic moieties or an end chain group
- C09K2019/0466—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit characterized by a linking chain between rings or ring systems, a bridging chain between extensive mesogenic moieties or an end chain group the linking chain being a -CF2O- chain
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K19/06—Non-steroidal liquid crystal compounds
- C09K19/08—Non-steroidal liquid crystal compounds containing at least two non-condensed rings
- C09K19/30—Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
- C09K19/3001—Cyclohexane rings
- C09K19/3003—Compounds containing at least two rings in which the different rings are directly linked (covalent bond)
- C09K2019/3009—Cy-Ph
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K19/06—Non-steroidal liquid crystal compounds
- C09K19/08—Non-steroidal liquid crystal compounds containing at least two non-condensed rings
- C09K19/30—Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
- C09K19/3001—Cyclohexane rings
- C09K19/3003—Compounds containing at least two rings in which the different rings are directly linked (covalent bond)
- C09K2019/301—Cy-Cy-Ph
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K19/06—Non-steroidal liquid crystal compounds
- C09K19/08—Non-steroidal liquid crystal compounds containing at least two non-condensed rings
- C09K19/30—Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
- C09K19/3001—Cyclohexane rings
- C09K19/3003—Compounds containing at least two rings in which the different rings are directly linked (covalent bond)
- C09K2019/3016—Cy-Ph-Ph
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K19/06—Non-steroidal liquid crystal compounds
- C09K19/08—Non-steroidal liquid crystal compounds containing at least two non-condensed rings
- C09K19/30—Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
- C09K19/3001—Cyclohexane rings
- C09K19/3059—Cyclohexane rings in which at least two rings are linked by a carbon chain containing carbon to carbon triple bonds
- C09K2019/3063—Cy-Ph-C≡C-Ph
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K19/06—Non-steroidal liquid crystal compounds
- C09K19/08—Non-steroidal liquid crystal compounds containing at least two non-condensed rings
- C09K19/30—Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
- C09K19/3001—Cyclohexane rings
- C09K19/3066—Cyclohexane rings in which the rings are linked by a chain containing carbon and oxygen atoms, e.g. esters or ethers
- C09K19/3068—Cyclohexane rings in which the rings are linked by a chain containing carbon and oxygen atoms, e.g. esters or ethers chain containing -COO- or -OCO- groups
- C09K2019/3075—Cy-COO-Ph
Definitions
- the invention relates to a compound of formula I, R 11 -MG 11 -X 11 -Sp 11 -X 12 -MG 12 -R 12 I wherein R 11 , R 22 , MG 11 , MG 12 , Sp 11 , X 11 and X 12 have one of the meanings as given herein below.
- the invention further relates to method of production of a compound of formula I, to the use of said compounds in LC media and to LC media comprising one or more compounds of formula I.
- the invention relates to a method of production of such LC media, to the use of such media in LC devices, in particular in flexoelectric LC devices and to a flexoelectric LC device comprising a LC medium according to the present invention.
- Background and Prior Art The flexoelectric effect is described, for example, by Chandrasekhar, "Liquid Crystals", 2 nd edition, Cambridge University Press (1992) and P.G. deGennes et al., "The Physics of Liquid Crystals", 2 nd edition, Oxford Science Publications (1995).
- Flexoelectric devices utilizing the flexoelectric effect for example ULH devices and liquid crystal media that are especially suitable for flexoelectric devices and are known from EP 0971016, GB 2356629 and Coles, H.J., Musgrave, B., Coles, M.J. and Willmott, J., J. Mater. Chem., 11, p.2709-2716 (2001).
- the Uniform Lying Helix (ULH) has high potential as a fast switching liquid crystal display mode. It is capable of sub millisecond switching at 35oC and possesses an intrinsically high aperture ratio, resulting in an energy efficient display mode.
- the materials commonly used in media suitable for the ULH mode are typically bimesogens.
- the corresponding LC media should exhibit favourable low ⁇ 1 values while preferably at the same time exhibiting:
- liquid crystal means a compound that under suitable conditions of temperature, pressure and concentration can exist as a mesophase (nematic, smectic, etc.) or in particular as a LC phase.
- Non-amphiphilic mesogenic compounds comprise for example one or more calamitic, banana-shaped or discotic mesogenic groups.
- the term “mesogenic group” means in this context, a group with the ability to induce liquid crystal (LC) phase behaviour.
- the compounds comprising mesogenic groups do not necessarily have to exhibit an LC phase themselves. It is also possible that they show LC phase behaviour only in mixtures with other compounds.
- the term “liquid crystal” is used hereinafter for both mesogenic and LC materials.
- aryl and heteroaryl groups encompass groups, which can be
- monocyclic or polycyclic i.e. they can have one ring (such as, for example, phenyl) or two or more rings, which may also be fused (such as, for example, naphthyl) or covalently linked (such as, for example, biphenyl) or contain a combination of fused and linked rings.
- Heteroaryl groups contain one or more heteroatoms, preferably selected from O, N, S and Se. Particular preference is given to mono-, bi- or tricyclic aryl groups having 6 to 25 C atoms and mono-, bi- or tricyclic heteroaryl groups having 2 to 25 C atoms, which optionally contain fused rings and which are optionally substituted.
- aryl and heteroaryl groups Preference is furthermore given to 5 , 6 or 7-membered aryl and heteroaryl groups, in which, in addition, one or more CH groups may be replaced by N, S or O in such a way that O atoms and/or S atoms are not linked directly to one another.
- Preferred aryl groups are, for example, phenyl, biphenyl, terphenyl,
- phenanthrene pyrene, dihydropyrene, chrysene, perylene, tetracene, pentacene, benzopyrene, fluorene, indene, indenofluorene,
- spirobifluorene more preferably 1,4- phenylene, 4,4’-biphenylene, 1, 4- tephenylene.
- Preferred heteroaryl groups are, for example, 5 membered rings, such as pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, furan, thiophene, selenophene, oxazole, isoxazole, 1,2 thiazole, 1,3-thiazole, 1,2,3-oxadiazole, 1,2,4 oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadiazole, 6 membered rings, such as pyridine, pyridazine, pyrimidine, pyrazine, 1,3,5-triazine
- heteroaryl groups may also be substituted by alkyl, alkoxy, thioalkyl, fluorine, fluoroalkyl or further aryl or heteroaryl groups.
- the term“(non-aromatic) alicyclic and heterocyclic groups” encompass both saturated rings, i.e. those that contain exclusively single bonds and partially unsaturated rings, i.e.
- Heterocyclic rings contain one or more heteroatoms, preferably selected from Si, O, N, S and Se.
- the (non-aromatic) alicyclic and heterocyclic groups can be monocyclic, i.e. contain only one ring (such as, for example, cyclohexane) or polycyclic, i.e. contain a plurality of rings (such as, for example, decahydro-naphthalene or bicyclooctane). Particular preference is given to saturated groups. Preference is furthermore given to mono-, bi- or tricyclic groups having 3 to 25 C atoms, which optionally contain fused rings and that are optionally substituted.
- Preferred alicyclic and heterocyclic groups are, for example, 5-membered groups, such as cyclopentane,
- tetrahydrofuran tetrahydrothiofuran
- pyrrolidine 6-membered groups, such as cyclohexane, silinane, cyclohexene, tetrahydropyran,
- aryl-, heteroaryl-, alicyclic- and heterocyclic groups are 1,4-phenylene, 4,4’-biphenylene, 1, 4-terphenylene, 1,4-cyclohexylene, 4,4’- bicyclohexylene and 3,17- hexadecahydro-cyclopenta[a]-phenanthrene, optionally being substituted by one or more identical or different groups L.
- Preferred substituents of the above-mentioned aryl-, heteroaryl-, alicyclic- and heterocyclic groups (L) are, for example, solubility-promoting groups, such as alkyl or alkoxy and electron-withdrawing groups, such as fluorine, nitro or nitrile.
- substituents are, for example, halogen, CN, NO 2 , CH 3 , C 2 H 5 , OCH 3 , OC 2 H 5 , COCH 3 , COC 2 H 5 , COOCH 3 , COOC 2 H 5 , CF 3 , OCF 3 , OCHF 2 or OC 2 F 5 .
- halogen denotes F, Cl, Br or I.
- alkyl also encompass polyvalent groups, for example alkylene, arylene,
- heteroarylene etc.
- aryl denotes an aromatic carbon group or a group derived there from.
- heteroaryl denotes "aryl” in accordance with the above definition containing one or more heteroatoms.
- Preferred alkyl groups are, for example, methyl, ethyl, n propyl, isopropyl, n butyl, isobutyl, s butyl, t butyl, 2 methylbutyl, n pentyl, s pentyl, cyclo- pentyl, n hexyl, cyclohexyl, 2 ethylhexyl, n heptyl, cycloheptyl, n octyl, cyclooctyl, n nonyl, n decyl, n undecyl, n dodecyl, dodecanyl, trifluoro- methyl, perfluoro-n
- Preferred alkoxy groups are, for example, methoxy, ethoxy, 2-methoxy- ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy, 2- methylbutoxy, n-pentoxy, n-hexoxy, n-heptoxy, n-octoxy, n-nonoxy, n- decoxy, n-undecoxy, n-dodecoxy.
- Preferred alkenyl groups are, for example, ethenyl, propenyl, butenyl, pentenyl, cyclopentenyl, hexenyl, cyclohexenyl, heptenyl, cycloheptenyl, octenyl, cyclooctenyl.
- Preferred alkynyl groups are, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, octynyl. Oxaalkyl, i.e.
- Preferred amino groups are, for example, dimethylamino, methylamino, methylphenylamino, phenylamino.
- the term“chiral” in general is used to describe an object that is non- superimposable on its mirror image. “Achiral” (non- chiral) objects are objects that are identical to their mirror image. The terms“chiral nematic” and“cholesteric” are used synonymously in this application, unless explicitly stated otherwise.
- the term“bimesogenic compound” relates to compounds comprising two mesogenic groups in the molecule. Just like normal mesogens, they can form many mesophases, depending on their structure.
- bimesogenic compound may induce a second nematic phase, when added to a nematic liquid crystal medium.
- Bimesogenic compounds are also known as“dimeric liquid crystals”.
- the term "director” is known in prior art and means the preferred orientation direction of the long molecular axes (in case of calamitic compounds) or short molecular axes (in case of discotic compounds) of the liquid-crystalline molecules. In case of uniaxial ordering of such anisotropic molecules, the director is the axis of anisotropy.
- the term“alignment” or“orientation” relates to alignment (orientation ordering) of anisotropic units of material such as small molecules or fragments of big molecules in a common direction named“alignment direction”.
- the liquid- crystalline director coincides with the alignment direction so that the alignment direction corresponds to the direction of the anisotropy axis of the material.
- plane orientation/alignment for example in a layer of an liquid-crystalline material, means that the long molecular axes (in case of calamitic compounds) or the short molecular axes (in case of discotic compounds) of a proportion of the liquid-crystalline molecules are oriented substantially parallel (about 180°) to the plane of the layer.
- the term "homeotropic orientation/alignment”, for example in a layer of a liquid-crystalline material, means that the long molecular axes (in case of calamitic compounds) or the short molecular axes (in case of discotic compounds) of a proportion of the liquid-crystalline molecules are oriented at an angle ⁇ ("tilt angle") between about 80° to 90° relative to the plane of the layer.
- the terms "uniform orientation” or “uniform alignment” of an liquid- crystalline material, for example in a layer of the material mean that the long molecular axes (in case of calamitic compounds) or the short molecular axes (in case of discotic compounds) of the liquid-crystalline molecules are oriented substantially in the same direction. In other words, the lines of liquid-crystalline director are parallel.
- the wavelength of light generally referred to in this application is 550 nm, unless explicitly specified otherwise.
- the birefringence ⁇ n herein is defined by the following equation
- n e is the extraordinary refractive index and n o is the ordinary refractive index and the effective average refractive index n av. is given by the following equation
- the extraordinary refractive index n e and the ordinary refractive index n o can be measured using an Abbe refractometer.
- the term“dielectrically positive” is used for compounds or components with “dielectrically neutral” with -1.5 and“dielectrically negative” with is determined at a frequency of 1 kHz and at 20°C.
- the dielectric anisotropy of the respective compound is determined from the results of a solution of 10 % of the respective individual compound in a nematic host mixture. In case the solubility of the respective compound in the host medium is less than 10 % its concentration is reduced by a factor of 2 until the resultant medium is stable enough at least to allow the determination of its properties.
- the concentration is kept at least at 5 %, however, in order to keep the significance of the results a high as possible.
- the capacitance of the test mixtures are determined both in a cell with homeotropic and with homogeneous alignment.
- the cell gap of both types of cells is approximately 20 ⁇ m.
- the voltage applied is a
- permittivity of the compounds is determined from the change of the respective values of a host medium upon addition of the compounds of interest.
- the values are extrapolated to a concentration of the compounds of interest.
- a typical host medium is ZLI-4792 or BL-087 both commercially available from Merck, Darmstadt.
- ZLI-4792 or BL-087 both commercially available from Merck, Darmstadt.
- the invention relates to a compound of formula I, R 11 -MG 11 -X 11 -Sp 11 -X 12 -MG 12 -R 12 I wherein R 11 and R 22 are each independently H, F, Cl, CN, NCS or a straight- chain or branched alkyl group, which may be
- F, Cl, CN a straight-chain or branched alkyl, alkenyl or alkoxy group which may be unsubstituted, mono- or polysubstituted by halogen or CN,
- F, CN or OCF 3 , MG 11 and MG 12 are each independently a mesogenic group
- each independently a mesogenic group which comprises one or more aryl-, heteroaryl-, alicyclic- and heterocyclic groups, which are optionally substituted by F, Cl, CN, OCH 3 , OCF 3 , preferably each independently a mesogenic group, which comprises two or more aryl-, heteroaryl-, alicyclic- and heterocyclic groups wherein two of these rings are optionally be linked by a linking group selected from -CO-O-, -O-CO-, -CH 2 -O-, -O-CH 2 -, -CF 2 O- and/or -OCF 2 -, Sp 11 is a spacer group comprising 1, 3 or 5 to 40 C atoms, wherein one or more non-adjacent and non-terminal CH 2 groups may also be replaced by -O-, -S-, -NH-, -N(CH 3 )-, -CO-, -O-CO-, -S-CO-, -S-
- the unit -X 11 -Sp 11 -X 12 - denotes -CF 2 O-Sp 11 -CF 2 O-, -OCF 2 - Sp 11 -OCF 2 -, -OCF 2 -Sp 11 -CF 2 O-, -CF 2 O-Sp 11 -OCF 2 -, -CF 2 O-Sp 11 -, -OCF 2 - Sp 11 -, -Sp 11 -CF 2 O-, or -Sp 11 -OCF 2 -.
- the compounds of formula I are preferably selected from compounds wherein the groups (R 11 -MG 11 -) and
- R 12 -MG 12 - in formula I are identical to each other.
- Further preferred compounds of formula I are compounds selected from the group of compounds of formulae Ia and/or Ib, R 11 -MG 11 -OCF 2 -Sp 11 -CF 2 O-MG 12 -R 12 Ia R 11 -MG 11 -Sp 11 -CF 2 O-MG 12 -R 12 Ib wherein R 11 , R 22 , MG 11 , MG 12 , Sp 11 , have one of the meanings as given above under formula I.
- Further preferred compounds of formula I are compounds selected from the group of compounds of formulae Ia-1 and/or Ib-1 R 11 -MG 11 -OCF 2 -(CH 2 ) n -CF 2 O-MG 12 -R 12 Ia-1 R 11 -MG 11 -(CH 2 ) n -CF 2 O-MG 12 -R 12 Ib-1 wherein R 11 , R 22 , MG 11 , MG 12 have one of the meanings as given above under formula I and n denotes 1, 3 or an integer from 5 to 15, more preferably an integer from 3 to 11, most preferably an odd integer (i.e.3, 5, 7, 9 or 11). If R 11 or R 12 is an alkyl or alkoxy radical, this may be straight chain or branched.
- It is preferably straight-chain, has 2, 3, 4, 5, 6, 7 or 8 carbon atoms and accordingly is preferably ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy or octoxy, furthermore methyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, nonoxy, decoxy, undecoxy, dodecoxy, tridecoxy or tetradecoxy, for example.
- R 11 or R 12 is an alkenyl group are, this may be straight-chain or branched, preferably straight-chain, with up to 15 C atoms and more preferably, ethenyl, propenyl, butenyl, pentenyl, cyclopentenyl, hexenyl, cyclohexenyl, heptenyl, cycloheptenyl, octenyl, cyclooctenyl and corresponding isomers.
- one of R 11 or R 12 is preferably alkenyl or alkinyl, preferably alkenyl, with up to 15 C atoms and the other is preferably alkyl, alkenyl or alkinyl, most preferably alky or alkenyl with 2 to 15 C atoms or alkoxy with 1 to 15, preferably 2 to 15, C atoms.
- compounds of formula I containing an achiral branched group R 11 and/or R 12 may occasionally be of importance, for example, due to a reduction in the tendency towards crystallisation. Branched groups of this type generally do not contain more than one chain branch.
- R 11 and/or R 12 are selected from CN, NO 2 , halogen, OCH 3 , OCN, SCN, COR x , COOR x or a mono- oligo- or polyfluorinated alkyl or alkoxy group with 1 to 4 C atoms.
- R x is optionally fluorinated alkyl with 1 to 4, preferably 1 to 3 C atoms.
- Halogen is preferably F or Cl.
- R 11 and R 12 in formula I are selected of H, alkenyl, F, Cl, CN, NO 2 , OCH 3 , COCH 3 , COC 2 H 5 , COOCH 3 , COOC 2 H 5 , CF 3 ,
- the compounds of formula Ia-1 are selected from the following compounds: R 11 -Phe-OCF 2 -(CH 2 ) n -CF 2 O-Phe-R12
- PheL is 1,4-phenylene, which is substituted by one, two or
- the compounds of formula Ib-1 are selected from the following compounds: R 11 -Phe-(CH 2 ) n -CF 2 O-Phe-R 12 Ib-1- I R 11 -PheL-(CH 2 ) n -CF 2 O-Phe-R 12 Ib-1- II R 11 -Phe-(CH2)n-CF2O-PheL-R 12 Ib-1- III R 11 -PheL-(CH2)n-CF2O-PheL-R 12 Ib-1- IV R 11 -Phe-(CH 2 ) n -CF 2 O-Phe-Z-Phe-R 12 Ib-1- V R 11 -PheL-(CH2)n-CF2O-Phe-Z-Phe-R 12 Ib-1- VI R 11 -Phe-(CH2)n-CF2O-Phe-Z-PheL-R 12 Ib-1- VII R 11 -Phe-(CH 2 ) n -CF 2 O-Phe-R 12
- R 11 , R 12 , Phe, PheL, Z and n have one of the meanings as given above.
- Further preferred compounds of formula I are compounds in which MG 11 and MG 12 are independently from one another a group of
- groups may be replaced by N, trans-1,4-cyclo- hexylene in which, in addition, one or two non- adjacent CH2 groups may be replaced by O and/or S, 1,4-cyclohexylene, naphthalene-2,6-diyl, decahydro- naphthalene-2,6-diyl, 1,2,3,4-tetrahydro-naphthalene- 2,6-diyl, it being possible for all these groups to be unsubstituted, mono-, di-, tri- or tetrasubstituted with F, Cl, CN or alkyl, alkoxy, alkylcarbonyl or
- alkoxycarbonyl groups wherein one or more H atoms may be substituted by F or Cl, preferably each independently in each occurrence 1,4- phenylene, wherein in addition one or more CH groups may be replaced by N or trans-1,4-cyclo- hexylene in which, in addition, one or two non- adjacent CH 2 groups may be replaced by O and/or S, it being possible for both ring groups to be
- alkoxycarbonyl groups wherein one or more H atoms may be substituted by F or Cl
- k is 0, 1, 2, 3 or 4, preferably 1, 2 or 3 and, most
- Phe in these groups is 1,4-phenylene
- PheL is a 1,4-phenylene group which is substituted by 1 to 4 groups L, with L being preferably F, Cl, CN, OH, NO 2 or an optionally fluorinated alkyl, alkoxy or alkanoyl group with 1 to 7 C atoms, very preferably F, Cl, CN, OH, NO 2 , CH 3 , C 2 H 5 , OCH 3 , OC 2 H 5 , COCH 3 , COC 2 H 5 , COOCH 3 , COOC 2 H 5 , CF 3 , OCF 3 , OCHF 2 , OC 2 F 5 , in particular F, Cl, CN, CH 3 , C 2 H 5 , OCH 3 , COCH 3 and OCF 3 , most preferably F, Cl, CH 3 , OCH 3 and COCH 3 and
- PheL is 1,4-phenylene, which is substituted by one, two or three fluorine atoms, by one or two Cl atoms or by one Cl atom and one F atom and
- the compounds of formula Ia-1 are selected from the following compounds: R 11 -Phe-Z-Phe-OCF 2 -(CH 2 ) n -CF 2 O-Phe-Z-Phe-R12
- R 11 , R 12 , Phe, PheL, Z and n have one of the meanings as given above.
- the compounds of formula Ib-1 are selected from the following compounds: R 11 -Phe-Z-Phe-(CH 2 ) n -CF 2 O-Phe-Z-Phe-R 12 Ib-1- 1 R 11 -Phe-Z-PheL-OCF2-(CH2)n-Phe-Z-Phe-R 12 Ib-1- 2 R 11 -PheL-Z-Phe-OCF2-(CH2)n-Phe-Z-Phe-R 12 Ib-1- 3 R 11 -Phe-Z-PheL-(CH 2 ) n -CF 2 O-Phe-Z-Phe-R 12 Ib-1- 4 R 11 -PheL-Z-Phe-(CH2)n-CF2O-Phe-Z-Phe-R 12 Ib-1- 5 R 11 -PheL-
- R 11 , R 12 , Phe and PheL have one of the meanings as given above and n denotes 5, 7, 9 or 11.
- Further preferred compounds of formula Ib-1 are selected from the following compounds: R 11 -Phe-Phe-(CH2)n-CF2O-Phe-Phe-R 12 Ib-1- 1 a R 11 -Phe-PheL-OCF 2 -(CH 2 ) n -Phe-Phe-R 12 Ib-1- 2 a R 11 -PheL-Phe-OCF2-(CH2)n-Phe-Phe-R 12 Ib-1- 3 a R 11 -Phe-PheL-(CH 2 ) n -CF 2 O-Phe-Phe-R 12 Ib-1- 4 a R 11 -PheL-Phe-(CH 2 ) n -CF 2 O-Phe-Phe-R 12 Ib-1- 5 a R 11 -PheL-P
- L is preferably F, Cl, CH 3 , OCH 3 and COCH 3 .
- R 11 , R 12 have one of the meanings as given above, preferably both R 11 and R 12 are identical and denote both CN or F, likewise preferably R 11 and R 12 are different and at least one of them denote CN or F and n preferably denotes 7 or 9.
- Further preferred compounds are of formula Ib-1, for example, are preferably selected from the following compounds:
- R 11 , R 12 have one of the meanings as given above, preferably both R 11 and R 12 are identical and denote both CN or F, likewise preferably R 11 and R 12 are different and at least one of them denote CN or F and n preferably denotes 7 or 9.
- the compounds of formula I can be synthesized according to or in analogy to methods which are known per se and which are described in standard works of organic chemistry such as, for example, Houben-Weyl, Methoden der organischen Chemie, Thieme-Verlag, Stuttgart.
- the compounds of formula Ia-1 can be s nthesized accordin to or in analo to the followin s nthesis scheme:
- the invention relates also to a method of production of compounds of formula Ia-1 com risin at least the step of reacting a compound of
- the compounds of formula Ib-1 can be synthesized according to or in analogy to the following synthesis scheme:
- the compounds of formula I and its subformulae can be beneficially utilized in LC media to improve the properties of such media, in particular in LC media for flexoelectric applications.
- one of the main advantages of using compounds of formula I in LC media for flexoelectric applications is improving the switching speed in the ULH (uniform lying helix) geometry, particularly at
- the invention also relates to the use of compounds of formula I in LC media and to a LC media comprising one or more compounds of formula I, as such.
- the LC media in accordance with the present invention comprise one or more compounds of formula II, R 21 -A 21 -A 22 -(CH2)a-A 23 -A 24 -R 22 II wherein
- R 21 and R 22 denote independently H, F, Cl, CN, NCS or a straight- chain or branched alkyl group, which may be
- F, Cl, CN a straight-chain or branched alkyl or alkoxy group which may be unsubstituted, mono- or polysubstituted by halogen or CN,
- a 21 to A 24 denote independently in each occurrence a aryl-,
- 1,4-phenylene wherein in addition one or more CH groups may be replaced by N, trans-1,4- cyclo-hexylene in which, in addition, one or two non- adjacent CH 2 groups may be replaced by O and/or S, 1,4-cyclohexenylene, 1,4-bicyclo-(2,2,2)-octylene, piperidine-1,4-diyl, naphthalene-2,6-diyl, decahydro- naphthalene-2,6-diyl, 1,2,3,4-tetrahydro-naphthalene- 2,6-diyl, cyclobutane-1,3-diyl, spiro[3.3]heptane-2,6- diyl or dispiro[3.1.3.1] decane-2,8-diyl, it being possible for all these groups to be unsubstituted, mono-, di-, tri- or tetrasubstituted with F, Cl,
- Preferred compounds of formula II are selected from compounds in which the groups (-A 21 -A 22 -) and (-A 23 -A 24 -) are each and independently selected from the following groups
- Phe in these groups is 1,4-phenylene
- PheL is a 1,4-phenylene group which is substituted by 1 to 4 groups L, with L being preferably F, Cl, CN, OH, NO 2 or an optionally fluorinated alkyl, alkoxy or alkanoyl group with 1 to 7 C atoms, very preferably F, Cl, CN, OH, NO 2 , CH 3 , C 2 H 5 , OCH 3 , OC 2 H 5 , COCH 3 , COC 2 H 5 , COOCH 3 ,
- Cyc is 1,4-cyclohexylene.
- compounds of formula II wherein the groups (R 21 -A 21 -A 22 -) and (-A 23 -A 24 -R 22 ) in formula II are identical or mirror images.
- compounds of formula II wherein (R 21 -A 21 -A 22 -) and (-A 23 -A 24 -R 22 ) in formula II are different.
- Preferred compounds of formula II are indicated below:
- n denotes an integer from 1 to 15, preferably an odd (i.e.
- the compounds of formula II can be synthesized according to or in analogy to methods which are known per se and which are described in standard works of organic chemistry such as, for example, Houben-Weyl, Methoden der organischen Chemie, Thieme-Verlag, Stuttgart. A preferred method of preparation can be taken from WO 2013/004333 A1.
- the utilization of compounds of formula II beside compounds of formula I is especially useful in order to further improve the switching speeds whilst maintaining a good phase range and a favorable value for e/K.
- the LC media in accordance with the present invention comprise one or more compounds of formula III, R 31 -A 31 -A 32 -(A 33 ) b -Z 31 -(CH 2 ) c -Z 32 -A 34 -A 35 -A 36 -R 32 III wherein
- R 31 and R 32 have each and independently from another one of the meanings as given for R 21 and R 22 under formula II, A 31 to A 36 have each and independently from another one of the meanings as given for A 21 to A 24 under formula II, Z 31 and Z 32 are each independently in each occurrence,
- -CH CH-COO-
- b denotes an integer from 1 to 15, preferably an odd (i.e.
- Preferred compounds of formula III are selected from compounds in which c denotes 0 and the group (-A 31 -A 32 -) is selected from the groups MG-1 to MG-8 as given above. Further preferred compounds of formula III are selected from compounds in which c denotes 1 and the groups (-A 24 -A 25 -A 26 -) and (-A 21 -A 22 -A 23 -) are each and independently selected from the following groups -Cyc-Cyc-Cyc- MG-9
- the compounds of formula III can be synthesized according to or in analogy to methods which are known per se and which are described in standard works of organic chemistry such as, for example, Houben-Weyl, Methoden der organischen Chemie, Thieme-Verlag, Stuttgart.
- the utilization of compounds of formula III beside compounds of formula I is especially useful in order to achieve high stabilities, favourable high clearing points and broad phase ranges, as well as, low appearances of the nematic twist-bend phase.
- the LC medium in accordance with the present invention comprises one or more compounds of formula IV, R 41 -A 41 -A 42 -Z 41 -(CH 2 ) d -Z 42 -A 43 -A 44 -R 42 IV wherein
- R 41 and R 42 have each and independently one of the meanings as given above for R 21 under formula II
- a 41 to A 44 have each and independently one of the meanings as given above for A 21 under formula II
- Z 41 and Z 42 are each independently in each occurrence
- -CH CH-COO-
- d denotes an integer from 1 to 15, preferably an odd (i.e.
- Preferred compounds of formula IV are selected from compounds in which the groups (-A 41 -A 42 -) and (-A 43 -A 44 -) are each and independently selected from the groups of MG-1 to MG-8 as given above.
- Especially preferred compounds of formula IV are selected from the group of compounds of the following formulae: - symmetrical ones (IVa and IVb):
- the LC medium in accordance with the present invention additionally comprises one or more compounds of formula V, R 51 -A 51 -Z 51 -(CH 2 ) e -Z 52 -A 52 -(A 53 ) f -R 52 V wherein
- R 51 and R 52 have each and independently one of the meanings as given above for R 21 under formula II
- a 51 to A 53 have each and independently one of the meanings as given above for A 21 under formula II
- Z 51 and Z 52 are each independently in each occurrence
- -CH CH-COO-
- e denotes an integer from 1 to 15, preferably an odd (i.e.
- a 51 is selected from the following group of formulae Va’ to Vh’ and the mirror images of formulae Vb’, Ve’ and Vf’
- R 51 and R 52 in formula V are selected of H, F, Cl, CN, NO2, OCH 3 , COCH 3 , COC2H5, COOCH 3 , COOC2H5, CF3, C2F5, OCF3, OCHF2 and OC 2 F 5 , in particular of H, F, Cl, CN, OCH 3 and OCF 3 , especially of H, F, CN and OCF 3.
- Preferred compounds of formula V are selected from the group of compounds of formulae VA to VE, preferably of formulae VA and/or VD, most preferably of formula VD,
- LG 51 is Z 51 -(CH2)z-Z 52 , (F) 0 denotes H and
- (F) 1 denotes F. and the other parameters have the respective meanings given above including the preferred meanings.
- Z 51 -(CH 2 ) z -Z 52 denotes -O-CO-(CH 2 ) n -CO-O-, -O-(CH 2 ) n -O- or -(CH 2 ) n -, more preferably -O-CO-(CH 2 ) n -CO-O-, wherein n denotes 3, 5, 7 or 9,
- Particularly preferred compounds of formula VA are selected from the group of compounds of formulae VA-1 to VA-3
- Particularly preferred compounds of formula VB are selected from the group of compounds of formulae VB-1 to VB-3
- Particularly preferred compounds of formula VC are selected from the group of compounds of formulae VC-1 and VC-2
- the LC medium in accordance with the present invention additionally comprises one or more compounds of formula VI, R 61 -A 61 -A 62 -(CH2)g-Z 61 -A 63 -A 64 -(A 65 )h-R 62 VI wherein R 61 and R 62 have each and independently one of the meanings as given above for R 21 under formula II, A 61 to A 64 have each and independently one of the meanings as given above for A 21 under formula II, Z 61 denotes -O-, -COO-, -OCO-, -O-CO-O-, -OCH 2 -, -CH 2 O,
- h denotes 0 or 1
- g denotes an integer from 1 to 15, preferably an odd (i.e.
- Preferred compounds of formula VI are selected from compounds in which the groups (-A 61 -A 62 -) and (-A 63 -A 64 -) are each and independently selected from the groups of MG-1 to MG-8 as given above. Further preferred are compounds of formula VI wherein h denotes 0 and the groups (-A 61 -A 62 -) and (-A 63 -A 64 -(A 65 ) h ) in formula VI are not identical or not mirror images or wherein h denotes 1 In particular preferred compounds of formula VI are selected from the group of compounds of the following formulae,
- the compounds of formula VI can be synthesized according to or in analogy to methods which are known per se and which are described in standard works of organic chemistry such as, for example, Houben-Weyl, Methoden der organischen Chemie, Thieme-Verlag, Stuttgart.
- the compounds of formula VI are synthesized according to or in analogy to methods which are disclosed for example in WO 2014/005672 A1.
- the utilization of compounds of formula VI beside compounds of formula I is especially useful in order to achieve high clearing points and also favorable values for e/K.
- the LC medium in accordance with the present invention additionally comprises one, two, three or more compounds of formula VII, R 71 -A 71 -Z 71 -A 72 -(Z 72 -A 73 ) i -(CH 2 ) j -(A 74 -Z 73 -) k -A 75 -Z 74 -A 76 -R 72 VII wherein
- R 71 and R 72 have each and independently one of the meanings as given above for R 21 under formula II
- a 71 to A 76 have each and independently one of the meanings as given above for A 21 under formula II
- Z 71 to Z 74 each and independently denotes -COO-, -OCO-,
- j denotes an integer from 1 to 15, preferably an odd (i.e.
- Preferred compounds of formula VII are selected from compounds in which at least one of the groups -A 71 -Z 71 -A 72 -(Z 72 -A 73 ) i -, -(A 74 -Z 73 -) k -A 75 -Z 74 -A 76 - are is selected from the groups of MGa to MGn (the two reference Nos.“MG i” and“MG l” being deliberately omitted to avoid any confusion) and their mirror images
- L is in each occurrence independently of each other preferably F, Cl, CN or an optionally fluorinated alkyl, alkoxy or alkanoyl group with 1 to 7 C atoms, very preferably F, Cl, CN, CH 3 , C2H5, OCH 3 , OC2H5, COCH 3 , COC2H5, COOCH 3 , COOC2H5, CF3, OCF3, OCHF2, OC2F5, in particular F, Cl, CN, CH 3 , C2H5, OCH 3 , COCH 3 and OCF3, most
- F, Cl, CH 3 , OCH 3 and COCH 3 and r is in each occurrence independently of each other 0, 1, 2, 3 or 4, preferably 0, 1 or 2.
- R 71 and R 72 each and independently denote F or CN.
- the compounds of formula VII can be synthesized according to or in analogy to methods which are known per se and which are described in standard works of organic chemistry such as, for example, Houben-Weyl, Methoden der organischen Chemie, Thieme-Verlag, Stuttgart.
- the compounds of formula VII are synthesized according to or in analogy to methods which are disclosed for example in WO 2013/174478 A1.
- the medium in accordance with the present invention optionally comprises one or more chiral dopants, especially when utilized in a flexoelectric device.
- the chiral compounds induce a chiral nematic texture with a pitch (P 0 ), which is in a first approximation inversely proportional to the
- HTP helical twisting power
- c concentration of the chiral compound.
- a uniform lying helix texture is realized using a chiral nematic liquid crystal with a short pitch, typically in the range from 0.2 ⁇ m to 1 ⁇ m, preferably of 1.0 ⁇ m or less, in particular of 0.5 ⁇ m or less, which is unidirectional aligned with its helical axis parallel to the substrates, e. g. glass plates, of a liquid crystal cell.
- the helical axis of the chiral nematic liquid crystal is equivalent to the optical axis of a birefringent plate.
- Preferred are chiral dopants with a high helical twisting power (HTP), in particular those disclosed in WO 98/00428.
- used chiral dopants are e.g. the commercially available
- the chiral dopants are preferably selected from formula VIII,
- the above-mentioned chiral dopants R/S-5011 and the compounds of formula VIII and IX exhibit a very high helical twisting power (HTP) and are therefore particularly useful for the purpose of the present invention.
- the liquid crystalline medium preferably comprises preferably 1 to 5, in particular 1 to 3, very preferably 1 or 2 chiral dopants, preferably selected from the above formula VIII, and/or formula IX and/or R-5011 or S-5011, very preferably, the chiral compound is R-5011, S- 5011.
- the amount of chiral compounds in the liquid crystalline medium is preferably from 0.1 to 15 %, in particular from 0.5 to 10 %, very preferably 1 to 5 % by weight of the total mixture.
- the LC medium comprises one or more nematic LC compounds selected from compounds indicated below:
- liquid crystal media may contain further additives like for example stabilizers, inhibitors, surface-active compounds, lubricating agents, wetting agents, dispersing agents, hydrophobing agents, adhesive agents, flow improvers, defoaming agents, deaerators, diluents, reactive diluents, auxiliaries, colourants, dyes, pigments or nanoparticles in usual concentrations.
- further additives like for example stabilizers, inhibitors, surface-active compounds, lubricating agents, wetting agents, dispersing agents, hydrophobing agents, adhesive agents, flow improvers, defoaming agents, deaerators, diluents, reactive diluents, auxiliaries, colourants, dyes, pigments or nanoparticles in usual concentrations.
- the total concentration of these further constituents is in the range of 0.1 % to 10 %, preferably 0.1 % to 6 %, based on the total mixture.
- the concentrations of the individual compounds used each are preferably in the range of 0.1 % to 3 %.
- the concentration of these and of similar additives is not taken into consideration for the values and ranges of the concentrations of the liquid crystal components and compounds of the liquid crystal media in this application. This also holds for the concentration of the dichroic dyes used in the mixtures, which are not counted when the concentrations of the compounds respectively the components of the host medium are specified.
- the concentration of the respective additives is always given relative to the final doped mixture. In general, the total concentration of all compounds in the media according to this application is 100 %.
- the liquid crystal media according to the present invention consists of several compounds, preferably of 2 to 40, more preferably of 3 to 30 and most preferably of 4 to 25 compounds.
- the media in accordance with the present invention exhibit high values of the elastic constant k 11 and a high flexoelectric coefficient e.
- the liquid crystal media preferably exhibit a k 11 ⁇ 100 pN, preferably ⁇ 20 pN.
- the liquid crystal media preferably exhibit a k 33 ⁇ 100 pN, preferably ⁇ 15 pN.
- the liquid crystal media preferably exhibit a flexoelectric coefficient ⁇ e 11 ⁇ 0.2 pC/m, preferably ⁇ 1 pC/m.
- the liquid crystal media preferably exhibit a flexoelectric coefficient ⁇ e 33 ⁇ 0.2 pC/m, preferably ⁇ 2 pC/m.
- the liquid crystal media preferably exhibit a flexo-elastic ratio ( ⁇ / K) in the range from 1 to 10 V -1 , preferably in the range from 1 to 7 V -1 , more preferably in the range from 1 to 5 V -1 .
- the media in accordance with the present invention exhibit high clearing points up to 60°C and higher, preferably up 65°C and higher and more preferably up to 70°C and higher.
- the media in accordance with the present invention exhibit broad nematic phases of 30°C and more, preferably 35°C and more or even 40°C or more.
- the media in accordance with the present invention exhibit N TB phases below 20°C or less, preferably below 15°C or less and more preferably below 0°C or less.
- the media in accordance with the present invention exhibit high stabilities against crystallization at room temperature of more than 100 h, preferably more than 250 h or more than 1000 h.
- the media in accordance with the present invention exhibit high stabilities against crystallization even at low temperatures (LTS).
- the media do not crystallize even at temperatures down to 0°C, preferably down to -10°C, more preferably down to -20°C.
- the LC medium comprises: ⁇ 1 to 10, preferably 1 to 5, more preferably 1 or 3, most preferably 1 or 2 compounds of formula I, preferably selected from formulae Ia-1-2a, Ia-1-5a, Ib-1-4a and/or Ib-1-9a. The amount of
- compounds of formula I in the liquid crystalline medium as a whole is preferably in the range from 5 to 50 %, in particular in the range from 6 to 30 %, especially in the range from 7 to 20 % by weight of the total mixture, and ⁇ optionally 1 to 10, preferably 1 to 5, more preferably 1 or 3, most preferably 1 or 2 compounds of formula II, preferably selected from compounds compounds of formula II wherein (-A 21 -A 22 -) and (-A 23 -A 24 -) in formula II are identical or mirror images, more preferably of compounds of formulae II’a-5 and/or II’a-6.
- the amount of compounds of formula II in the liquid crystalline medium is preferably in the range from 0 to 30 %, more preferably in the range from 1 to 20 %, even more preferably in the range from 2 to 10 % by weight of the total mixture, and/or ⁇ optionally 1 to 10, preferably 1 to 5, more preferably 1 or 3, most preferably 1 or 2 compounds of formula III, preferably selected from symmetrical compounds of the above formulae IIIc-2 and/or IIIc-3.
- the amount of compounds of formula III in the liquid crystalline medium, if present, is preferably in the range from 1 to 50 %, more preferably in the range from 5 to 30 %, even more preferably in the range from 10 to 20 % by weight of the total mixture, and/or
- ⁇ optionally, 1 to 10, preferably 1 to 5, more preferably 1 or 3, most preferably 1 or 2 compounds of formula IV, preferably selected from the symmetrical ones IVb and/or non-symmetrical ones IVc, more preferably from formulae IVb-5, IVc-2, IVc-3, IVc-12 and or IVc-15.
- the amount of compounds of formula IV in the liquid crystalline medium, if present, is preferably in the range from 1 to 98 %, more preferably in the range from 20 to 80 %, even more preferably in the range from 30 to 60 % by weight of the total mixture, and/or ⁇ optionally, 1 to 6, in particular 2 to 5, very preferably 3 or 4
- compounds of formula V preferably selected from the above formulae VA-1, VD-2 and/or VD-3.
- the amount of compounds of formula V in the liquid crystalline medium is preferably in the range from 1 to 70 %, more preferably in the range from 10 to 60 %, even more preferably in the range from 20 to 50 % by weight of the total mixture, and/or ⁇ optionally 1 to 10, preferably 1 to 5, more preferably 1 or 3, most preferably 1 or 2 compounds from the above formulae VI, preferably form compounds of formula VI-4, VI-5, VI-7 and/or VI-9.
- the amount of compounds of formula VI in the liquid crystalline medium is preferably from 1 to 40 %, in particular from 5 to 25 %, very preferably 10 to 15 % by weight of the total mixture, and/or ⁇ optionally 1 to 10, preferably 1 to 5, more preferably 1 or 3, most preferably 1 or 2 compounds from the above formulae VII, preferably form compounds of formula VII-4, VII-5 and/or VII-8.
- the amount of compounds of formula VII in the liquid crystalline medium, if present, is preferably from 1 to 35 %, in particular from 5 to 25 %, very preferably 10 to 15 % by weight of the total mixture,
- the chiral compound is R-5011 or S-5011.
- the amount of chiral compounds in the liquid crystalline medium is preferably from 1 to 15 %, in particular from 0.5 to 10 %, very preferably 0.1 to 5 % by weight of the total mixture, and/or ⁇ optionally up to 25, in particular up to 20, very preferably up to 15, different compounds selected from compounds of formula X.
- the amount of compounds of formula X in the liquid crystalline medium as a whole is preferably from 1 to 50 %, in particular from 5 to 30 %, very preferably 10 to 25 % by weight of the total mixture, and/or ⁇ optionally further additives, such as for example stabilizers, antioxidants, etc. in usual concentrations.
- the total concentration of these further constituents, if present, is in the range of 0.1 to 10 %, preferably 0.1 to 6 %, based on the total mixture.
- the concentrations of the individual compounds used each are preferably in the range of 0.1 to 3 %.
- the LC medium of the present invention consists only of compounds selected from formula I to X, very preferably the LC medium consists only of compounds selected from formula I to IX.
- the compounds forming the LC medium in accordance with the present invention are mixed in conventional way. As a rule, the required amount of the compound used in the smaller amount is dissolved in the compound used in the greater amount. In case the temperature is above the clearing point of the compound used in the higher concentration, it is particularly easy to observe completion of the process of dissolution. It is, however, also possible to prepare the media by other conventional ways, e.g. using so-called pre-mixtures, which can be e.g.
- the invention also relates to a process for the production of an LC medium as described above and below.
- the invention relates to a process for the production of an LC medium comprising the steps of mixing one or more compounds of formula I, with at least one compound selected from compounds of formulae II to X.
- liquid crystalline media in accordance with the present invention can be used in electro optic devices, for example liquid crystal devices, such as STN, TN, AMD-TN, temperature compensation, guest-host, phase change or surface stabilized or polymer stabilized cholesteric texture (SSCT, PSCT) displays, in active and passive optical elements like polarizers, compensators, reflectors, alignment layers, colour filters or holographic elements, in adhesives, synthetic resins with anisotropic mechanical properties, cosmetics, diagnostics, liquid crystal pigments, for decorative and security applications, in nonlinear optics, optical information storage or as chiral dopants.
- a LC medium comprising at least one compound of formula I in electro optic devices.
- a flexoelectric display according to a preferred embodiment of the present invention comprises two plane parallel substrates, preferably glass plates covered with a transparent conductive layer such as indium tin oxide (ITO) on their inner surfaces, optionally alignment layers and a medium comprising one or more compounds of formula I and a chiral dopant as described above and below.
- ITO indium tin oxide
- the optical axis is rotated in the plane of the cell, similar as the director of a ferroelectric liquid crystal rotate as in a surface stabilized ferroelectric liquid crystal display.
- the field induces a splay bend structure in the director, which is accommodated by a tilt in the optical axis.
- the angle of the rotation of the axis is in first approximation directly and linearly proportional to the strength of the electrical field. The optical effect is best seen when the liquid crystal cell is placed between crossed polarizers with the optical axis in the unpowered state at an angle of 22.5° to the absorption axis of one of the polarizers.
- This angle of 22.5° is also the ideal angle of rotation of the electric field, as thus, by the inversion the electrical field, the optical axis is rotated by 45° and by appropriate selection of the relative orientations of the preferred direction of the axis of the helix, the absorption axis of the polarizer and the direction of the electric field, the optical axis can be switched from parallel to one polarizer to the centre angle between both polarizers. The optimum contrast is then achieved when the total angle of the switching of the optical axis is 45°.
- the arrangement can be used as a switchable quarter wave plate, provided the optical retardation, i. e. the product of the effective birefringence of the liquid crystal and the cell gap, is selected to be the quarter of the wavelength.
- the wavelength referred to is 550 nm, the wavelength for which the sensitivity of the human eye is highest, unless explicitly stated otherwise.
- the angle of rotation of the optical axis ( ⁇ ) is given in good
- P 0 is the undisturbed pitch of the cholesteric liquid crystal
- E is the electrical field strength
- the flexoelectric effect is characterized by fast response times (T on+ T off at 35°C) typically ranging from 1 ms to 10 ms, preferably ⁇ 5ms and even more preferably ⁇ 3ms. It further features excellent grey scale capability.
- T on+ T off at 35°C fast response times
- E c critical field
- inventive media in accordance with the present invention can be aligned in their cholesteric phase into different states of orientation by methods that are known to the expert, such as surface treatment or electric fields. For example, they can be aligned into the planar
- mesogenic material in a display cell or on a substrate means that the mesogenic groups in the liquid crystal or mesogenic material are oriented substantially parallel to the plane of the cell or substrate, respectively.
- the term“homeotropic alignment” or orientation of a liquid crystal or mesogenic material in a display cell or on a substrate means that the mesogenic groups in the liquid crystal or mesogenic material are oriented substantially perpendicular to the plane of the cell or substrate, respectively.
- This state is also known as Grandjean state and the texture of the sample, which is observable e.g. in a polarization microscope, as Grandjean texture.
- Planar alignment can be achieved e.g. by surface treatment of the cell walls, for example by rubbing and/or coating with an alignment layer such as polyimide.
- a Grandjean state with a high quality of alignment and only few defects can further be achieved by heating the sample to the isotropic phase, subsequently cooling to the chiral nematic phase at a temperature close to the chiral nematic-isotropic phase transition and flow alignment by lightly pressing the cell.
- the sample shows selective reflection of incident light, with the central wavelength of reflection depending on the helical pitch and the mean refractive index of the material.
- the sample When an electric field is applied to the electrodes, for example with a frequency from 10 Hz to 1 kHz and an amplitude of up to 12 V rms / ⁇ m, the sample is being switched into a homeotropic state where the helix is unwound and the molecules are oriented parallel to the field, i.e. normal to the plane of the electrodes.
- the sample In the homeotropic state, the sample is transmissive when viewed in normal daylight and appears black when being put between crossed polarizers.
- the sample Upon reduction or removal of the electric field in the homeotropic state, the sample adopts a focal conic texture, where the molecules exhibit a helically twisted structure with the helical axis being oriented
- a focal conic state can also be achieved by applying only a weak electric field to a sample in its planar state. In the focal conic state the sample is scattering when viewed in normal daylight and appears bright between crossed polarizers.
- a sample of a medium in accordance with the present invention in different states of orientation exhibits different transmission of light.
- the respective state of orientation, as well as its quality of alignment can be controlled by measuring the light transmission of the sample depending on the strength of the applied electric field. Thereby it is also possible to determine the electric field strength required to
- the above-described focal conic state consists of many disordered
- the LC media may also comprise compounds in which, for example, H, N, O, Cl, F have been replaced by the corresponding isotopes.
- T N,I clearing point
- K crystalline
- N nematic
- N TB second nematic
- S or Sm smectic
- Ch cholesteric
- I isotropic
- Tg glass transition.
- the numbers between the symbols indicate the phase transition temperatures in°C.
- n, m and l denote an integer between 1 and 12.
- Table A lists the symbols used for the ring elements, table B those for the linking groups and table C those for the symbols for the left hand and the right hand end groups of the molecules.
- 2-Trimethylsilyl-1,3-dithiane 3 (52.8 g, 269 mmol) is dissolved in 190 ml tetrahydrofuran and cooled to -70°C.
- Butyllithium (107.5 ml of a 2.5 M solution in hexanes, 269 mmol) is slowly added. After the addition is complete, the mixture is warmed to room temperature for 2 hours and then cooled again to -70°C.20 g of dialdehyde 2 in 80 ml tetrahydrofuran is slowly added at that temperature. After the addition is complete, the mixture is warmed to room temperature and worked up as usual. The residue is distilled under reduced pressure and gave 22.9 g of product 4 with a boiling point of 67-74°C at a pressure of 0.1 mbar.
- Bis(dithiane) 4 (15.4 mmol) is suspended in 200 ml dichloromethane and cooled to -30°C.
- Trifluoromethane sulfonic acid (2.98 ml, 34 mmol) is added dropwise while stirring and the mixture is warmed to room temperature for 30 min. It is then cooled again to -70°C, the two phenols 5 (3.1 g, 15.4 mmol) and 6 (3.3 g, 15.4 mmol) together with triethylamine (7.7 ml, 56 mmol) and 70 ml dichloromethane are added dropwise to the mixture.
- Triethylamine trishydrofluoride (24.9 ml, 154 mmol) is added and subsequently within a period of 60 min bromine (7.9 ml, 154 mmol) in 65 ml dichloromethane. After stirring for one hour at -70°C, the mixture is allowed to warm to -30°C and morpholine (13.5 ml, 154 mmol) is added below -20°C. After warming to 0°C, the mixture is poured onto 200 ml ice water and 19.7 ml aqueous KOH (47 %). The pH is adjusted to approximately 9.0 with additional small amounts of the KOH solution. The organic phase is separated and worked up as usual. After chromatography, of compound 7 (F-PGI-QI-9-Q-PP-N) is isolated.
- Dithiane 4 (18.3 mmol) is suspended in 230 ml dichloromethane, cooled to -30°C and trifluoromethane sulfonic acid (3.5 ml, 40.3 mmol) is added dropwise. The mixture is allowed to warm to room temperature, stirred for 30 min and cooled again to -70°C. A mixture of 4-bromophenol 9 (7 g, 40.3 mmol) and triethylamine (9.1 ml, 65.9 mmol) dissolved in 100 ml dichloromethane is added. After the addition is complete, the mixture is stirred at -70°C for one hour.
- Triethylamine trishydrofluoride (29.5 ml, 183 mmol) is added and after one hour bromine (9.4 ml, 183 mmol) in 50 ml dichloromethane. Stirring is continued for one hour and the mixture is warmed to -30°C. Morpholine (15.9 ml, 183 mmol) is added below -20°C. Workup is carried out as described above for compound 7 and gave compound 10. Step 2.2
- 2-Trimethylsilyl-1,3-dithiane (6.7 ml, 35.4 mmol) is dissolved in 40 ml tetrahydrofuran and cooled to -70°C.
- Butyllithium in hexanes (23.4 ml of a 15 % solution, 37.2 mmol) is added dropwise and the mixture is warmed to -20°C and stirred for 4 hours. It is then cooled again to -70°C and 19 (37.2 mmol) dissolved in 40 ml dichloromethane is added dropwise. After warming to room temperature followed by the usual workup, 20 is obtained as a yellow oil.
- Triethylamine trishydrofluoride (13.9 ml, 86 mmol) is added dropwise and after 1 hour 4.4 ml (86 mmol) bromine in 100 ml dichloromethane. The mixture is stirred for 1 hour at -70°C. After warming to -20°C, morpholine (7.5 ml, 86 mmol) is added and stirring is continued for 1h at 0°C. After the usual workup 21 (N-PP-QI-5-GP-N) is obtained as a white powder.
- C H 3 B Test cells and methods Typically a 3 ⁇ m thick cell, having an anti-parallel rubbed PI alignment layer, is filled on a hotplate at a temperature at which the flexoelectric mixture in the isotropic phase. After the cell has been filled, the phase transitions including clearing point and the crystallization behavior are determined using Differential Scanning Calorimetry (DSC) and verified by optical inspection. For optical phase transition measurements, a Mettler FP90 hot-stage controller connected to a FP82 hot-stage is used to control the temperature of the cell. The temperature is increased from ambient temperature at a rate of 5 degrees C per minute, until the onset of the isotropic phase is observed.
- DSC Differential Scanning Calorimetry
- the texture change is observed through crossed polarizers using an Olympus BX51 microscope and the respective temperature noted. Wires are then attached to the ITO electrodes of the cell using indium metal.
- the cell is secured in a Linkam THMS600 hot-stage connected to a Linkam TMS93 hot-stage controller.
- the hot-stage is secured to a rotation stage in an Olympus BX51 microscope.
- the cell is heated until the liquid crystal is completely isotropic.
- the cell is then cooled under an applied electric field until the sample is
- the driving waveform is supplied by a Tektronix AFG3021B arbitrary function generator, which is sent through a
- the applied field is monitored using a HP 34401A multimeter.
- the tilt angle is measured using the aforementioned microscope and oscilloscope.
- the undisturbed cholesteric pitch, P 0 is measured using an Ocean Optics USB4000 spectrometer attached to a computer.
- the selective reflection band is obtained and the pitch determined from the spectral data.
- the media shown in the following examples are well suitable for use in ULH-displays.
- the material containing BM-4 in accordance with the present has a significant advantage with respect to the switching speed when compared to material comprising a compound of the prior art (CM*-2).
- the TNI is also similar, something that is surprising when considering conventional liquid crystal materials with differing switching speeds when normally a strong inverse relationship between TNI and switching speeds is observed (i.e. higher TNI leads to reduced switching speeds).
- the material containing BM-6 in accordance with the present has a significant advantage with respect to the switching speed when compared to material comprising a compound of the prior art (CM*-3).
- the TNI is also similar, something that is surprising when considering conventional liquid crystal materials with differing switching speeds when normally a strong inverse relationship between TNI and switching speeds is observed (i.e. higher TNI leads to reduced switching speeds).
Landscapes
- Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal Substances (AREA)
Abstract
The invention relates to a compound of formula (I), R11-MG11-X11-Sp11-X12-MG12-R12 wherein R11, R22, MG11, MG12, Sp11, X11 and X12 have one of the meanings as given herein below. The invention further relates to method of production of a compound of formula I, to the use of said compounds in LC media and to LC media comprising one or more compounds of formula I. Further, the invention relates to a method of production of such LC media, to the use of such media in LC devices, in particular in flexoelectric LC devices and to a flexoelectric LC device comprising a LC medium according to the present invention. P16272 SL -118- Abstract The invention relates to a compound of formula (I), R 11 -MG 11 -X 11 -Sp 11 -X 12 -MG 12 -R 12 I wherein R 11, R 22, MG 11, MG 12, Sp 11, X 11 and X 12 have one of the meanings as given herein below. The invention further relates to method of production of a compound of formula (I), to the use of said compounds in LC media and to LC media comprising one or more compounds of formula (I). Further, the invention relates to a method of production of such LC media, to the use of such media in LC devices, in particular in flexoelectric LC devices and to a flexoelectric LC device comprising a LC medium according to the present invention.
Description
Liquid Crystal Medium and Liquid Crystal Device The invention relates to a compound of formula I, R11-MG11-X11-Sp11-X12-MG12-R12 I wherein R11, R22, MG11, MG12, Sp11, X11 and X12 have one of the meanings as given herein below. The invention further relates to method of production of a compound of formula I, to the use of said compounds in LC media and to LC media comprising one or more compounds of formula I. Further, the invention relates to a method of production of such LC media, to the use of such media in LC devices, in particular in flexoelectric LC devices and to a flexoelectric LC device comprising a LC medium according to the present invention. Background and Prior Art The flexoelectric effect is described, for example, by Chandrasekhar, "Liquid Crystals", 2nd edition, Cambridge University Press (1992) and P.G. deGennes et al., "The Physics of Liquid Crystals", 2nd edition, Oxford Science Publications (1995). Flexoelectric devices utilizing the flexoelectric effect, for example ULH devices and liquid crystal media that are especially suitable for flexoelectric devices and are known from EP 0971016, GB 2356629 and Coles, H.J., Musgrave, B., Coles, M.J. and Willmott, J., J. Mater. Chem., 11, p.2709-2716 (2001). The Uniform Lying Helix (ULH) has high potential as a fast switching liquid crystal display mode. It is capable of sub millisecond switching at 35ºC and possesses an intrinsically high aperture ratio, resulting in an energy efficient display mode. The materials commonly used in media suitable for the ULH mode are typically bimesogens. Due to the size of these materials and the presence of polar groups, such as, for example terminal cyano groups,
they normally have high rotational viscosities (γ)1 in the order of many thousands mPa.s at 35ºC. The high values for γ1 are not problematically at increased temperatures of, for example, 35ºC, since the switching speed is directly proportional to γ.1 On the other hand, the values for ^1 are also proportional to the chiral pitch squared. Since the chiral pitch is normally in the region of 300nm this means that, the switching speeds are still very fast, in the region of 1 millisecond or a few milliseconds. However, upon reaching lower temperatures, such as room temperature at which the ULH devices are typically operated, the value for γ1 increases exponentially and even with a short pitch material the switching speeds increase beyond favourable levels. In order to maintain fast switching speeds at temperatures below 35ºC, the value γ1 of the LC mixtures needs to be reduced and therefore mixture components with lower γ1 need to be identified. Accordingly, there is a great demand for new bimesogenic compounds, which exhibit favourable low γ1 values while preferably at the same time exhibiting:
● favourable e/K (V-1) values,
● favourable broad nematic phase ranges and
● high clearing points. In addition to those requirements, the corresponding LC media should exhibit favourable low γ1 values while preferably at the same time exhibiting:
● low melting points,
● high clearing points,
● broad chiral nematic phase ranges,
● short temperature independent pitch lengths,
● high flexoelectric coefficients and
● a favourable low temperature stability without crystallization
effects in cells as well as in the bulk.
Other aims of the present invention are immediately evident to the person skilled in the art from the following detailed description. Surprisingly, the inventors have found out that one or more of the above- mentioned aims can be achieved by providing a compound according to claim 1. Terms and Definitions
The term "liquid crystal", "mesomorphic compound” or "mesogenic compound" (also shortly referred to as "mesogen") means a compound that under suitable conditions of temperature, pressure and concentration can exist as a mesophase (nematic, smectic, etc.) or in particular as a LC phase. Non-amphiphilic mesogenic compounds comprise for example one or more calamitic, banana-shaped or discotic mesogenic groups. The term "mesogenic group" means in this context, a group with the ability to induce liquid crystal (LC) phase behaviour. The compounds comprising mesogenic groups do not necessarily have to exhibit an LC phase themselves. It is also possible that they show LC phase behaviour only in mixtures with other compounds. For the sake of simplicity, the term "liquid crystal" is used hereinafter for both mesogenic and LC materials. Throughout the application, unless stated explicitly otherwise, the term “aryl and heteroaryl groups” encompass groups, which can be
monocyclic or polycyclic, i.e. they can have one ring (such as, for example, phenyl) or two or more rings, which may also be fused (such as, for example, naphthyl) or covalently linked (such as, for example, biphenyl) or contain a combination of fused and linked rings. Heteroaryl groups contain one or more heteroatoms, preferably selected from O, N, S and Se. Particular preference is given to mono-, bi- or tricyclic aryl groups having 6 to 25 C atoms and mono-, bi- or tricyclic heteroaryl groups having 2 to 25 C atoms, which optionally contain fused rings and which are optionally substituted. Preference is furthermore given to 5 , 6 or 7-membered aryl and heteroaryl groups, in which, in
addition, one or more CH groups may be replaced by N, S or O in such a way that O atoms and/or S atoms are not linked directly to one another. Preferred aryl groups are, for example, phenyl, biphenyl, terphenyl,
[1,1':3',1'']terphenyl-2'-yl, naphthyl, anthracene, binaphthyl,
phenanthrene, pyrene, dihydropyrene, chrysene, perylene, tetracene, pentacene, benzopyrene, fluorene, indene, indenofluorene,
spirobifluorene, more preferably 1,4- phenylene, 4,4’-biphenylene, 1, 4- tephenylene. Preferred heteroaryl groups are, for example, 5 membered rings, such as pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, furan, thiophene, selenophene, oxazole, isoxazole, 1,2 thiazole, 1,3-thiazole, 1,2,3-oxadiazole, 1,2,4 oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadiazole, 6 membered rings, such as pyridine, pyridazine, pyrimidine, pyrazine, 1,3,5-triazine, 1,2,4-triazine, 1,2,3-triazine, 1,2,4,5-tetrazine, 1,2,3,4- tetrazine, 1,2,3,5-tetrazine or condensed groups, such as indole, iso- indole, indolizine, indazole, benzimidazole, benzotriazole, purine, naphth- imidazole, phenanthrimidazole, pyridimidazole, pyrazinimidazole, quinoxalinimidazole, benzoxazole, naphthoxazole, anthroxazole, phen- anthroxazole, isoxazole, benzothiazole, benzofuran, isobenzofuran, dibenzofuran, quinoline, isoquinoline, pteridine, benzo-5,6-quinoline, benzo-6,7-quino¬line, benzo-7,8-quinoline, benzoisoquinoline, acridine, phenothiazine, phenoxazine, benzopyridazine, benzopyrimidine, quinoxaline, phenazine, naphthyridine, azacarbazole, benzocarboline, phenanthridine, phenanthroline, thieno[2,3b]thiophene, thieno[3,2b]- thiophene, dithienothiophene, isobenzothiophene, dibenzothiophene, benzothiadiazothiophene or combinations of these groups. The heteroaryl groups may also be substituted by alkyl, alkoxy, thioalkyl, fluorine, fluoroalkyl or further aryl or heteroaryl groups. In the context of this application, the term“(non-aromatic) alicyclic and heterocyclic groups” encompass both saturated rings, i.e. those that contain exclusively single bonds and partially unsaturated rings, i.e.
those that may also contain multiple bonds. Heterocyclic rings contain one or more heteroatoms, preferably selected from Si, O, N, S and Se.
The (non-aromatic) alicyclic and heterocyclic groups can be monocyclic, i.e. contain only one ring (such as, for example, cyclohexane) or polycyclic, i.e. contain a plurality of rings (such as, for example, decahydro-naphthalene or bicyclooctane). Particular preference is given to saturated groups. Preference is furthermore given to mono-, bi- or tricyclic groups having 3 to 25 C atoms, which optionally contain fused rings and that are optionally substituted. Preference is furthermore given to 5-, 6-, 7- or 8-membered carbocyclic groups in which, in addition, one or more C atoms may be replaced by Si and/or one or more CH groups may be replaced by N and/or one or more non-adjacent CH2 groups may be replaced by -O- and/or -S-. Preferred alicyclic and heterocyclic groups are, for example, 5-membered groups, such as cyclopentane,
tetrahydrofuran, tetrahydrothiofuran, pyrrolidine, 6-membered groups, such as cyclohexane, silinane, cyclohexene, tetrahydropyran,
tetrahydrothiopyran, 1,3-dioxane, 1,3-dithiane, piperidine, 7-membered groups, such as cycloheptane and fused groups, such as
tetrahydronaphthalene, decahydronaphthalene, indane,
bicyclo[1.1.1]¬pentane-1,3-diyl, bicyclo[2.2.2]octane-1,4-diyl,
spiro[3.3]heptane-2,6-diyl, octahydro-4,7-methanoindane-2,5-diyl, more preferably 1,4-cyclohexylene 4,4’- bicyclohexylene, 3,17-hexadecahydro- cyclopenta[a]phenanthrene, optionally being substituted by one or more identical or different groups L. Especially preferred aryl-, heteroaryl-, alicyclic- and heterocyclic groups are 1,4-phenylene, 4,4’-biphenylene, 1, 4-terphenylene, 1,4-cyclohexylene, 4,4’- bicyclohexylene and 3,17- hexadecahydro-cyclopenta[a]-phenanthrene, optionally being substituted by one or more identical or different groups L. Preferred substituents of the above-mentioned aryl-, heteroaryl-, alicyclic- and heterocyclic groups (L) are, for example, solubility-promoting groups, such as alkyl or alkoxy and electron-withdrawing groups, such as fluorine, nitro or nitrile. Particularly preferred substituents are, for example, halogen, CN, NO2, CH3, C2H5, OCH3, OC2H5, COCH3, COC2H5, COOCH3, COOC2H5, CF3, OCF3, OCHF2 or OC2F5.
Above and below "halogen" denotes F, Cl, Br or I. Above and below, the terms "alkyl", "aryl", "heteroaryl", etc., also encompass polyvalent groups, for example alkylene, arylene,
heteroarylene, etc. The term "aryl" denotes an aromatic carbon group or a group derived there from. The term "heteroaryl" denotes "aryl" in accordance with the above definition containing one or more heteroatoms. Preferred alkyl groups are, for example, methyl, ethyl, n propyl, isopropyl, n butyl, isobutyl, s butyl, t butyl, 2 methylbutyl, n pentyl, s pentyl, cyclo- pentyl, n hexyl, cyclohexyl, 2 ethylhexyl, n heptyl, cycloheptyl, n octyl, cyclooctyl, n nonyl, n decyl, n undecyl, n dodecyl, dodecanyl, trifluoro- methyl, perfluoro-n-butyl, 2,2,2-trifluoroethyl, perfluorooctyl, perfluoro- hexyl, etc. Preferred alkoxy groups are, for example, methoxy, ethoxy, 2-methoxy- ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy, 2- methylbutoxy, n-pentoxy, n-hexoxy, n-heptoxy, n-octoxy, n-nonoxy, n- decoxy, n-undecoxy, n-dodecoxy. Preferred alkenyl groups are, for example, ethenyl, propenyl, butenyl, pentenyl, cyclopentenyl, hexenyl, cyclohexenyl, heptenyl, cycloheptenyl, octenyl, cyclooctenyl. Preferred alkynyl groups are, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, octynyl. Oxaalkyl, i.e. where one CH2 group is replaced by -O-, is preferably straight-chain 2-oxapropyl (= methoxymethyl), 2- (= ethoxymethyl) or 3-oxabutyl (= 2-methoxyethyl), 2-, 3- or 4-oxapentyl, 2-, 3-, 4- or 5- oxahexyl, 2-, 3-, 4-, 5- or 6-oxaheptyl, 2-, 3-, 4-, 5-, 6- or 7-oxaoctyl, 2-,
3-, 4-, 5-, 6-, 7- or 8-oxanonyl or 2-, 3-, 4-, 5-, 6-,7-, 8- or 9-oxadecyl, for example. Preferred amino groups are, for example, dimethylamino, methylamino, methylphenylamino, phenylamino. The term“chiral” in general is used to describe an object that is non- superimposable on its mirror image. “Achiral” (non- chiral) objects are objects that are identical to their mirror image. The terms“chiral nematic” and“cholesteric” are used synonymously in this application, unless explicitly stated otherwise. The term“bimesogenic compound” relates to compounds comprising two mesogenic groups in the molecule. Just like normal mesogens, they can form many mesophases, depending on their structure. In particular, bimesogenic compound may induce a second nematic phase, when added to a nematic liquid crystal medium. Bimesogenic compounds are also known as“dimeric liquid crystals”. The term "director" is known in prior art and means the preferred orientation direction of the long molecular axes (in case of calamitic compounds) or short molecular axes (in case of discotic compounds) of the liquid-crystalline molecules. In case of uniaxial ordering of such anisotropic molecules, the director is the axis of anisotropy. The term“alignment” or“orientation” relates to alignment (orientation ordering) of anisotropic units of material such as small molecules or fragments of big molecules in a common direction named“alignment direction”. In an aligned layer of liquid-crystalline material, the liquid- crystalline director coincides with the alignment direction so that the alignment direction corresponds to the direction of the anisotropy axis of the material.
The term "planar orientation/alignment", for example in a layer of an liquid-crystalline material, means that the long molecular axes (in case of calamitic compounds) or the short molecular axes (in case of discotic compounds) of a proportion of the liquid-crystalline molecules are oriented substantially parallel (about 180°) to the plane of the layer. The term "homeotropic orientation/alignment", for example in a layer of a liquid-crystalline material, means that the long molecular axes (in case of calamitic compounds) or the short molecular axes (in case of discotic compounds) of a proportion of the liquid-crystalline molecules are oriented at an angle θ ("tilt angle") between about 80° to 90° relative to the plane of the layer. The terms "uniform orientation" or "uniform alignment" of an liquid- crystalline material, for example in a layer of the material, mean that the long molecular axes (in case of calamitic compounds) or the short molecular axes (in case of discotic compounds) of the liquid-crystalline molecules are oriented substantially in the same direction. In other words, the lines of liquid-crystalline director are parallel.
The wavelength of light generally referred to in this application is 550 nm, unless explicitly specified otherwise. The birefringence Δn herein is defined by the following equation
wherein ne is the extraordinary refractive index and no is the ordinary refractive index and the effective average refractive index nav. is given by the following equation
The extraordinary refractive index ne and the ordinary refractive index no can be measured using an Abbe refractometer.
In the present application the term“dielectrically positive” is used for compounds or components with
“dielectrically neutral” with -1.5
and“dielectrically negative” with
is determined at a frequency of 1 kHz and at 20°C. The dielectric anisotropy of the respective compound is determined from the results of a solution of 10 % of the respective individual compound in a nematic host mixture. In case the solubility of the respective compound in the host medium is less than 10 % its concentration is reduced by a factor of 2 until the resultant medium is stable enough at least to allow the determination of its properties. Preferably, the concentration is kept at least at 5 %, however, in order to keep the significance of the results a high as possible. The capacitance of the test mixtures are determined both in a cell with homeotropic and with homogeneous alignment. The cell gap of both types of cells is approximately 20 µm. The voltage applied is a
rectangular wave with a frequency of 1 kHz and a root mean square value typically of 0.5 V to 1.0 V; however, it is always selected to be below the capacitive threshold of the respective test mixture. is defined as whereas is The dielectric
permittivity of the compounds is determined from the change of the respective values of a host medium upon addition of the compounds of interest. The values are extrapolated to a concentration of the
compounds of interest of 100 %. A typical host medium is ZLI-4792 or BL-087 both commercially available from Merck, Darmstadt. For the present invention,
denote trans-1,4-cyclohexylene,
denote 1,4-phenylene.
Furthermore, the definitions as given in C. Tschierske, G. Pelzl and S. Diele, Angew. Chem.2004, 116, 6340-6368 shall apply to non-defined terms related to liquid crystal materials in the instant application. Detailed description The invention relates to a compound of formula I, R11-MG11-X11-Sp11-X12-MG12-R12 I wherein R11 and R22 are each independently H, F, Cl, CN, NCS or a straight- chain or branched alkyl group, which may be
unsubstituted, mono- or polysubstituted by halogen or CN and in which one or more non-adjacent and non- terminal CH2 groups may be replaced, in each occurrence independently from one another, by -O-, -S-, -NH-, -N(CH3)-, -CO-, -COO-, -OCO-, -O-CO-O-, -S-CO-, -CO-S-, -CH=CH-, -CH=CF-, -CF=CF- or -C≡C- in such a manner that oxygen atoms are not linked directly to one another,
preferably F, Cl, CN, a straight-chain or branched alkyl, alkenyl or alkoxy group which may be unsubstituted, mono- or polysubstituted by halogen or CN,
more preferably F, CN or OCF3, MG11 and MG12 are each independently a mesogenic group,
preferably, each independently a mesogenic group, which comprises one or more aryl-, heteroaryl-, alicyclic- and heterocyclic groups, which are optionally substituted by F, Cl, CN, OCH3, OCF3, preferably each independently a mesogenic group, which comprises two or more aryl-, heteroaryl-, alicyclic- and heterocyclic groups wherein two of these
rings are optionally be linked by a linking group selected from -CO-O-, -O-CO-, -CH2-O-, -O-CH2-, -CF2O- and/or -OCF2-, Sp11 is a spacer group comprising 1, 3 or 5 to 40 C atoms, wherein one or more non-adjacent and non-terminal CH2 groups may also be replaced by -O-, -S-, -NH-, -N(CH3)-, -CO-, -O-CO-, -S-CO-, -O-COO-, -CO-S-, -CO-O-, -CF2-, -CF2O-, -OCF2- -C(OH)-, -CH(alkyl)-, -CH(alkenyl)-,-CH(alkoxyl)-, -CH(oxaalkyl)-, -CH=CH- or -C ^C-, however in such a way that no two O-atoms are adjacent to one another and no two groups selected from -O-CO-, -S-CO-, -O-COO-, -CO-S-, -CO-O- and -CH=CH- are adjacent to each other, preferably–(CH2)n-, with n 1, 3 or an integer from 5 to 15, more preferably from 3 to 11, most preferably an odd integer (i.e.3, 5, 7, 9 or 11), X11 and X12 are -CF2-O-, -O-CF2- or a single bond, whereby at least one of X11 or X12 denotes -CF2-O-, or -O-CF2-. Preferably the unit -X11-Sp11-X12- denotes -CF2O-Sp11-CF2O-, -OCF2- Sp11-OCF2-, -OCF2-Sp11-CF2O-, -CF2O-Sp11-OCF2-, -CF2O-Sp11-, -OCF2- Sp11-, -Sp11-CF2O-, or -Sp11-OCF2-. Preferred are compounds of formula I wherein the mesogenic groups R11-MG11- and R12-MG12- are different from each other. In another embodiment, the compounds of formula I are preferably selected from compounds wherein the groups (R11-MG11-) and
(R12-MG12-) in formula I are identical to each other. Further preferred compounds of formula I are compounds selected from the group of compounds of formulae Ia and/or Ib, R11-MG11-OCF2-Sp11-CF2O-MG12-R12 Ia
R11-MG11-Sp11-CF2O-MG12-R12 Ib wherein R11, R22, MG11, MG12, Sp11, have one of the meanings as given above under formula I. Further preferred compounds of formula I are compounds selected from the group of compounds of formulae Ia-1 and/or Ib-1 R11-MG11-OCF2-(CH2)n-CF2O-MG12-R12 Ia-1 R11-MG11-(CH2)n-CF2O-MG12-R12 Ib-1 wherein R11, R22, MG11, MG12 have one of the meanings as given above under formula I and n denotes 1, 3 or an integer from 5 to 15, more preferably an integer from 3 to 11, most preferably an odd integer (i.e.3, 5, 7, 9 or 11). If R11 or R12 is an alkyl or alkoxy radical, this may be straight chain or branched. It is preferably straight-chain, has 2, 3, 4, 5, 6, 7 or 8 carbon atoms and accordingly is preferably ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy or octoxy, furthermore methyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, nonoxy, decoxy, undecoxy, dodecoxy, tridecoxy or tetradecoxy, for example. If R11 or R12 is an alkenyl group are, this may be straight-chain or branched, preferably straight-chain, with up to 15 C atoms and more preferably, ethenyl, propenyl, butenyl, pentenyl, cyclopentenyl, hexenyl, cyclohexenyl, heptenyl, cycloheptenyl, octenyl, cyclooctenyl and corresponding isomers. In case of compounds with two non-polar groups, one of R11 or R12 is preferably alkenyl or alkinyl, preferably alkenyl, with up to 15 C atoms and the other is preferably alkyl, alkenyl or alkinyl, most preferably alky or
alkenyl with 2 to 15 C atoms or alkoxy with 1 to 15, preferably 2 to 15, C atoms. In addition, compounds of formula I containing an achiral branched group R11 and/or R12 may occasionally be of importance, for example, due to a reduction in the tendency towards crystallisation. Branched groups of this type generally do not contain more than one chain branch. Preferred achiral branched groups are isopropyl, isobutyl (=methylpropyl), isopentyl (=3-methylbutyl), isopropoxy, 2-methyl-propoxy and 3-methylbutoxy. In case of a compounds with a terminal polar group, R11 and/or R12 are selected from CN, NO2, halogen, OCH3, OCN, SCN, CORx, COORx or a mono- oligo- or polyfluorinated alkyl or alkoxy group with 1 to 4 C atoms.
Rx is optionally fluorinated alkyl with 1 to 4, preferably 1 to 3 C atoms.
Halogen is preferably F or Cl. Especially preferably R11 and R12 in formula I are selected of H, alkenyl, F, Cl, CN, NO2, OCH3, COCH3, COC2H5, COOCH3, COOC2H5, CF3,
C2F5, OCF3, OCHF2 and OC2F5, in particular of ethenyl, propenyl,
butenyl, F, Cl, CN, CF3, OCH3 and OCF3, especially of propenyl, butenyl, F, CN and OCF3. In a preferred embodiment the compounds of formula Ia-1 are selected from the following compounds: R11-Phe-OCF2-(CH2)n-CF2O-Phe-R12
Ia-1- I R11-PheL-OCF2-(CH2)n-CF2O-Phe-R12
Ia-1- II R11-PheL-OCF2-(CH2)n-CF2O-PheL-R12
Ia-1- III R11-Phe-OCF2-(CH2)n-CF2O-Phe-Z-Phe-R12
Ia-1- IV R11-PheL-OCF2-(CH2)n-CF2O-Phe-Z-Phe-R12
Ia-1- V R11-Phe-OCF2-(CH2)n-CF2O-PheL-Z-Phe-R12
Ia-1- VI R11-Phe-OCF2-(CH2)n-CF2O-Phe-Z-PheL-R12
Ia-1- VII R11-Phe-OCF2-(CH2)n-CF2O-PheL-Z-PheL-R12
Ia-1- VIII
R11-PheL-OCF2-(CH2)n-CF2O-PheL-Z-Phe-R12
Ia-1- IX R11-PheL-OCF2-(CH2)n-CF2O-Phe-Z-PheL-R12
Ia-1- X R11-PheL-OCF2-(CH2)n-CF2O-PheL-Z-PheL-R12
Ia-1- XI wherein, R11, R12 have one of the meanings as given above and Phe is 1,4-phenylene,
PheL is 1,4-phenylene, which is substituted by one, two or
three fluorine atoms, by one or two Cl atoms or by one Cl atom and one F atom and
Z has one of the meanings of Z11 as given under partial formula II and if present twice, at least one is preferably selected from -C≡C-, -C=C-, -COO-, -OCO-, -O-CO-O-, -OCH2-, -CH2O-, -OCF2- or -CF2O-. In a preferred embodiment the compounds of formula Ib-1 are selected from the following compounds: R11-Phe-(CH2)n-CF2O-Phe-R12 Ib-1- I R11-PheL-(CH2)n-CF2O-Phe-R12 Ib-1- II R11-Phe-(CH2)n-CF2O-PheL-R12 Ib-1- III R11-PheL-(CH2)n-CF2O-PheL-R12 Ib-1- IV R11-Phe-(CH2)n-CF2O-Phe-Z-Phe-R12 Ib-1- V R11-PheL-(CH2)n-CF2O-Phe-Z-Phe-R12 Ib-1- VI R11-Phe-(CH2)n-CF2O-Phe-Z-PheL-R12 Ib-1- VII R11-Phe-(CH2)n-CF2O-PheL-Z-Phe-R12 Ib-1- VIII R11-Phe-(CH2)n-CF2O-PheL-Z-PheL-R12 Ib-1- IX R11-PheL-(CH2)n-CF2O-PheL-Z-Phe-R12 Ib-1- X R11-PheL-(CH2)n-CF2O-Phe-Z-PheL-R12 Ib-1- XI R11-PheL-(CH2)n-CF2O-PheL-Z-PheL-R12 Ib-1- XII R11-Phe-OCF2-(CH2)n-Phe-R12 Ib-1- XIII R11-PheL-OCF2-(CH2)n-Phe-R12 Ib-1- XIV
R11-Phe-OCF2-(CH2)n-PheL-R12 Ib-1- XV R11-PheL-OCF2-(CH2)n-PheL-R12 Ib-1- XVI R11-Phe-OCF2-(CH2)n-Phe-Z-Phe-R12 Ib-1- XVII R11-PheL-OCF2-(CH2)n-Phe-Z-Phe-R12 Ib-1- XVIII R11-Phe-OCF2-(CH2)n-PheL-Z-Phe-R12 Ib-1- XIX R11-Phe-OCF2-(CH2)n-Phe-Z-PheL-R12
R11-Phe-OCF2-(CH2)n-PheL-Z-PheL-R12 Ib-1- XX R11-PheL-OCF2-(CH2)n-PheL-Z-Phe-R12 Ib-1- XXI R11-PheL-OCF2-(CH2)n-Phe-Z-PheL-R12 Ib-1- XXII R11-PheL-OCF2-(CH2)n-PheL-Z-PheL-R12 Ib-1- XXIII wherein, R11, R12, Phe, PheL, Z and n have one of the meanings as given above. Further preferred compounds of formula I are compounds in which MG11 and MG12 are independently from one another a group of
(partial) formula I* -A11-(Z11-A12)k- I* Wherein A11 and A12 each independently in each occurrence denote, 1,4- phenylene, wherein in addition one or more CH
groups may be replaced by N, trans-1,4-cyclo- hexylene in which, in addition, one or two non- adjacent CH2 groups may be replaced by O and/or S, 1,4-cyclohexylene, naphthalene-2,6-diyl, decahydro- naphthalene-2,6-diyl, 1,2,3,4-tetrahydro-naphthalene- 2,6-diyl, it being possible for all these groups to be unsubstituted, mono-, di-, tri- or tetrasubstituted with F, Cl, CN or alkyl, alkoxy, alkylcarbonyl or
alkoxycarbonyl groups, wherein one or more H atoms may be substituted by F or Cl,
preferably each independently in each occurrence 1,4- phenylene, wherein in addition one or more CH groups may be replaced by N or trans-1,4-cyclo- hexylene in which, in addition, one or two non- adjacent CH2 groups may be replaced by O and/or S, it being possible for both ring groups to be
unsubstituted, mono-, di-, tri- or tetrasubstituted with F, Cl, CN or alkyl, alkoxy, alkylcarbonyl or
alkoxycarbonyl groups, wherein one or more H atoms may be substituted by F or Cl, Z11 are, independently of each other in each occurrence, a single bond, -COO-, -OCO-, -O-CO-O-, -OCH2-, -CH2O-, -OCF2-, -CF2O-, -CH2CH2-, -(CH2)4-, -CF2CF2-, -CH=CH-, -CF=CF-, -CH=CH-COO-, -OCO-CH=CH- or -C ^C-, optionally substituted with one or more of F, S and/or Si,
preferably a single bond, k is 0, 1, 2, 3 or 4, preferably 1, 2 or 3 and, most
preferably 1 or 2. A smaller group of preferred mesogenic groups comprising only 6- membered rings is listed below. For reasons of simplicity, Phe in these groups is 1,4-phenylene, PheL is a 1,4-phenylene group which is substituted by 1 to 4 groups L, with L being preferably F, Cl, CN, OH, NO2 or an optionally fluorinated alkyl, alkoxy or alkanoyl group with 1 to 7 C atoms, very preferably F, Cl, CN, OH, NO2, CH3, C2H5, OCH3, OC2H5, COCH3, COC2H5, COOCH3, COOC2H5, CF3, OCF3, OCHF2, OC2F5, in particular F, Cl, CN, CH3, C2H5, OCH3, COCH3 and OCF3, most preferably F, Cl, CH3, OCH3 and COCH3 and Cyc is 1,4-cyclohexylene. This list comprises the subformulae shown below as well as their mirror images -Phe-Z-Phe- I*-1 -Phe-Z-Cyc- I*-2
-Cyc-Z-Cyc- I*-3 -Phe-Z-PheL- I*-4 -PheL-Z-Phe- I*-5 -PheL-Z-Cyc- I*-6 -PheL-Z-PheL- I*-7 -Phe-Z-Phe-Z-Phe- I*-8 -Phe-Z-Phe-Z-Cyc- I*-9 -Phe-Z-Cyc-Z-Phe- I*-10 -Cyc-Z-Phe-Z-Cyc- I*-11 -Phe-Z-Cyc-Z-Cyc- I*-12 -Cyc-Z-Cyc-Z-Cyc- I*-13 -Phe-Z-Phe-Z-PheL- I*-14 -Phe-Z-PheL-Z-Phe- I*-15 -PheL-Z-Phe-Z-Phe- I*-16 -PheL-Z-Phe-Z-PheL- I*-17 -PheL-Z-PheL-Z-Phe- I*-18 -PheL-Z-PheL-Z-PheL- I*-19 -Phe-Z-PheL-Z-Cyc- I*-20 -Phe-Z-Cyc-Z-PheL- I*-21 -Cyc-Z-Phe-Z-PheL- I*-22 -PheL-Z-Cyc-Z-PheL- I*-23 -PheL-Z-PheL-Z-Cyc- I*-24 -PheL-Z-Cyc-Z-Cyc- I*-25 -Cyc-Z-PheL-Z-Cyc- I*-26 wherein Cyc is 1,4-cyclohexlene, preferably trans-1,4-cyclohexlene, Phe is 1,4-phenylene,
PheL is 1,4-phenylene, which is substituted by one, two or three fluorine atoms, by one or two Cl atoms or by one Cl atom and one F atom and
Z has one of the meanings of Z11 as given under partial formula II and if present twice, at least one is preferably selected from -C≡C-, -C=C-, -COO-, -OCO-, -O-CO-O-, -OCH2-, -CH2O-, -OCF2- or -CF2O-.
Particularly preferred are the sub-formulae I*-1, I*-4, I*-5, I*-7, I*-8, I*-14, I*-15, I*-16, I*-17, I*-18 and I*-19, wherein Z in each case independently has one of the meanings of Z11 as given under formula I and if present twice, preferably one of Z is -COO-, -OCO-, -CH2-O-, -O-CH2-, -CF2-O- or -O-CF2-. In a preferred embodiment the compounds of formula Ia-1 are selected from the following compounds: R11-Phe-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-Phe-R12
Ia-1- 1 R11-Phe-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-Phe-R12
Ia-1- 2 R11-PheL-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-Phe-R12
Ia-1- 3 R11-PheL-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-Phe-R12
Ia-1- 4 R11-PheL-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-PheL-R12
Ia-1- 5 R11-Phe-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-Phe-R12
Ia-1- 6 R11-PheL-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-Phe-R12
Ia-1- 7 R11-PheL-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-PheL-R12
Ia-1- 8 R11-PheL-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-PheL-R12
Ia-1- 9 R11-Phe-Z-Phe-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-Phe-R12
Ia-1- 10 R11-PheL-Z-Phe-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-Phe-R12
Ia-1- 11 R11-Phe-Z-PheL-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-Phe-R12
Ia-1- 12 R11-Phe-Z-Phe-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-Phe-R12
Ia-1- 13 R11-Phe-Z-Phe-Z-Phe-OCF2-(CH2)n-CF2O-PheL-Z-Phe-R12
Ia-1- 14 R11-Phe-Z-Phe-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-PheL-R12
Ia-1- 15 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-Phe-R12
Ia-1- 16 R11-PheL-Z-Phe-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-Phe-R12
Ia-1- 17 R11-PheL-Z-Phe-Z-Phe-OCF2-(CH2)n-CF2O-PheL-Z-Phe-R12
Ia-1- 18 R11-PheL-Z-Phe-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-PheL-R12
Ia-1- 19
R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-Phe-R12
Ia-1- 20 R11-Phe-Z-PheL-Z-Phe-OCF2-(CH2)n-CF2O-PheL-Z-Phe-R12
Ia-1- 21 R11-Phe-Z-PheL-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-PheL-R12
Ia-1- 22 R11-Phe-Z-Phe-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-Phe-R12
Ia-1- 23 R11-Phe-Z-Phe-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-PheL-R12
Ia-1- 24 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-Phe-R12
Ia-1- 25 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-CF2O-PheL-Z-Phe-R12
Ia-1- 26 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-PheL-R12
Ia-1- 27 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-Phe-R12
Ia-1- 28 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-PheL-R12
Ia-1- 29 R11-Phe-Z-Phe-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-PheL-R12
Ia-1- 30 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-Phe-R12
Ia-1- 31 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-PheL-R12
Ia-1- 32 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-CF2O-PheL-Z-PheL-R12
Ia-1- 33 R11-PheL-Z-Phe-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-PheL-R12
Ia-1- 34 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-PheL-R12
Ia-1- 35 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-PheL-R12
Ia-1- 36 R11-Phe-Z-Phe-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-Phe-Z-Phe-R12
Ia-1- 37 R11-PheL-Z-Phe-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-Phe-Z-Phe-R12
Ia-1- 38 R11-Phe-Z-PheL-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-Phe-Z-Phe-R12
Ia-1- 39 R11-Phe-Z-Phe-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-Phe-Z-Phe-R12
Ia-1- 40 R11-Phe-Z-Phe-Z-Phe-OCF2-(CH2)n-CF2O-PheL-Z-Phe-Z-Phe-R12
Ia-1- 41 R11-Phe-Z-Phe-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-PheL-Z-Phe-R12
Ia-1- 42 R11-Phe-Z-Phe-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-Phe-Z-PheL-R12
Ia-1- 43 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-Phe-Z-Phe-R12
Ia-1- 44 R11-PheL-Z-Phe-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-Phe-Z-Phe-R12
Ia-1- 45 R11-PheL-Z-Phe-Z-Phe-OCF2-(CH2)n-CF2O-PheL-Z-Phe-Z-Phe-R12
Ia-1- 46
R11-PheL-Z-Phe-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-PheL-Z-Phe-R12
Ia-1- 47 R11-PheL-Z-Phe-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-Phe-Z-PheL-R12
Ia-1- 48 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-Phe-Z-Phe-R12
Ia-1- 49 R11-Phe-Z-PheL-Z-Phe-OCF2-(CH2)n-CF2O-PheL-Z-Phe-Z-Phe-R12
Ia-1- 50 R11-Phe-Z-PheL-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-PheL-Z-Phe-R12
Ia-1- 51 R11-Phe-Z-Phe-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-Phe-Z-Phe-R12
Ia-1- 52 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-Phe-Z-Phe-R12
Ia-1- 53 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-CF2O-PheL-Z-Phe-Z-Phe-R12
Ia-1- 54 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-PheL-Z-Phe-R12
Ia-1- 55 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-CF2O-Phe-Z-Phe-Z-PheL-R12
Ia-1- 56 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-Phe-Z-Phe-R12
Ia-1- 57 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-PheL-Z-Phe-R12
Ia-1- 58 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-Phe-Z-Phe-R12
Ia-1- 59 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-PheL-Z-Phe-R12
Ia-1- 60 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-Phe-Z-PheL-R12
Ia-1- 61 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-PheL-Z-Phe-R12
Ia-1- 62 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-Phe-Z-PheL-Z-PheL-R12
Ia-1- 63 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-PheL-Z-Phe-R12
Ia-1- 64 R11-PheL-Z-Phe-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-PheL-Z-PheL-R12
Ia-1- 65 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-CF2O-PheL-Z-PheL-Z-PheL-R12
Ia-1- 66 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-CF2O-PheL-Z-PheL-Z-PheL-R12
Ia-1- 67 wherein, R11, R12, Phe, PheL, Z and n have one of the meanings as given above. In a preferred embodiment the compounds of formula Ib-1 are selected from the following compounds: R11-Phe-Z-Phe-(CH2)n-CF2O-Phe-Z-Phe-R12 Ib-1- 1 R11-Phe-Z-PheL-OCF2-(CH2)n-Phe-Z-Phe-R12 Ib-1- 2
R11-PheL-Z-Phe-OCF2-(CH2)n-Phe-Z-Phe-R12 Ib-1- 3 R11-Phe-Z-PheL-(CH2)n-CF2O-Phe-Z-Phe-R12 Ib-1- 4 R11-PheL-Z-Phe-(CH2)n-CF2O-Phe-Z-Phe-R12 Ib-1- 5 R11-PheL-Z-PheL-OCF2-(CH2)n-Phe-Z-Phe-R12 Ib-1- 6 R11-PheL-Z-Phe-OCF2-(CH2)n-Phe-Z-PheL-R12 Ib-1- 7 R11-Phe-Z-PheL-OCF2-(CH2)n-PheL-Z-Phe-R12 Ib-1- 8 R11-PheL-Z-PheL-(CH2)n-CF2O-Phe-Z-Phe-R12 Ib-1- 9 R11-PheL-Z-Phe-(CH2)n-CF2O-Phe-Z-PheL-R12 Ib-1- 10 R11-Phe-Z-PheL-(CH2)n-CF2O-PheL-Z-Phe-R12 Ib-1- 11 R11-PheL-Z-PheL-OCF2-(CH2)n-PheL-Z-Phe-R12 Ib-1- 12 R11-PheL-Z-PheL-OCF2-(CH2)n-Phe-Z-PheL-R12 Ib-1- 13 R11-PheL-Z-PheL-(CH2)n-CF2O-PheL-Z-Phe-R12 Ib-1- 14 R11-PheL-Z-PheL-(CH2)n-CF2O-Phe-Z-PheL-R12 Ib-1- 15 R11-PheL-Z-PheL-OCF2-(CH2)n-PheL-Z-PheL-R12 Ib-1- 16 R11-Phe-Z-Phe-Z-Phe-(CH2)n-CF2O-Phe-Z-Phe-R12 Ib-1- 17 R11-Phe-Z-Phe-Z-Phe-OCF2-(CH2)n-Phe-Z-Phe-R12 Ib-1- 18 R11-PheL-Z-Phe-Z-Phe-OCF2-(CH2)n-Phe-Z-Phe-R12 Ib-1- 19 R11-Phe-Z-PheL-Z-Phe-OCF2-(CH2)n-Phe-Z-Phe-R12 Ib-1- 20 R11-Phe-Z-Phe-Z-PheL-OCF2-(CH2)n-Phe-Z-Phe-R12 Ib-1- 21 R11-Phe-Z-Phe-Z-Phe-OCF2-(CH2)n-PheL-Z-Phe-R12 Ib-1- 22 R11-Phe-Z-Phe-Z-Phe-OCF2-(CH2)n-Phe-Z-PheL-R12 Ib-1- 23 R11-PheL-Z-Phe-Z-Phe-(CH2)n-CF2O-Phe-Z-Phe-R12 Ib-1- 24 R11-Phe-Z-PheL-Z-Phe-(CH2)n-CF2O-Phe-Z-Phe-R12 Ib-1- 25 R11-Phe-Z-Phe-Z-PheL-(CH2)n-CF2O-Phe-Z-Phe-R12 Ib-1- 26
R11-Phe-Z-Phe-Z-Phe-(CH2)n-CF2O-PheL-Z-Phe-R12 Ib-1- 27 R11-Phe-Z-Phe-Z-Phe-(CH2)n-CF2O-Phe-Z-PheL-R12 Ib-1- 28 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-Phe-Z-Phe-R12 Ib-1- 29 R11-PheL-Z-Phe-Z-PheL-OCF2-(CH2)n-Phe-Z-Phe-R12 Ib-1- 30 R11-PheL-Z-Phe-Z-Phe-OCF2-(CH2)n-PheL-Z-Phe-R12 Ib-1- 31 R11-PheL-Z-Phe-Z-Phe-OCF2-(CH2)n-Phe-Z-PheL-R12 Ib-1- 32 R11-PheL-Z-PheL-Z-Phe-(CH2)n-CF2O-Phe-Z-Phe-R12 Ib-1- 33 R11-PheL-Z-Phe-Z-PheL-(CH2)n-CF2O-Phe-Z-Phe-R12 Ib-1- 34 R11-PheL-Z-Phe-Z-Phe-(CH2)n-CF2O-PheL-Z-Phe-R12 Ib-1- 35 R11-PheL-Z-Phe-Z-Phe-(CH2)n-CF2O-Phe-Z-PheL-R12 Ib-1- 36 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-Phe-Z-Phe-R12 Ib-1- 37 R11-Phe-Z-PheL-Z-Phe-OCF2-(CH2)n-PheL-Z-Phe-R12 Ib-1- 38 R11-Phe-Z-PheL-Z-Phe-OCF2-(CH2)n-Phe-Z-PheL-R12 Ib-1- 39 R11-Phe-Z-Phe-Z-PheL-OCF2-(CH2)n-PheL-Z-Phe-R12 Ib-1- 40 R11-Phe-Z-Phe-Z-PheL-OCF2-(CH2)n-Phe-Z-PheL-R12 Ib-1- 41 R11-Phe-Z-PheL-Z-PheL(CH2)n-CF2O-Phe-Z-Phe-R12 Ib-1- 42 R11-Phe-Z-PheL-Z-Phe-(CH2)n-CF2O-PheL-Z-Phe-R12 Ib-1- 43 R11-Phe-Z-PheL-Z-Phe-(CH2)n-CF2O-Phe-Z-PheL-R12 Ib-1- 44 R11-Phe-Z-Phe-Z-PheL-(CH2)n-CF2O-PheL-Z-Phe-R12 Ib-1- 45 R11-Phe-Z-Phe-Z-PheL-(CH2)n-CF2O-Phe-Z-PheL-R12 Ib-1- 46 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-Phe-Z-Phe-R12 Ib-1- 47 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-PheL-Z-Phe-R12 Ib-1- 48 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-Phe-Z-PheL-R12 Ib-1- 49 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-PheL-Z-Phe-R12 Ib-1- 50 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-Phe-Z-PheL-R12 Ib-1- 51 R11-Phe-Z-Phe-Z-PheL-OCF2-(CH2)n-PheL-Z-PheL-R12 Ib-1- 52 R11-PheL-Z-PheL-Z-PheL-(CH2)n-CF2O-Phe-Z-Phe-R12 Ib-1- 53
R11-PheL-Z-PheL-Z-Phe-(CH2)n-CF2O-PheL-Z-Phe-R12 Ib-1- 54 R11-PheL-Z-PheL-Z-Phe-(CH2)n-CF2O-Phe-Z-PheL-R12 Ib-1- 55 R11-Phe-Z-PheL-Z-PheL-(CH2)n-CF2O-PheL-Z-Phe-R12 Ib-1- 56 R11-Phe-Z-PheL-Z-PheL-(CH2)n-CF2O-Phe-Z-PheL-R12 Ib-1- 57 R11-Phe-Z-Phe-Z-PheL-(CH2)n-CF2O-PheL-Z-PheL-R12 Ib-1- 58 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-PheL-Z-Phe-R12 Ib-1- 59 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-Phe-Z-PheL-R12 Ib-1- 60 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-PheL-Z-PheL-R12 Ib-1- 61 R11-PheL-Z-Phe-Z-PheL-OCF2-(CH2)n-PheL-Z-PheL-R12 Ib-1- 62 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-PheL-Z-PheL-R12 Ib-1- 63 R11-PheL-Z-PheL-Z-PheL-(CH2)n-CF2O-PheL-Z-Phe-R12 Ib-1- 64 R11-PheL-Z-PheL-Z-PheL-(CH2)n-CF2O-Phe-Z-PheL-R12 Ib-1- 65 R11-PheL-Z-PheL-Z-Phe-(CH2)n-CF2O-PheL-Z-PheL-R12 Ib-1- 66 R11-PheL-Z-Phe-Z-PheL-(CH2)n-CF2O-PheL-Z-PheL-R12 Ib-1- 67 R11-Phe-Z-PheL-Z-PheL-(CH2)n-CF2O-PheL-Z-PheL-R12 Ib-1- 68 R11-PheL-Z-PheL-Z-PheL-(CH2)n-CF2O-PheL-Z-PheL-R12 Ib-1- 69 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)nPheL-Z-PheL-R12 Ib-1- 70 R11-Phe-Z-Phe-Z-Phe-OCF2-(CH2)n-Phe-Z-Phe-Z-Phe-R12 Ib-1- 71 R11-PheL-Z-Phe-Z-Phe-(CH2)n-CF2O-Phe-Z-Phe-Z-Phe-R12 Ib-1- 72 R11-Phe-Z-PheL-Z-Phe-(CH2)n-CF2O-Phe-Z-Phe-Z-Phe-R12 Ib-1- 73 R11-Phe-Z-Phe-Z-PheL-(CH2)n-CF2O-Phe-Z-Phe-Z-Phe-R12 Ib-1- 74 R11-Phe-Z-Phe-Z-Phe-(CH2)n-CF2O-PheL-Z-Phe-Z-Phe-R12 Ib-1- 75 R11-Phe-Z-Phe-Z-Phe-(CH2)n-CF2O-Phe-Z-PheL-Z-Phe-R12 Ib-1- 76 R11-Phe-Z-Phe-Z-Phe-(CH2)n-CF2O-Phe-Z-Phe-Z-PheL-R12 Ib-1- 77 R11-PheL-Z-Phe-Z-Phe-OCF2-(CH2)n-Phe-Z-Phe-Z-Phe-R12 Ib-1- 78 R11-Phe-Z-PheL-Z-Phe-OCF2-(CH2)n-Phe-Z-Phe-Z-Phe-R12 Ib-1- 79 R11-Phe-Z-Phe-Z-PheL-OCF2-(CH2)n-Phe-Z-Phe-Z-Phe-R12 Ib-1- 80
R11-Phe-Z-Phe-Z-Phe-OCF2-(CH2)n-PheL-Z-Phe-Z-Phe-R12 Ib-1- 81 R11-Phe-Z-Phe-Z-Phe-OCF2-(CH2)n-Phe-Z-PheL-Z-Phe-R12 Ib-1- 82 R11-Phe-Z-Phe-Z-Phe-OCF2-(CH2)n-Phe-Z-Phe-Z-PheL-R12 Ib-1- 83 R11-PheL-Z-PheL-Z-Phe-(CH2)n-CF2O-Phe-Z-Phe-Z-Phe-R12 Ib-1- 84 R11-PheL-Z-Phe-Z-PheL-(CH2)n-CF2O-Phe-Z-Phe-Z-Phe-R12 Ib-1- 85 R11-PheL-Z-Phe-Z-Phe-(CH2)n-CF2O-PheL-Z-Phe-Z-Phe-R12 Ib-1- 86 R11-PheL-Z-Phe-Z-Phe-(CH2)n-CF2O-Phe-Z-PheL-Z-Phe-R12 Ib-1- 87 R11-PheL-Z-Phe-Z-Phe-(CH2)n-CF2O-Phe-Z-Phe-Z-PheL-R12 Ib-1- 88 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-Phe-Z-Phe-Z-Phe-R12 Ib-1- 89 R11-PheL-Z-Phe-Z-PheL-OCF2-(CH2)n-Phe-Z-Phe-Z-Phe-R12 Ib-1- 90 R11-PheL-Z-Phe-Z-Phe-OCF2-(CH2)n-PheL-Z-Phe-Z-Phe-R12 Ib-1- 91 R11-PheL-Z-Phe-Z-Phe-OCF2-(CH2)n-Phe-Z-PheL-Z-Phe-R12 Ib-1- 92 R11-PheL-Z-Phe-Z-Phe-OCF2-(CH2)n-Phe-Z-Phe-Z-PheL-R12 Ib-1- 93 R11-Phe-Z-PheL-Z-PheL-(CH2)n-CF2O-Phe-Z-Phe-Z-Phe-R12 Ib-1- 94 R11-Phe-Z-PheL-Z-Phe-(CH2)n-CF2O-PheL-Z-Phe-Z-Phe-R12 Ib-1- 95 R11-Phe-Z-PheL-Z-Phe-(CH2)n-CF2O-Phe-Z-PheL-Z-Phe-R12 Ib-1- 96 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-Phe-Z-Phe-Z-Phe-R12 Ib-1- 97 R11-Phe-Z-PheL-Z-Phe-OCF2-(CH2)n-PheL-Z-Phe-Z-Phe-R12 Ib-1- 98 R11-Phe-Z-PheL-Z-Phe-OCF2-(CH2)n-Phe-Z-PheL-Z-Phe-R12 Ib-1- 99 R11-Phe-Z-Phe-Z-PheL-OCF2-(CH2)n-PheL-Z-Phe-Z-Phe-R12 Ib-1- 100 R11-PheL-Z-PheL-Z-PheL-(CH2)n-CF2O-Phe-Z-Phe-Z-Phe-R12 Ib-1- 101 R11-PheL-Z-PheL-Z-Phe-(CH2)n-CF2O-PheL-Z-Phe-Z-Phe-R12 Ib-1- 102 R11-PheL-Z-PheL-Z-Phe-(CH2)n-CF2O-Phe-Z-PheL-Z-Phe-R12 Ib-1- 103 R11-PheL-Z-PheL-Z-Phe-(CH2)n-CF2O-Phe-Z-Phe-Z-PheL-R12 Ib-1- 104 R11-Phe-Z-PheL-Z-PheL-(CH2)n-CF2O-PheL-Z-Phe-Z-Phe-R12 Ib-1- 105 R11-Phe-Z-PheL-Z-PheL-(CH2)n-CF2O-Phe-Z-PheL-Z-Phe-R12 Ib-1- 106 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-Phe-Z-Phe-Z-Phe-R12 Ib-1- 107
R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-PheL-Z-Phe-Z-Phe-R12 Ib-1- 108 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-Phe-Z-PheL-Z-Phe-R12 Ib-1- 109 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-Phe-Z-Phe-Z-PheL-R12 Ib-1- 110 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-PheL-Z-Phe-Z-Phe-R12 Ib-1- 111 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-Phe-Z-PheL-Z-Phe-R12 Ib-1- 112 R11-PheL-Z-PheL-Z-PheL-(CH2)n-CF2O-PheL-Z-Phe-Z-Phe-R12 Ib-1- 113 R11-PheL-Z-PheL-Z-PheL-(CH2)n-CF2O-Phe-Z-PheL-Z-Phe-R12 Ib-1- 114 R11-PheL-Z-PheL-Z-PheL-(CH2)n-CF2O-Phe-Z-Phe-Z-PheL-R12 Ib-1- 115 R11-Phe-Z-PheL-Z-PheL-(CH2)n-CF2O-PheL-Z-PheL-Z-Phe-R12 Ib-1- 116 R11-Phe-Z-PheL-Z-PheL-(CH2)n-CF2O-Phe-Z-PheL-Z-PheL-R12 Ib-1- 117 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-PheL-Z-Phe-Z-Phe-R12 Ib-1- 118 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-Phe-Z-PheL-Z-Phe-R12 Ib-1- 119 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-Phe-Z-Phe-Z-PheL-R12 Ib-1- 120 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-PheL-Z-PheL-Z-Phe-R12 Ib-1- 121 R11-Phe-Z-PheL-Z-PheL-OCF2-(CH2)n-Phe-Z-PheL-Z-PheL-R12 Ib-1- 122 R11-PheL-Z-PheL-Z-PheL-(CH2)n-CF2O-PheL-Z-PheL-Z-Phe-R12 Ib-1- 123 R11-PheL-Z-Phe-Z-PheL-(CH2)n-CF2O-PheL-Z-PheL-Z-PheL-R12 Ib-1- 124 R11-PheL-Z-PheL-Z-Phe-(CH2)n-CF2O-PheL-Z-PheL-Z-PheL-R12 Ib-1- 125 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-PheL-Z-PheL-Z-Phe-R12 Ib-1- 126 R11-PheL-Z-Phe-Z-PheL-OCF2-(CH2)n-PheL-Z-PheL-Z-PheL-R12 Ib-1- 127 R11-PheL-Z-PheL-Z-Phe-OCF2-(CH2)n-PheL-Z-PheL-Z-PheL-R12 Ib-1- 128 R11-PheL-Z-PheL-Z-PheL-OCF2-(CH2)n-PheL-Z-PheL-Z-PheL-R12 Ib-1- 129 wherein, R11, R12, Phe, PheL, Z and n have one of the meanings as given above. Further preferred compounds of formula Ia-1 are selected from the group of compounds with the following formulae: R11-Phe-Phe-OCF2-(CH2)n-CF2O-Phe-Phe-R12
Ia-1- 1 a
R11-Phe-PheL-OCF2-(CH2)n-CF2O-Phe-Phe-R12
Ia-1- 2 a R11-PheL-Phe-OCF2-(CH2)n-CF2O-Phe-Phe-R12
Ia-1- 3 a R11-PheL-PheL-OCF2-(CH2)n-CF2O-Phe-Phe-R12
Ia-1- 4 a R11-PheL-Phe-OCF2-(CH2)n-CF2O-Phe-PheL-R12
Ia-1- 5 a R11-Phe-PheL-OCF2-(CH2)n-CF2O-PheL-Phe-R12
Ia-1- 6 a R11-PheL-PheL-OCF2-(CH2)n-CF2O-PheL-Phe-R12
Ia-1- 7 a R11-PheL-PheL-OCF2-(CH2)n-CF2O-Phe-PheL-R12
Ia-1- 8 a R11-PheL-PheL-OCF2-(CH2)n-CF2O-PheL-PheL-R12
Ia-1- 9 a R11-Phe-Phe-Phe-OCF2-(CH2)n-CF2O-Phe-Phe-R12
Ia-1- 10 a R11-PheL-Phe-Phe-OCF2-(CH2)n-CF2O-Phe-Phe-R12
Ia-1- 11 a R11-Phe-PheL-Phe-OCF2-(CH2)n-CF2O-Phe-Phe-R12
Ia-1- 12 a R11-Phe-Phe-PheL-OCF2-(CH2)n-CF2O-Phe-Phe-R12
Ia-1- 13 a R11-Phe-Phe-Phe-OCF2-(CH2)n-CF2O-PheL-Phe-R12
Ia-1- 14 a R11-Phe-Phe-Phe-OCF2-(CH2)n-CF2O-Phe-PheL-R12
Ia-1- 15 a R11-PheL-PheL-Phe-OCF2-(CH2)n-CF2O-Phe-Phe-R12
Ia-1- 16 a R11-PheL-Phe-PheL-OCF2-(CH2)n-CF2O-Phe-Phe-R12
Ia-1- 17 a R11-PheL-Phe-Phe-OCF2-(CH2)n-CF2O-PheL-Phe-R12
Ia-1- 18 a R11-PheL-Phe-Phe-OCF2-(CH2)n-CF2O-Phe-PheL-R12
Ia-1- 19 a R11-Phe-PheL-PheL-OCF2-(CH2)n-CF2O-Phe-Phe-R12
Ia-1- 20 a R11-Phe-PheL-Phe-OCF2-(CH2)n-CF2O-PheL-Phe-R12
Ia-1- 21 a R11-Phe-PheL-Phe-OCF2-(CH2)n-CF2O-Phe-PheL-R12
Ia-1- 22 a R11-Phe-Phe-PheL-OCF2-(CH2)n-CF2O-PheL-Phe-R12
Ia-1- 23 a R11-Phe-Phe-PheL-OCF2-(CH2)n-CF2O-Phe-PheL-R12
Ia-1- 24 a R11-PheL-PheL-PheL-OCF2-(CH2)n-CF2O-Phe-Phe-R12
Ia-1- 25 a R11-PheL-PheL-Phe-OCF2-(CH2)n-CF2O-PheL-Phe-R12
Ia-1- 26 a R11-PheL-PheL-Phe-OCF2-(CH2)n-CF2O-Phe-PheL-R12
Ia-1- 27 a
R11-Phe-PheL-PheL-OCF2-(CH2)n-CF2O-PheL-Phe-R12
Ia-1- 28 a R11-Phe-PheL-PheL-OCF2-(CH2)n-CF2O-Phe-PheL-R12
Ia-1- 29 a R11-Phe-Phe-PheL-OCF2-(CH2)n-CF2O-PheL-PheL-R12
Ia-1- 30 a R11-PheL-PheL-PheL-OCF2-(CH2)n-CF2O-PheL-Phe-R12
Ia-1- 31 a R11-PheL-PheL-PheL-OCF2-(CH2)n-CF2O-Phe-PheL-R12
Ia-1- 32 a R11-PheL-PheL-Phe-OCF2-(CH2)n-CF2O-PheL-PheL-R12
Ia-1- 33 a R11-PheL-Phe-PheL-OCF2-(CH2)n-CF2O-PheL-PheL-R12
Ia-1- 34 a R11-Phe-PheL-PheL-OCF2-(CH2)n-CF2O-PheL-PheL-R12
Ia-1- 35 a R11-PheL-PheL-PheL-OCF2-(CH2)n-CF2O-PheL-PheL-R12
Ia-1- 36 a R11-Phe-Phe-Phe-OCF2-(CH2)n-CF2O-Phe-Phe-Phe-R12
Ia-1- 37 a R11-PheL-Phe-Phe-OCF2-(CH2)n-CF2O-Phe-Phe-Phe-R12
Ia-1- 38 a R11-Phe-PheL-Phe-OCF2-(CH2)n-CF2O-Phe-Phe-Phe-R12
Ia-1- 39 a R11-Phe-Phe-PheL-OCF2-(CH2)n-CF2O-Phe-Phe-Phe-R12
Ia-1- 40 a R11-Phe-Phe-Phe-OCF2-(CH2)n-CF2O-PheL-Phe-Phe-R12
Ia-1- 41 a R11-Phe-Phe-Phe-OCF2-(CH2)n-CF2O-Phe-PheL-Phe-R12
Ia-1- 42 a R11-Phe-Phe-Phe-OCF2-(CH2)n-CF2O-Phe-Phe-PheL-R12
Ia-1- 43 a R11-PheL-PheL-Phe-OCF2-(CH2)n-CF2O-Phe-Phe-Phe-R12
Ia-1- 44 a R11-PheL-Phe-PheL-OCF2-(CH2)n-CF2O-Phe-Phe-Phe-R12
Ia-1- 45 a R11-PheL-Phe-Phe-OCF2-(CH2)n-CF2O-PheL-Phe-Phe-R12
Ia-1- 46 a R11-PheL-Phe-Phe-OCF2-(CH2)n-CF2O-Phe-PheL-Phe-R12
Ia-1- 47 a R11-PheL-Phe-Phe-OCF2-(CH2)n-CF2O-Phe-Phe-PheL-R12
Ia-1- 48 a R11-Phe-PheL-PheL-OCF2-(CH2)n-CF2O-Phe-Phe-Phe-R12
Ia-1- 49 a R11-Phe-PheL-Phe-OCF2-(CH2)n-CF2O-PheL-Phe-Phe-R12
Ia-1- 50 a R11-Phe-PheL-Phe-OCF2-(CH2)n-CF2O-Phe-PheL-Phe-R12
Ia-1- 51 a R11-Phe-Phe-PheL-OCF2-(CH2)n-CF2O-PheL-Phe-Phe-R12
Ia-1- 52 a R11-PheL-PheL-PheL-OCF2-(CH2)n-CF2O-Phe-Phe-Phe-R12
Ia-1- 53 a R11-PheL-PheL-Phe-OCF2-(CH2)n-CF2O-PheL-Phe-Phe-R12
Ia-1- 54 a
R11-PheL-PheL-Phe-OCF2-(CH2)n-CF2O-Phe-PheL-Phe-R12
Ia-1- 55 a R11-PheL-PheL-Phe-OCF2-(CH2)n-CF2O-Phe-Phe-PheL-R12
Ia-1- 56 a R11-Phe-PheL-PheL-OCF2-(CH2)n-CF2O-PheL-Phe-Phe-R12
Ia-1- 57 a R11-Phe-PheL-PheL-OCF2-(CH2)n-CF2O-Phe-PheL-Phe-R12
Ia-1- 58 a R11-PheL-PheL-PheL-OCF2-(CH2)n-CF2O-PheL-Phe-Phe-R12
Ia-1- 59 a R11-PheL-PheL-PheL-OCF2-(CH2)n-CF2O-Phe-PheL-Phe-R12
Ia-1- 60 a R11-PheL-PheL-PheL-OCF2-(CH2)n-CF2O-Phe-Phe-PheL-R12
Ia-1- 61 a R11-Phe-PheL-PheL-OCF2-(CH2)n-CF2O-PheL-PheL-Phe-R12
Ia-1- 62 a R11-Phe-PheL-PheL-OCF2-(CH2)n-CF2O-Phe-PheL-PheL-R12
Ia-1- 63 a R11-PheL-PheL-PheL-OCF2-(CH2)n-CF2O-PheL-PheL-Phe-R12
Ia-1- 64 a R11-PheL-Phe-PheL-OCF2-(CH2)n-CF2O-PheL-PheL-PheL-R12
Ia-1- 65 a R11-PheL-PheL-Phe-OCF2-(CH2)n-CF2O-PheL-PheL-PheL-R12
Ia-1- 66 a R11-PheL-PheL-PheL-OCF2-(CH2)n-CF2O-PheL-PheL-PheL-R12
Ia-1- 67 a wherein, R11, R12, Phe and PheL have one of the meanings as given above and n denotes 5, 7, 9 or 11. Further preferred compounds of formula Ib-1 are selected from the following compounds: R11-Phe-Phe-(CH2)n-CF2O-Phe-Phe-R12 Ib-1- 1 a R11-Phe-PheL-OCF2-(CH2)n-Phe-Phe-R12 Ib-1- 2 a R11-PheL-Phe-OCF2-(CH2)n-Phe-Phe-R12 Ib-1- 3 a R11-Phe-PheL-(CH2)n-CF2O-Phe-Phe-R12 Ib-1- 4 a R11-PheL-Phe-(CH2)n-CF2O-Phe-Phe-R12 Ib-1- 5 a R11-PheL-PheL-OCF2-(CH2)n-Phe-Phe-R12 Ib-1- 6 a R11-PheL-Phe-OCF2-(CH2)n-Phe-PheL-R12 Ib-1- 7 a R11-Phe-PheL-OCF2-(CH2)n-PheL-Phe-R12 Ib-1- 8 a
R11-PheL-PheL-(CH2)n-CF2O-Phe-Phe-R12 Ib-1- 9 a R11-PheL-Phe-(CH2)n-CF2O-Phe-PheL-R12 Ib-1- 10 a R11-Phe-PheL-(CH2)n-CF2O-PheL-Phe-R12 Ib-1- 11 a R11-PheL-PheL-OCF2-(CH2)n-PheL-Phe-R12 Ib-1- 12 a R11-PheL-PheL-OCF2-(CH2)n-Phe-PheL-R12 Ib-1- 13 a R11-PheL-PheL-(CH2)n-CF2O-PheL-Phe-R12 Ib-1- 14 a R11-PheL-PheL-(CH2)n-CF2O-Phe-PheL-R12 Ib-1- 15 a R11-PheL-PheL-OCF2-(CH2)n-PheL-PheL-R12 Ib-1- 16 a R11-Phe-Phe-Phe-(CH2)n-CF2O-Phe-Phe-R12 Ib-1- 17 a R11-Phe-Phe-Phe-OCF2-(CH2)n-Phe-Phe-R12 Ib-1- 18 a R11-PheL-Phe-Phe-OCF2-(CH2)n-Phe-Phe-R12 Ib-1- 19 a R11-Phe-PheL-Phe-OCF2-(CH2)n-Phe-Phe-R12 Ib-1- 20 a R11-Phe-Phe-PheL-OCF2-(CH2)n-Phe-Phe-R12 Ib-1- 21 a R11-Phe-Phe-Phe-OCF2-(CH2)n-PheL-Phe-R12 Ib-1- 22 a R11-Phe-Phe-Phe-OCF2-(CH2)n-Phe-PheL-R12 Ib-1- 23 a R11-PheL-Phe-Phe-(CH2)n-CF2O-Phe-Phe-R12 Ib-1- 24 a R11-Phe-PheL-Phe-(CH2)n-CF2O-Phe-Phe-R12 Ib-1- 25 a R11-Phe-Phe-PheL-(CH2)n-CF2O-Phe-Phe-R12 Ib-1- 26 a R11-Phe-Phe-Phe-(CH2)n-CF2O-PheL-Phe-R12 Ib-1- 27 a R11-Phe-Phe-Phe-(CH2)n-CF2O-Phe-PheL-R12 Ib-1- 28 a R11-PheL-PheL-Phe-OCF2-(CH2)n-Phe-Phe-R12 Ib-1- 29 a R11-PheL-Phe-PheL-OCF2-(CH2)n-Phe-Phe-R12 Ib-1- 30 a R11-PheL-Phe-Phe-OCF2-(CH2)n-PheL-Phe-R12 Ib-1- 31 a R11-PheL-Phe-Phe-OCF2-(CH2)n-Phe-PheL-R12 Ib-1- 32 a R11-PheL-PheL-Phe-(CH2)n-CF2O-Phe-Phe-R12 Ib-1- 33 a
R11-PheL-Phe-PheL-(CH2)n-CF2O-Phe-Phe-R12 Ib-1- 34 a R11-PheL-Phe-Phe-(CH2)n-CF2O-PheL-Phe-R12 Ib-1- 35 a R11-PheL-Phe-Phe-(CH2)n-CF2O-Phe-PheL-R12 Ib-1- 36 a R11-Phe-PheL-PheL-OCF2-(CH2)n-Phe-Phe-R12 Ib-1- 37 a R11-Phe-PheL-Phe-OCF2-(CH2)n-PheL-Phe-R12 Ib-1- 38 a R11-Phe-PheL-Phe-OCF2-(CH2)n-Phe-PheL-R12 Ib-1- 39 a R11-Phe-Phe-PheL-OCF2-(CH2)n-PheL-Phe-R12 Ib-1- 40 a R11-Phe-Phe-PheL-OCF2-(CH2)n-Phe-PheL-R12 Ib-1- 41 a R11-Phe-PheL-PheL(CH2)n-CF2O-Phe-Phe-R12 Ib-1- 42 a R11-Phe-PheL-Phe-(CH2)n-CF2O-PheL-Phe-R12 Ib-1- 43 a R11-Phe-PheL-Phe-(CH2)n-CF2O-Phe-PheL-R12 Ib-1- 44 a R11-Phe-Phe-PheL-(CH2)n-CF2O-PheL-Phe-R12 Ib-1- 45 a R11-Phe-Phe-PheL-(CH2)n-CF2O-Phe-PheL-R12 Ib-1- 46 a R11-PheL-PheL-PheL-OCF2-(CH2)n-Phe-Phe-R12 Ib-1- 47 a R11-PheL-PheL-Phe-OCF2-(CH2)n-PheL-Phe-R12 Ib-1- 48 a R11-PheL-PheL-Phe-OCF2-(CH2)n-Phe-PheL-R12 Ib-1- 49 a R11-Phe-PheL-PheL-OCF2-(CH2)n-PheL-Phe-R12 Ib-1- 50 a R11-Phe-PheL-PheL-OCF2-(CH2)n-Phe-PheL-R12 Ib-1- 51 a R11-Phe-Phe-PheL-OCF2-(CH2)n-PheL-PheL-R12 Ib-1- 52 a R11-PheL-PheL-PheL-(CH2)n-CF2O-Phe-Phe-R12 Ib-1- 53 a R11-PheL-PheL-Phe-(CH2)n-CF2O-PheL-Phe-R12 Ib-1- 54 a R11-PheL-PheL-Phe-(CH2)n-CF2O-Phe-PheL-R12 Ib-1- 55 a R11-Phe-PheL-PheL-(CH2)n-CF2O-PheL-Phe-R12 Ib-1- 56 a R11-Phe-PheL-PheL-(CH2)n-CF2O-Phe-PheL-R12 Ib-1- 57 a R11-Phe-Phe-PheL-(CH2)n-CF2O-PheL-PheL-R12 Ib-1- 58 a R11-PheL-PheL-PheL-OCF2-(CH2)n-PheL-Phe-R12 Ib-1- 59 a R11-PheL-PheL-PheL-OCF2-(CH2)n-Phe-PheL-R12 Ib-1- 60 a R11-PheL-PheL-Phe-OCF2-(CH2)n-PheL-PheL-R12 Ib-1- 61 a
R11-PheL-Phe-PheL-OCF2-(CH2)n-PheL-PheL-R12 Ib-1- 62 a R11-Phe-PheL-PheL-OCF2-(CH2)n-PheL-PheL-R12 Ib-1- 63 a R11-PheL-PheL-PheL-(CH2)n-CF2O-PheL-Phe-R12 Ib-1- 64 a R11-PheL-PheL-PheL-(CH2)n-CF2O-Phe-PheL-R12 Ib-1- 65 a R11-PheL-PheL-Phe-(CH2)n-CF2O-PheL-PheL-R12 Ib-1- 66 a R11-PheL-Phe-PheL-(CH2)n-CF2O-PheL-PheL-R12 Ib-1- 67 a R11-Phe-PheL-PheL-(CH2)n-CF2O-PheL-PheL-R12 Ib-1- 68 a R11-PheL-PheL-PheL-(CH2)n-CF2O-PheL-PheL-R12 Ib-1- 69 a R11-PheL-PheL-PheL-OCF2-(CH2)nPheL-PheL-R12 Ib-1- 70 a R11-Phe-Phe-Phe-OCF2-(CH2)n-Phe-Phe-Phe-R12 Ib-1- 71 a R11-PheL-Phe-Phe-(CH2)n-CF2O-Phe-Phe-Phe-R12 Ib-1- 72 a R11-Phe-PheL-Phe-(CH2)n-CF2O-Phe-Phe-Phe-R12 Ib-1- 73 a R11-Phe-Phe-PheL-(CH2)n-CF2O-Phe-Phe-Phe-R12 Ib-1- 74 a R11-Phe-Phe-Phe-(CH2)n-CF2O-PheL-Phe-Phe-R12 Ib-1- 75 a R11-Phe-Phe-Phe-(CH2)n-CF2O-Phe-PheL-Phe-R12 Ib-1- 76 a R11-Phe-Phe-Phe-(CH2)n-CF2O-Phe-Phe-PheL-R12 Ib-1- 77 a R11-PheL-Phe-Phe-OCF2-(CH2)n-Phe-Phe-Phe-R12 Ib-1- 78 a R11-Phe-PheL-Phe-OCF2-(CH2)n-Phe-Phe-Phe-R12 Ib-1- 79 a R11-Phe-Phe-PheL-OCF2-(CH2)n-Phe-Phe-Phe-R12 Ib-1- 80 a R11-Phe-Phe-Phe-OCF2-(CH2)n-PheL-Phe-Phe-R12 Ib-1- 81 a R11-Phe-Phe-Phe-OCF2-(CH2)n-Phe-PheL-Phe-R12 Ib-1- 82 a R11-Phe-Phe-Phe-OCF2-(CH2)n-Phe-Phe-PheL-R12 Ib-1- 83 a R11-PheL-PheL-Phe-(CH2)n-CF2O-Phe-Phe-Phe-R12 Ib-1- 84 a R11-PheL-Phe-PheL-(CH2)n-CF2O-Phe-Phe-Phe-R12 Ib-1- 85 a R11-PheL-Phe-Phe-(CH2)n-CF2O-PheL-Phe-Phe-R12 Ib-1- 86 a R11-PheL-Phe-Phe-(CH2)n-CF2O-Phe-PheL-Phe-R12 Ib-1- 87 a R11-PheL-Phe-Phe-(CH2)n-CF2O-Phe-Phe-PheL-R12 Ib-1- 88 a
R11-PheL-PheL-Phe-OCF2-(CH2)n-Phe-Phe-Phe-R12 Ib-1- 89 a R11-PheL-Phe-PheL-OCF2-(CH2)n-Phe-Phe-Phe-R12 Ib-1- 90 a R11-PheL-Phe-Phe-OCF2-(CH2)n-PheL-Phe-Phe-R12 Ib-1- 91 a R11-PheL-Phe-Phe-OCF2-(CH2)n-Phe-PheL-Phe-R12 Ib-1- 92 a R11-PheL-Phe-Phe-OCF2-(CH2)n-Phe-Phe-PheL-R12 Ib-1- 93 a R11-Phe-PheL-PheL-(CH2)n-CF2O-Phe-Phe-Phe-R12 Ib-1- 94 a R11-Phe-PheL-Phe-(CH2)n-CF2O-PheL-Phe-Phe-R12 Ib-1- 95 a R11-Phe-PheL-Phe-(CH2)n-CF2O-Phe-PheL-Phe-R12 Ib-1- 96 a R11-Phe-PheL-PheL-OCF2-(CH2)n-Phe-Phe-Phe-R12 Ib-1- 97 a R11-Phe-PheL-Phe-OCF2-(CH2)n-PheL-Phe-Phe-R12 Ib-1- 98 a R11-Phe-PheL-Phe-OCF2-(CH2)n-Phe-PheL-Phe-R12 Ib-1- 99 a R11-Phe-Phe-PheL-OCF2-(CH2)n-PheL-Phe-Phe-R12 Ib-1- 100 a R11-PheL-PheL-PheL-(CH2)n-CF2O-Phe-Phe-Phe-R12 Ib-1- 101 a R11-PheL-PheL-Phe-(CH2)n-CF2O-PheL-Phe-Phe-R12 Ib-1- 102 a R11-PheL-PheL-Phe-(CH2)n-CF2O-Phe-PheL-Phe-R12 Ib-1- 103 a R11-PheL-PheL-Phe-(CH2)n-CF2O-Phe-Phe-PheL-R12 Ib-1- 104 a R11-Phe-PheL-PheL-(CH2)n-CF2O-PheL-Phe-Phe-R12 Ib-1- 105 a R11-Phe-PheL-PheL-(CH2)n-CF2O-Phe-PheL-Phe-R12 Ib-1- 106 a R11-PheL-PheL-PheL-OCF2-(CH2)n-Phe-Phe-Phe-R12 Ib-1- 107 a R11-PheL-PheL-Phe-OCF2-(CH2)n-PheL-Phe-Phe-R12 Ib-1- 108 a R11-PheL-PheL-Phe-OCF2-(CH2)n-Phe-PheL-Phe-R12 Ib-1- 109 a R11-PheL-PheL-Phe-OCF2-(CH2)n-Phe-Phe-PheL-R12 Ib-1- 110 a R11-Phe-PheL-PheL-OCF2-(CH2)n-PheL-Phe-Phe-R12 Ib-1- 111 a R11-Phe-PheL-PheL-OCF2-(CH2)n-Phe-PheL-Phe-R12 Ib-1- 112 a R11-PheL-PheL-PheL-(CH2)n-CF2O-PheL-Phe-Phe-R12 Ib-1- 113 a R11-PheL-PheL-PheL-(CH2)n-CF2O-Phe-PheL-Phe-R12 Ib-1- 114 a R11-PheL-PheL-PheL-(CH2)n-CF2O-Phe-Phe-PheL-R12 Ib-1- 115 a
R11-Phe-PheL-PheL-(CH2)n-CF2O-PheL-PheL-Phe-R12 Ib-1- 116 a R11-Phe-PheL-PheL-(CH2)n-CF2O-Phe-PheL-PheL-R12 Ib-1- 117 a R11-PheL-PheL-PheL-OCF2-(CH2)n-PheL-Phe-Phe-R12 Ib-1- 118 a R11-PheL-PheL-PheL-OCF2-(CH2)n-Phe-PheL-Phe-R12 Ib-1- 119 a R11-PheL-PheL-PheL-OCF2-(CH2)n-Phe-Phe-PheL-R12 Ib-1- 120 a R11-Phe-PheL-PheL-OCF2-(CH2)n-PheL-PheL-Phe-R12 Ib-1- 121 a R11-Phe-PheL-PheL-OCF2-(CH2)n-Phe-PheL-PheL-R12 Ib-1- 122 a R11-PheL-PheL-PheL-(CH2)n-CF2O-PheL-PheL-Phe-R12 Ib-1- 123 a R11-PheL-Phe-PheL-(CH2)n-CF2O-PheL-PheL-PheL-R12 Ib-1- 124 a R11-PheL-PheL-Phe-(CH2)n-CF2O-PheL-PheL-PheL-R12 Ib-1- 125 a R11-PheL-PheL-PheL-OCF2-(CH2)n-PheL-PheL-Phe-R12 Ib-1- 126 a R11-PheL-Phe-PheL-OCF2-(CH2)n-PheL-PheL-PheL-R12 Ib-1- 127 a R11-PheL-PheL-Phe-OCF2-(CH2)n-PheL-PheL-PheL-R12 Ib-1- 128 a R11-PheL-PheL-PheL-OCF2-(CH2)n-PheL-PheL-PheL-R12 Ib-1- 129 a wherein, R11, R12, Phe and PheL have one of the meanings as given above and n denotes 5,7, 9 or 11. In the above given preferred subformulae of formula I, PheL preferably
(L) denotes the group
wherein L is preferably F, Cl, CH3, OCH3 and COCH3.
Thus, further preferred compounds of formula Ia-1 are selected, for example, from the following compounds:
R11, R12 have one of the meanings as given above, preferably both R11 and R12 are identical and denote both CN or F, likewise preferably R11 and R12 are different and at least one of them denote CN or F and n preferably denotes 7 or 9. Further preferred compounds are of formula Ib-1, for example, are preferably selected from the following compounds:
R11, R12 have one of the meanings as given above, preferably both R11 and R12 are identical and denote both CN or F, likewise preferably R11 and R12 are different and at least one of them denote CN or F and n preferably denotes 7 or 9. The compounds of formula I can be synthesized according to or in analogy to methods which are known per se and which are described in standard works of organic chemistry such as, for example, Houben-Weyl, Methoden der organischen Chemie, Thieme-Verlag, Stuttgart. In a preferred embodiment, the compounds of formula Ia-1 can be s nthesized accordin to or in analo to the followin s nthesis scheme:
wherein the given parameters have one of the meanings as given above under formula Ia-1.
Thus, the invention relates also to a method of production of compounds of formula Ia-1 com risin at least the step of reacting a compound of
with one or more compounds of formula R11-MG11-OH or R12-MG12-OH, wherein the parameters have one of the meanings as given above under formula Ia-1. In another preferred embodiment, the compounds of formula Ib-1 can be synthesized according to or in analogy to the following synthesis scheme:
wherein the parameters have one of the meanings as given above under formula Ib-1.
Thus the invention relates also to a method of production of compounds of formula Ib-1, comprising at least the step of reacting one compound of the followin formula:
with at least one compound of formula R12-MG12-OH, wherein the parameters have one of the meanings as given above under formula Ib- 1. The compounds of formula I and its subformulae can be beneficially utilized in LC media to improve the properties of such media, in particular in LC media for flexoelectric applications. For example, one of the main advantages of using compounds of formula I in LC media for flexoelectric applications is improving the switching speed in the ULH (uniform lying helix) geometry, particularly at
temperatures below 35ºC. Benefits are also observed in terms of the phase range, in terms of an increased isotropic to nematic clearing point and also in terms of a reduced nematic to nematic twist bend transition temperature below room temperature. Therefore, the invention also relates to the use of compounds of formula I in LC media and to a LC media comprising one or more compounds of formula I, as such. In a preferred embodiment, the LC media in accordance with the present invention comprise one or more compounds of formula II, R21-A21-A22-(CH2)a-A23-A24-R22 II wherein
R21 and R22 denote independently H, F, Cl, CN, NCS or a straight- chain or branched alkyl group, which may be
unsubstituted, mono- or polysubstituted by halogen or CN, it being also possible for one or more non-adjacent
CH2 groups to be replaced, in each occurrence independently from one another, by -O-, -S-,
-NH-, -N(CH3)-, -CO-, -COO-, -OCO-, -O-CO-O-, -S-CO-, -CO-S-, -CH=CH-, -CH=CF-, -CF=CF- or -C≡C- in such a manner that oxygen atoms are not linked directly to one another,
preferably F, Cl, CN, a straight-chain or branched alkyl or alkoxy group which may be unsubstituted, mono- or polysubstituted by halogen or CN,
more preferably F, CN or OCF3, A21 to A24 denote independently in each occurrence a aryl-,
heteroaryl-, alicyclic- and heterocyclic group,
preferably 1,4-phenylene, wherein in addition one or more CH groups may be replaced by N, trans-1,4- cyclo-hexylene in which, in addition, one or two non- adjacent CH2 groups may be replaced by O and/or S, 1,4-cyclohexenylene, 1,4-bicyclo-(2,2,2)-octylene, piperidine-1,4-diyl, naphthalene-2,6-diyl, decahydro- naphthalene-2,6-diyl, 1,2,3,4-tetrahydro-naphthalene- 2,6-diyl, cyclobutane-1,3-diyl, spiro[3.3]heptane-2,6- diyl or dispiro[3.1.3.1] decane-2,8-diyl, it being possible for all these groups to be unsubstituted, mono-, di-, tri- or tetrasubstituted with F, Cl, CN or alkyl, alkoxy, alkylcarbonyl or alkoxycarbonyl groups, wherein one or more H atoms may be substituted by F or Cl,
more preferably each independently in each
occurrence 1,4-phenylene, wherein in addition one or more CH groups may be replaced by N or trans-1,4- cyclohexylene in which, in addition, one or two non- adjacent CH2 groups may be replaced by O and/or S, it being possible for both ring groups to be
unsubstituted, mono-, di-, tri- or tetrasubstituted with F, Cl, CN or alkyl, alkoxy, alkylcarbonyl or
alkoxycarbonyl groups, wherein one or more H atoms may be substituted by F or Cl, a denotes an integer from 1 to 15, preferably an odd (i.e.
uneven) integer and, more preferably 3, 5, 7, 9 or 11. Preferred compounds of formula II are selected from compounds in which the groups (-A21-A22-) and (-A23-A24-) are each and independently selected from the following groups
-Phe-Phe- MG-1 -Phe-Cyc- MG-2 -PheL-PheL- MG-3 -Phe-PheL- MG-4 -PheL-Phe- MG-5 -PheL-Cyc- MG-6 -Cyc-PheL- MG-7 -Cyc-Cyc- MG-8 wherein,
Phe in these groups is 1,4-phenylene,
PheL is a 1,4-phenylene group which is substituted by 1 to 4 groups L, with L being preferably F, Cl, CN, OH, NO2 or an optionally fluorinated alkyl, alkoxy or alkanoyl group with 1 to 7 C atoms, very preferably F, Cl, CN, OH, NO2, CH3, C2H5, OCH3, OC2H5, COCH3, COC2H5, COOCH3,
COOC2H5, CF3, OCF3, OCHF2, OC2F5, in particular F, Cl, CN, CH3, C2H5, OCH3, COCH3 and OCF3, most preferably F, Cl, CH3, OCH3 and COCH3 and
Cyc is 1,4-cyclohexylene. Preferred are compounds of formula II wherein the groups (R21-A21-A22-) and (-A23-A24-R22) in formula II are identical or mirror images. Likewise preferred are compounds of formula II wherein (R21-A21-A22-) and (-A23-A24-R22) in formula II are different.
Preferred compounds of formula II are indicated below:
wherein
n denotes an integer from 1 to 15, preferably an odd (i.e.
uneven) integer and, more preferably 3, 5, 7, 9 or 11. The compounds of formula II can be synthesized according to or in analogy to methods which are known per se and which are described in standard works of organic chemistry such as, for example, Houben-Weyl, Methoden der organischen Chemie, Thieme-Verlag, Stuttgart. A preferred method of preparation can be taken from WO 2013/004333 A1. In the mixture according to the present invention, the utilization of compounds of formula II beside compounds of formula I, is especially useful in order to further improve the switching speeds whilst maintaining a good phase range and a favorable value for e/K. In a preferred embodiment, the LC media in accordance with the present invention comprise one or more compounds of formula III,
R31-A31-A32-(A33)b-Z31-(CH2)c-Z32-A34-A35-A36-R32 III wherein
R31 and R32 have each and independently from another one of the meanings as given for R21 and R22 under formula II, A31 to A36 have each and independently from another one of the meanings as given for A21 to A24 under formula II, Z31 and Z32 are each independently in each occurrence,
-COO-, -OCO-, -O-CO-O-, -OCH2-, -CH2O-, -CH2CH2-, -(CH2)4-, -CF2CF2-, -CH=CH-, -CF=CF-,
-CH=CH-COO-, -OCO-CH=CH- or -C ^C-, optionally substituted with one or more of F, S and/or Si, preferably -COO-, -OCO- or -O-CO-O-,
more preferably -COO- or -OCO-, b denotes an integer from 1 to 15, preferably an odd (i.e.
uneven) integer and, more preferably 3, 5, 7 or 9 and c denotes 0 or 1, preferably 0. Preferred compounds of formula III are selected from compounds in which c denotes 0 and the group (-A31-A32-) is selected from the groups MG-1 to MG-8 as given above. Further preferred compounds of formula III are selected from compounds in which c denotes 1 and the groups (-A24-A25-A26-) and (-A21-A22-A23-) are each and independently selected from the following groups -Cyc-Cyc-Cyc- MG-9
-Phe-Phe-Cyc- MG-10
-Phe-Cyc-Phe- MG-11
-Cyc-Phe-Cyc- MG-12
-Phe-Cyc-Cyc- MG-13
-Phe-Phe-Phe- MG-14
-Phe-Phe-PheL- MG-15
-Phe-PheL-Phe- MG-16
-PheL-Phe-Phe- MG-17
-PheL-Phe-PheL- MG-18
-PheL-PheL-Phe- MG-19
-PheL-PheL-PheL- MG-20
-Phe-PheL-Cyc- MG-21
-Phe-Cyc-PheL- MG-22
-Cyc-Phe-PheL- MG-23
-PheL-Cyc-PheL- MG-24
-PheL-PheL-Cyc- MG-25
-PheL-Cyc-Cyc- MG-26
-Cyc-PheL-Cyc- MG-27 wherein Cyc, Phe, PheL an L have one of the meanings given above for the groups MG-1 to MG-8. Further preferred compounds of formula III are selected from compounds in which c denotes 0 and the group (-A21-A22-) is selected from the groups MG-1 to MG-8 as given above and in which the group (-A24-A25- A26-) is selected from the groups MG-9 to MG-27. Especially preferred compounds of formula III are selected from the rou of com ounds of the followin formulae
The compounds of formula III can be synthesized according to or in analogy to methods which are known per se and which are described in standard works of organic chemistry such as, for example, Houben-Weyl, Methoden der organischen Chemie, Thieme-Verlag, Stuttgart.
In the mixture according to the present invention, the utilization of compounds of formula III beside compounds of formula I, is especially useful in order to achieve high stabilities, favourable high clearing points and broad phase ranges, as well as, low appearances of the nematic twist-bend phase. In further preferred embodiment, the LC medium in accordance with the present invention comprises one or more compounds of formula IV, R41-A41-A42-Z41-(CH2)d-Z42-A43-A44-R42 IV wherein
R41 and R42 have each and independently one of the meanings as given above for R21 under formula II, A41 to A44 have each and independently one of the meanings as given above for A21 under formula II, Z41 and Z42 are each independently in each occurrence,
-COO-, -OCO-, -O-CO-O-, -OCH2-, -CH2O-, -CH2CH2-, -(CH2)4-, -CF2CF2-, -CH=CH-, -CF=CF-,
-CH=CH-COO-, -OCO-CH=CH- or -C ^C-, optionally substituted with one or more of F, S and/or Si, preferably -COO-, -OCO- or -O-CO-O-,
more preferably -COO- or -OCO-. d denotes an integer from 1 to 15, preferably an odd (i.e.
uneven) integer and, more preferably 3, 5, 7 or 9. Preferred compounds of formula IV are selected from compounds in which the groups (-A41-A42-) and (-A43-A44-) are each and independently selected from the groups of MG-1 to MG-8 as given above. Especially preferred compounds of formula IV are selected from the group of compounds of the following formulae:
- symmetrical ones (IVa and IVb):
- non-symmetrical ones IVc:
The compounds of formula IV are either known or can be synthesized according to or in analogy to methods which are known per se and which are described in standard works of organic chemistry such as, for example, Houben-Weyl, Methoden der organischen Chemie, Thieme- Verlag, Stuttgart. In the mixture according to the present invention, the utilization of compounds of formula IV beside compounds of formula I, is especially useful in order to reduce the nematic twist bend phase whilst maintaining favorable values for e/K. In further preferred embodiment, the LC medium in accordance with the present invention additionally comprises one or more compounds of formula V, R51-A51-Z51-(CH2)e-Z52-A52-(A53)f-R52 V wherein
R51 and R52 have each and independently one of the meanings as given above for R21 under formula II, A51 to A53 have each and independently one of the meanings as given above for A21 under formula II, Z51 and Z52 are each independently in each occurrence,
-COO-, -OCO-, -O-CO-O-, -OCH2-, -CH2O-, -CH2CH2-, -(CH2)4-, -CF2CF2-, -CH=CH-, -CF=CF-,
-CH=CH-COO-, -OCO-CH=CH- or -C ^C-, optionally substituted with one or more of F, S and/or Si, preferably -COO-, -OCO- or -O-CO-O-,
more preferably -COO- or -OCO-, e denotes an integer from 1 to 15, preferably an odd (i.e.
uneven) integer and, more preferably 3, 5, 7 or 9 and f denotes 0 or 1.
Especially preferred are compounds of formula V wherein the A51 is selected from the following group of formulae Va’ to Vh’ and the mirror images of formulae Vb’, Ve’ and Vf’
In a preferred embodiment of the present invention are compounds of formula I, wherein A51 and is selected from the group of formulae Va’ to Vc’ or their mirror images. Preferably R51 and R52 in formula V are selected of H, F, Cl, CN, NO2, OCH3, COCH3, COC2H5, COOCH3, COOC2H5, CF3, C2F5, OCF3, OCHF2
and OC2F5, in particular of H, F, Cl, CN, OCH3 and OCF3, especially of H, F, CN and OCF3. Preferred compounds of formula V are selected from the group of compounds of formulae VA to VE, preferably of formulae VA and/or VD, most preferably of formula VD,
wherein LG51 is Z51-(CH2)z-Z52,
(F)0 denotes H and
(F)1 denotes F. and the other parameters have the respective meanings given above including the preferred meanings. Preferably Z51-(CH2)z-Z52 denotes -O-CO-(CH2)n-CO-O-, -O-(CH2)n-O- or -(CH2)n -, more preferably -O-CO-(CH2)n-CO-O-, wherein n denotes 3, 5, 7 or 9, Particularly preferred compounds of formula VA are selected from the group of compounds of formulae VA-1 to VA-3
wherein the parameters have the respective meanings given above including the preferred meanings. Particularly preferred compounds of formula VB are selected from the group of compounds of formulae VB-1 to VB-3
F wherein the parameters have the respective meanings given above including the preferred meanings. Particularly preferred compounds of formula VC are selected from the group of compounds of formulae VC-1 and VC-2
wherein the parameters have the respective meanings given above including the preferred meanings.
Compounds of formula VD are very much preferred. And of these particularly preferred compounds are selected from the group of compounds of formulae VD-1 to VD-3
wherein the parameters have the respective meanings given above including the preferred meanings. The compounds of formula V can be synthesized according to or in analogy to methods which are known per se and which are described in standard works of organic chemistry such as, for example, Houben- Weyl, Methoden der organischen Chemie, Thieme-Verlag, Stuttgart. A preferred method of preparation is disclosed for example in
WO2015/036079 A1. In a further preferred embodiment, the LC medium in accordance with the present invention additionally comprises one or more compounds of formula VI, R61-A61-A62-(CH2)g-Z61-A63-A64-(A65)h-R62 VI wherein
R61 and R62 have each and independently one of the meanings as given above for R21 under formula II, A61 to A64 have each and independently one of the meanings as given above for A21 under formula II, Z61 denotes -O-, -COO-, -OCO-, -O-CO-O-, -OCH2-, -CH2O,
-CH2CH2-, -(CH2)4-, -CF2CF2-, -CH=CH-, -CF=CF-, -CH=CH-COO-, -OCO-CH=CH- or -C ^C-, optionally substituted with one or more of F, S and/or Si, preferably -O-, -COO-, -OCO- or -O-CO-O-,
more preferably -O-, -COO- or -OCO-, most preferably -COO- or -OCO-, h denotes 0 or 1 and g denotes an integer from 1 to 15, preferably an odd (i.e.
uneven) integer and, more preferably 3, 5, 7 or 9. Preferred compounds of formula VI are selected from compounds in which the groups (-A61-A62-) and (-A63-A64-) are each and independently selected from the groups of MG-1 to MG-8 as given above. Further preferred are compounds of formula VI wherein h denotes 0 and the groups (-A61-A62-) and (-A63-A64-(A65)h) in formula VI are not identical or not mirror images or wherein h denotes 1 In particular preferred compounds of formula VI are selected from the group of compounds of the following formulae,
The compounds of formula VI can be synthesized according to or in analogy to methods which are known per se and which are described in standard works of organic chemistry such as, for example, Houben-Weyl, Methoden der organischen Chemie, Thieme-Verlag, Stuttgart. Preferably, the compounds of formula VI are synthesized according to or in analogy to methods which are disclosed for example in WO 2014/005672 A1. In the mixture according to the present invention, the utilization of compounds of formula VI beside compounds of formula I is especially
useful in order to achieve high clearing points and also favorable values for e/K. In a further preferred embodiment, the LC medium in accordance with the present invention additionally comprises one, two, three or more compounds of formula VII, R71-A71-Z71-A72-(Z72-A73)i-(CH2)j-(A74-Z73-)k-A75-Z74-A76-R72 VII wherein
R71 and R72 have each and independently one of the meanings as given above for R21 under formula II, A71 to A76 have each and independently one of the meanings as given above for A21 under formula II, Z71 to Z74 each and independently denotes -COO-, -OCO-,
-O-CO-O-, -OCH2-, -CH2O-, -OCF2-, -CF2O-, -CH2CH2-, -(CH2)4-,-CF2CF2-, -CH=CH-, -CF=CF-, -CH=CH-COO-, -OCO-CH=CH- or -C ^C-, optionally substituted with one or more of F, S and/or Si or a single bond,
preferably -COO-, -OCO-, -O-CO-O-, -OCF2-, -CF2O- or a single bond
more preferably -COO-, -OCO-, -OCF2-, -CF2O- or a single bond,
with the proviso that at least one of Z71 to Z74 is not a single bond, j denotes an integer from 1 to 15, preferably an odd (i.e.
uneven) integer and, more preferably 3, 5, 7 or 9 and i and k each and independently denotes 0 or 1. Preferred compounds of formula VII are selected from compounds in which at least one of the groups -A71-Z71-A72-(Z72-A73)i-,
-(A74-Z73-)k-A75-Z74-A76- are is selected from the groups of MGa to MGn (the two reference Nos.“MG i” and“MG l” being deliberately omitted to avoid any confusion) and their mirror images
wherein wherein L is in each occurrence independently of each other preferably F, Cl, CN or an optionally fluorinated alkyl, alkoxy or alkanoyl group with 1 to 7 C atoms, very preferably F, Cl, CN, CH3, C2H5, OCH3, OC2H5, COCH3, COC2H5, COOCH3, COOC2H5, CF3, OCF3, OCHF2, OC2F5, in particular F, Cl, CN, CH3, C2H5, OCH3, COCH3 and OCF3, most
preferably F, Cl, CH3, OCH3 and COCH3 and r is in each occurrence independently of each other 0, 1, 2, 3 or 4, preferably 0, 1 or 2.
wherein L is preferably F, Cl, CH3, OCH3 and COCH3. Further preferred are compounds of formula VII wherein the groups -A71- Z71-A72-(Z72-A73)i- and -(A74-Z73-)k-A75-Z74-A76- in formula VII are identical or mirror images with the proviso that at least one of Z71 to Z74 is not a single bond. Further preferred are compounds of formula VII, wherein i and k both denote 1, more preferably one of i and k denotes 0 and the other 1, most preferably i and k both denote 0.
Especially preferred compounds of formula VII are selected from the group of compounds of the following formulae,
wherein R71 and R72, each and independently denote F or CN.
The compounds of formula VII can be synthesized according to or in analogy to methods which are known per se and which are described in standard works of organic chemistry such as, for example, Houben-Weyl, Methoden der organischen Chemie, Thieme-Verlag, Stuttgart. Preferably, the compounds of formula VII are synthesized according to or in analogy to methods which are disclosed for example in WO 2013/174478 A1. In a further preferred embodiment, the medium in accordance with the present invention optionally comprises one or more chiral dopants, especially when utilized in a flexoelectric device. The chiral compounds induce a chiral nematic texture with a pitch (P0), which is in a first approximation inversely proportional to the
concentration (c) of the chiral material used. The constant of
proportionality of this relation is called the helical twisting power (HTP) of the chiral substance and defined by the following equation HTP≡ 1 / (c·P0) (1) wherein
c is concentration of the chiral compound. For example, a uniform lying helix texture is realized using a chiral nematic liquid crystal with a short pitch, typically in the range from 0.2 µm to 1 µm, preferably of 1.0 µm or less, in particular of 0.5 µm or less, which is unidirectional aligned with its helical axis parallel to the substrates, e. g. glass plates, of a liquid crystal cell. In this configuration, the helical axis of the chiral nematic liquid crystal is equivalent to the optical axis of a birefringent plate. Preferred are chiral dopants with a high helical twisting power (HTP), in particular those disclosed in WO 98/00428. Typically, used chiral dopants are e.g. the commercially available
R/S-5011, CD-1, R/S-811 and CB-15 (from Merck KGaA, Darmstadt, Germany).
In another preferred embodiment, the chiral dopants are preferably selected from formula VIII,
including the respective (S,S) enantiomer, wherein E and F are each independently 1,4-phenylene or trans-1,4- cyclohexylene, v is 0 or 1, Z0 is -COO-, -OCO-, -CH2CH2- or a single bond and R is alkyl, alkoxy or alkanoyl with 1 to 12 C atoms. The compounds of formula VIII and their synthesis are described in WO 98/00428. The compounds of formula IX and their synthesis are described in GB 2,328,207. The above-mentioned chiral dopants R/S-5011 and the compounds of formula VIII and IX exhibit a very high helical twisting power (HTP) and are therefore particularly useful for the purpose of the present invention. The liquid crystalline medium preferably comprises preferably 1 to 5, in particular 1 to 3, very preferably 1 or 2 chiral dopants, preferably selected from the above formula VIII, and/or formula IX and/or
R-5011 or S-5011, very preferably, the chiral compound is R-5011, S- 5011. The amount of chiral compounds in the liquid crystalline medium is preferably from 0.1 to 15 %, in particular from 0.5 to 10 %, very preferably 1 to 5 % by weight of the total mixture. Preferably, the LC medium comprises one or more nematic LC compounds selected from compounds indicated below:
R2A denotes H, an alkyl or alkoxy radical having 1 to 15 C atoms, where, in addition, one or more CH2 groups in these radicals may each be replaced, independently of one another, by -C ^C-, -CF2O-, -CH=CH-, ,
, -O-, -CO-O- or -O-CO- in such a way that O atoms are not linked directly to one another and in
which, in addition, one or more H atoms may be replaced by halogen, L1 and L2 each, independently of one another, denote F, Cl, CF3 or CHF2, preferably each denote F, Z2 and Z2’ each, independently of one another, denote a single bond, -CH2CH2-, -CH=CH-, -C≡C- , -CF2O-, -OCF2-, -CH2O-, -OCH2-, -COO-, -OCO-, -C2F 4-, -CF=CF- or
-CH=CHCH2O-, p denotes 0, 1 or 2, q denotes 0 or 1, (O)CvH2v+1 denotes OCvH2v+1 or CvH2v+1 and v denotes 1 to 6. The liquid crystal media may contain further additives like for example stabilizers, inhibitors, surface-active compounds, lubricating agents, wetting agents, dispersing agents, hydrophobing agents, adhesive agents, flow improvers, defoaming agents, deaerators, diluents, reactive diluents, auxiliaries, colourants, dyes, pigments or nanoparticles in usual concentrations. The total concentration of these further constituents is in the range of 0.1 % to 10 %, preferably 0.1 % to 6 %, based on the total mixture. The concentrations of the individual compounds used each are preferably in the range of 0.1 % to 3 %. The concentration of these and of similar additives is not taken into consideration for the values and ranges of the concentrations of the liquid crystal components and compounds of the liquid crystal media in this application. This also holds for the concentration of the dichroic dyes used in the mixtures, which are not counted when the concentrations of the compounds respectively the components of the host medium are
specified. The concentration of the respective additives is always given relative to the final doped mixture. In general, the total concentration of all compounds in the media according to this application is 100 %. The liquid crystal media according to the present invention consists of several compounds, preferably of 2 to 40, more preferably of 3 to 30 and most preferably of 4 to 25 compounds. The media in accordance with the present invention exhibit high values of the elastic constant k11 and a high flexoelectric coefficient e. The liquid crystal media preferably exhibit a k11≤ 100 pN, preferably≤ 20 pN. The liquid crystal media preferably exhibit a k33≤ 100 pN, preferably ≤ 15 pN. The liquid crystal media preferably exhibit a flexoelectric coefficient │e11│≥ 0.2 pC/m, preferably≥ 1 pC/m. The liquid crystal media preferably exhibit a flexoelectric coefficient │e33│≥ 0.2 pC/m, preferably≥ 2 pC/m. The liquid crystal media preferably exhibit a flexo-elastic ratio (ē / K) in the range from 1 to 10 V-1, preferably in the range from 1 to 7 V-1, more preferably in the range from 1 to 5 V-1. The media in accordance with the present invention exhibit high clearing points up to 60°C and higher, preferably up 65°C and higher and more preferably up to 70°C and higher. The media in accordance with the present invention exhibit broad nematic phases of 30°C and more, preferably 35°C and more or even 40°C or more.
The media in accordance with the present invention exhibit NTB phases below 20°C or less, preferably below 15°C or less and more preferably below 0°C or less. The media in accordance with the present invention exhibit high stabilities against crystallization at room temperature of more than 100 h, preferably more than 250 h or more than 1000 h. The media in accordance with the present invention exhibit high stabilities against crystallization even at low temperatures (LTS).
Accordingly, the media do not crystallize even at temperatures down to 0°C, preferably down to -10°C, more preferably down to -20°C. In a preferred embodiment, the LC medium comprises: ● 1 to 10, preferably 1 to 5, more preferably 1 or 3, most preferably 1 or 2 compounds of formula I, preferably selected from formulae Ia-1-2a, Ia-1-5a, Ib-1-4a and/or Ib-1-9a. The amount of
compounds of formula I in the liquid crystalline medium as a whole is preferably in the range from 5 to 50 %, in particular in the range from 6 to 30 %, especially in the range from 7 to 20 % by weight of the total mixture, and ● optionally 1 to 10, preferably 1 to 5, more preferably 1 or 3, most preferably 1 or 2 compounds of formula II, preferably selected from compounds compounds of formula II wherein (-A21-A22-) and (-A23-A24-) in formula II are identical or mirror images, more preferably of compounds of formulae II’a-5 and/or II’a-6. The amount of compounds of formula II in the liquid crystalline medium, if present, is preferably in the range from 0 to 30 %, more preferably in the range from 1 to 20 %, even more preferably in the range from 2 to 10 % by weight of the total mixture, and/or
● optionally 1 to 10, preferably 1 to 5, more preferably 1 or 3, most preferably 1 or 2 compounds of formula III, preferably selected from symmetrical compounds of the above formulae IIIc-2 and/or IIIc-3. The amount of compounds of formula III in the liquid crystalline medium, if present, is preferably in the range from 1 to 50 %, more preferably in the range from 5 to 30 %, even more preferably in the range from 10 to 20 % by weight of the total mixture, and/or
● optionally, 1 to 10, preferably 1 to 5, more preferably 1 or 3, most preferably 1 or 2 compounds of formula IV, preferably selected from the symmetrical ones IVb and/or non-symmetrical ones IVc, more preferably from formulae IVb-5, IVc-2, IVc-3, IVc-12 and or IVc-15. The amount of compounds of formula IV in the liquid crystalline medium, if present, is preferably in the range from 1 to 98 %, more preferably in the range from 20 to 80 %, even more preferably in the range from 30 to 60 % by weight of the total mixture, and/or ● optionally, 1 to 6, in particular 2 to 5, very preferably 3 or 4
compounds of formula V, preferably selected from the above formulae VA-1, VD-2 and/or VD-3. The amount of compounds of formula V in the liquid crystalline medium , if present, is preferably in the range from 1 to 70 %, more preferably in the range from 10 to 60 %, even more preferably in the range from 20 to 50 % by weight of the total mixture, and/or ● optionally 1 to 10, preferably 1 to 5, more preferably 1 or 3, most preferably 1 or 2 compounds from the above formulae VI, preferably form compounds of formula VI-4, VI-5, VI-7 and/or VI-9.
The amount of compounds of formula VI in the liquid crystalline medium, if present, is preferably from 1 to 40 %, in particular from 5 to 25 %, very preferably 10 to 15 % by weight of the total mixture, and/or ● optionally 1 to 10, preferably 1 to 5, more preferably 1 or 3, most preferably 1 or 2 compounds from the above formulae VII, preferably form compounds of formula VII-4, VII-5 and/or VII-8. The amount of compounds of formula VII in the liquid crystalline medium, if present, is preferably from 1 to 35 %, in particular from 5 to 25 %, very preferably 10 to 15 % by weight of the total mixture,
and/or ● optionally, 1 to 5, in particular 1 to 3, very preferably 1 or 2 chiral dopants, preferably selected from the above formula VIII and/or formula IX and/or R-5011 or S-5011, very preferably, the chiral compound is R-5011 or S-5011. The amount of chiral compounds in the liquid crystalline medium, if present, is preferably from 1 to 15 %, in particular from 0.5 to 10 %, very preferably 0.1 to 5 % by weight of the total mixture, and/or ● optionally up to 25, in particular up to 20, very preferably up to 15, different compounds selected from compounds of formula X. If present, the amount of compounds of formula X in the liquid crystalline medium as a whole, is preferably from 1 to 50 %, in particular from 5 to 30 %, very preferably 10 to 25 % by weight of the total mixture, and/or
● optionally further additives, such as for example stabilizers, antioxidants, etc. in usual concentrations. The total concentration of these further constituents, if present, is in the range of 0.1 to 10 %, preferably 0.1 to 6 %, based on the total mixture. The concentrations of the individual compounds used each are preferably in the range of 0.1 to 3 %. In another preferred embodiment, the LC medium of the present invention consists only of compounds selected from formula I to X, very preferably the LC medium consists only of compounds selected from formula I to IX. The compounds forming the LC medium in accordance with the present invention are mixed in conventional way. As a rule, the required amount of the compound used in the smaller amount is dissolved in the compound used in the greater amount. In case the temperature is above the clearing point of the compound used in the higher concentration, it is particularly easy to observe completion of the process of dissolution. It is, however, also possible to prepare the media by other conventional ways, e.g. using so-called pre-mixtures, which can be e.g. homologous or eutectic media of compounds or using so-called multi-bottle-systems, the constituents of which are ready to use media themselves. Thus, the invention also relates to a process for the production of an LC medium as described above and below. In particular, the invention relates to a process for the production of an LC medium comprising the steps of mixing one or more compounds of formula I, with at least one compound selected from compounds of formulae II to X. The liquid crystalline media in accordance with the present invention can be used in electro optic devices, for example liquid crystal devices, such as STN, TN, AMD-TN, temperature compensation, guest-host, phase change or surface stabilized or polymer stabilized cholesteric texture (SSCT, PSCT) displays, in active and passive optical elements like polarizers, compensators, reflectors, alignment layers, colour filters or
holographic elements, in adhesives, synthetic resins with anisotropic mechanical properties, cosmetics, diagnostics, liquid crystal pigments, for decorative and security applications, in nonlinear optics, optical information storage or as chiral dopants. Thus, another aspect of the present invention is the use of a LC medium, comprising at least one compound of formula I in electro optic devices. Since the media in accordance with the present invention are particularly beneficially for flexoelectric liquid crystal display applications, such as, for example, devices of the ULH or USH mode. Thus, another object of the present invention is a liquid crystal device, preferably a flexoelectric device, comprising a medium, which comprises one or more compounds of formula I. A flexoelectric display according to a preferred embodiment of the present invention comprises two plane parallel substrates, preferably glass plates covered with a transparent conductive layer such as indium tin oxide (ITO) on their inner surfaces, optionally alignment layers and a medium comprising one or more compounds of formula I and a chiral dopant as described above and below. If an electrical field is applied to this configuration normal to the helical axis, the optical axis is rotated in the plane of the cell, similar as the director of a ferroelectric liquid crystal rotate as in a surface stabilized ferroelectric liquid crystal display. The field induces a splay bend structure in the director, which is accommodated by a tilt in the optical axis. The angle of the rotation of the axis is in first approximation directly and linearly proportional to the strength of the electrical field. The optical effect is best seen when the liquid crystal cell is placed between crossed polarizers with the optical axis in the unpowered state at an angle of 22.5° to the absorption axis of one of the polarizers. This angle of 22.5° is also the ideal angle of rotation of the electric field, as thus, by the inversion the electrical field, the optical axis is rotated by 45° and by appropriate selection of the
relative orientations of the preferred direction of the axis of the helix, the absorption axis of the polarizer and the direction of the electric field, the optical axis can be switched from parallel to one polarizer to the centre angle between both polarizers. The optimum contrast is then achieved when the total angle of the switching of the optical axis is 45°. In that case, the arrangement can be used as a switchable quarter wave plate, provided the optical retardation, i. e. the product of the effective birefringence of the liquid crystal and the cell gap, is selected to be the quarter of the wavelength. In this context, the wavelength referred to is 550 nm, the wavelength for which the sensitivity of the human eye is highest, unless explicitly stated otherwise. The angle of rotation of the optical axis ( ^) is given in good
approximation by the formula: tan ^ = e P0 E / (2 ^ K)
wherein
P0 is the undisturbed pitch of the cholesteric liquid crystal, ē is the average [ē = ½ (e11 + e33)] of the splay flexoelectric
coefficient (e11) and the bend flexoelectric coefficient (e33), E is the electrical field strength and
K is the average [K = ½ (k11 + k33)] of the splay elastic constant (k11) and the bend elastic constant (k33)
and wherein
e / K is called the flexo-elastic ratio. This angle of rotation is half the switching angle in a flexoelectric switching element. The response time
of this electro-optical effect is given in good approximation by the formula:
wherein
is the effective viscosity coefficient associated with the distortion of the helix.
The flexoelectric effect is characterized by fast response times (Ton+Toff at 35°C) typically ranging from 1 ms to 10 ms, preferably < 5ms and even more preferably < 3ms. It further features excellent grey scale capability. There is a critical field (Ec) to unwind the helix, which can be obtained from equation
wherein
The inventive media in accordance with the present invention can be aligned in their cholesteric phase into different states of orientation by methods that are known to the expert, such as surface treatment or electric fields. For example, they can be aligned into the planar
(Grandjean) state, into the focal conic state or into the homeotropic state. The term“planar alignment” or orientation of a liquid crystal or
mesogenic material in a display cell or on a substrate means that the mesogenic groups in the liquid crystal or mesogenic material are oriented substantially parallel to the plane of the cell or substrate, respectively. The term“homeotropic alignment” or orientation of a liquid crystal or mesogenic material in a display cell or on a substrate means that the mesogenic groups in the liquid crystal or mesogenic material are oriented substantially perpendicular to the plane of the cell or substrate, respectively.
The switching between different states of orientation according to a preferred embodiment of the present invention is exemplarily described below in detail. According to this preferred embodiment, the sample is placed into a cell comprising two plane-parallel glass plates coated with electrode layers, e.g. ITO layers and aligned in its cholesteric phase into a planar state wherein the axis of the cholesteric helix is oriented normal to the cell walls. This state is also known as Grandjean state and the texture of the sample, which is observable e.g. in a polarization microscope, as Grandjean texture. Planar alignment can be achieved e.g. by surface treatment of the cell walls, for example by rubbing and/or coating with an alignment layer such as polyimide. A Grandjean state with a high quality of alignment and only few defects can further be achieved by heating the sample to the isotropic phase, subsequently cooling to the chiral nematic phase at a temperature close to the chiral nematic-isotropic phase transition and flow alignment by lightly pressing the cell. In the planar state, the sample shows selective reflection of incident light, with the central wavelength of reflection depending on the helical pitch and the mean refractive index of the material. When an electric field is applied to the electrodes, for example with a frequency from 10 Hz to 1 kHz and an amplitude of up to 12 Vrms/µm, the sample is being switched into a homeotropic state where the helix is unwound and the molecules are oriented parallel to the field, i.e. normal to the plane of the electrodes. In the homeotropic state, the sample is transmissive when viewed in normal daylight and appears black when being put between crossed polarizers. Upon reduction or removal of the electric field in the homeotropic state, the sample adopts a focal conic texture, where the molecules exhibit a helically twisted structure with the helical axis being oriented
perpendicular to the field, i.e. parallel to the plane of the electrodes. A
focal conic state can also be achieved by applying only a weak electric field to a sample in its planar state. In the focal conic state the sample is scattering when viewed in normal daylight and appears bright between crossed polarizers. A sample of a medium in accordance with the present invention in different states of orientation exhibits different transmission of light.
Therefore, the respective state of orientation, as well as its quality of alignment, can be controlled by measuring the light transmission of the sample depending on the strength of the applied electric field. Thereby it is also possible to determine the electric field strength required to
achieve specific states of orientation and transitions between these different states. In a sample of a medium in accordance with the present invention, the above-described focal conic state consists of many disordered
birefringent small domains. By applying an electric field greater than the field for nucleation of the focal conic texture, preferably with additional shearing of the cell, a uniformly aligned texture is achieved where the helical axis is parallel to the plane of the electrodes in large, well-aligned areas. In accordance with the literature on state of the art chiral nematic materials, such as P. Rudquist et al., Liq. Cryst.23 (4), 503 (1997), this texture is also called uniformly lying helix (ULH) texture. This texture is required to characterize the flexoelectric properties of the inventive compound. Starting from the ULH texture, the inventive media can be subjected to flexoelectric switching by application of an electric field. This causes rotation of the optic axis of the material in the plane of the cell substrates, which leads to a change in transmission when placing the material between crossed polarizers. The flexoelectric switching of inventive materials is further described in detail in the introduction above and in the examples. It is also possible to obtain the ULH texture, starting from the focal conic texture, by applying an electric field with a high frequency, of for example 10 kHz, to the sample whilst cooling slowly from the isotropic phase into
the cholesteric phase and shearing the cell. The field frequency may differ for different compounds. Apart from the use in flexoelectric devices, the media in accordance with the present invention are also suitable for other types of displays and other optical and electro optical applications, such as optical
compensation or polarizing films, colour filters, reflective cholesterics, optical rotatory power and optical information storage. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention fully. The following examples are, therefore, to be construed as merely illustrative and not limitative of the remainder of the disclosure in any way whatsoever. Unless the context clearly indicates otherwise, as used herein plural forms of the terms herein are to be construed as including the singular form and vice versa. Throughout the description and claims of this specification, the words “comprise” and“contain” and variations of the words, for example “comprising” and“comprises”, mean“including but not limited to” and are not intended to (and do not) exclude other components. Throughout the present application it is to be understood that the angles of the bonds at a C atom being bound to three adjacent atoms, e.g. in a C=C or C=O double bond or e.g. in a benzene ring, are 120° and that the angles of the bonds at a C atom being bound to two adjacent atoms, e.g. in a C≡C or in a C≡N triple bond or in an allylic position C=C=C are 180°, unless these angles are otherwise restricted, e.g. like being part of small rings, like 3-, 4- or 5-atomic rings, notwithstanding that in some instances in some structural formulae these angles are not represented exactly. It will be appreciated that variations to the foregoing embodiments of the invention can be made while still falling within the scope of the invention.
Each feature disclosed in this specification, unless stated otherwise, may be replaced by alternative features serving the same, equivalent or similar purpose. Thus, unless stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features. All of the features disclosed in this specification may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. In particular, the preferred features of the invention are applicable to all aspects of the invention and may be used in any combination. Likewise, features described in non-essential combinations may be used separately (not in combination). The parameter ranges indicated in this application all include the limit values including the maximum permissible errors as known by the expert. The different upper and lower limit values indicated for various ranges of properties in combination with one another give rise to additional preferred ranges. The total concentration of all compounds in the media according to this application is 100 %. All concentrations are given in % w/w, unless explicitly stated otherwise. In the foregoing and in the following examples, unless otherwise indicated, all temperatures are set forth uncorrected in degrees Celsius and all parts and percentages are by weight. It goes without saying to the person skilled in the art that the LC media may also comprise compounds in which, for example, H, N, O, Cl, F have been replaced by the corresponding isotopes. The following abbreviations are used to illustrate the liquid crystalline phase behaviour of the compounds: TN,I = clearing point; K = crystalline; N = nematic; NTB = second nematic; S or Sm = smectic; Ch = cholesteric; I = isotropic; Tg = glass transition. The numbers between the symbols indicate the phase transition temperatures in°C.
In the present application and especially in the following examples, the structures of the liquid crystal compounds are represented by
abbreviations, which are also called“acronyms”. The transformation of the abbreviations into the corresponding structures is straightforward according to the following three tables A to C. All groups CnH2n+1, CmH2m+1 and CIH2I+I are preferably straight chain alkyl groups with n, m and l C-atoms, respectively, all groups CnH2n, CmH2m and CIH2I are preferably (CH2)n, (CH2)m and (CH2)I, respectively and -CH=CH- preferably is trans- respectively E vinylene. Preferably n, m and l denote an integer between 1 and 12. Table A lists the symbols used for the ring elements, table B those for the linking groups and table C those for the symbols for the left hand and the right hand end groups of the molecules.
wherein n und m each are integers and three points“...” indicate a space for other symbols of this table.
Examples A. Compound examples: A.1. Synthesis of BM-1 (7) and BM-2 (8) Step 1.1
Pyridinium chlorochromate (103.6 g, 480 mmol) and 140 g Celite are suspended in 480 ml dichloromethane at room temperature. While stirring, 1,9-nonanediol 1 (35 g, 218 mmol) dissolved in 50 ml tetrahydrofuran and 150 ml dichloromethane is added dropwise between 20 and 30°C. The mixture is filtered, the solvent removed in vacuum and the residue chromatographed on silica gel/dichloromethane; 20 g of crude dialdehyde 2 is obtained and is used in the next step without further purification.
2-Trimethylsilyl-1,3-dithiane 3 (52.8 g, 269 mmol) is dissolved in 190 ml tetrahydrofuran and cooled to -70°C. Butyllithium (107.5 ml of a 2.5 M solution in hexanes, 269 mmol) is slowly added. After the addition is complete, the mixture is warmed to room temperature for 2 hours and then cooled again to -70°C.20 g of dialdehyde 2 in 80 ml tetrahydrofuran is slowly added at that temperature. After the addition is complete, the mixture is warmed to room temperature and worked up as usual. The residue is distilled under reduced pressure and gave 22.9 g of product 4 with a boiling point of 67-74°C at a pressure of 0.1 mbar.
Bis(dithiane) 4 (15.4 mmol) is suspended in 200 ml dichloromethane and cooled to -30°C. Trifluoromethane sulfonic acid (2.98 ml, 34 mmol) is added dropwise while stirring and the mixture is warmed to room temperature for 30 min. It is then cooled again to -70°C, the two phenols 5 (3.1 g, 15.4 mmol) and 6 (3.3 g, 15.4 mmol) together with triethylamine (7.7 ml, 56 mmol) and 70 ml dichloromethane are added dropwise to the mixture. Triethylamine trishydrofluoride (24.9 ml, 154 mmol) is added and subsequently within a period of 60 min bromine (7.9 ml, 154 mmol) in 65 ml dichloromethane. After stirring for one hour at -70°C, the mixture is allowed to warm to -30°C and morpholine (13.5 ml, 154 mmol) is added below -20°C. After warming to 0°C, the mixture is poured onto 200 ml ice water and 19.7 ml aqueous KOH (47 %). The pH is adjusted to approximately 9.0 with additional small amounts of the KOH solution. The organic phase is separated and worked up as usual. After chromatography, of compound 7 (F-PGI-QI-9-Q-PP-N) is isolated.
1H NMR (500 MHz, Chloroform-d) δ 7.75– 7.69 (m), 7.68– 7.60 (m), 7.59– 7.50 (m), 7.48 (ddt, J = 6.9, 5.3, 1.6 Hz), 7.32– 7.24 (m), 7.17– 7.08 (m), 7.08– 6.99 (m), 2.16 (qt, J = 11.3, 5.8 Hz), 1.66 (ddd, J = 11.9, 6.8, 3.3 Hz), 1.39 (dt, J = 24.3, 6.1 Hz).
1H NMR (500 MHz, Chloroform-d) δ 7.75– 7.69 (m), 7.68– 7.62 (m), 7.58– 7.52 (m), 7.29 (d, J = 8.5 Hz), 3.73 (dtd, J = 14.1, 6.8, 5.4 Hz), 2.23– 2.11 (m), 1.62 (s), 1.46– 1.34 (m), 1.31– 1.21 (m). 2. Synthesis of BM-3 (12)
Step 2.1
Dithiane 4 (18.3 mmol) is suspended in 230 ml dichloromethane, cooled to -30°C and trifluoromethane sulfonic acid (3.5 ml, 40.3 mmol) is added dropwise. The mixture is allowed to warm to room temperature, stirred for 30 min and cooled again to -70°C. A mixture of 4-bromophenol 9 (7 g, 40.3 mmol) and triethylamine (9.1 ml, 65.9 mmol) dissolved in 100 ml dichloromethane is added. After the addition is complete, the mixture is stirred at -70°C for one hour. Triethylamine trishydrofluoride (29.5 ml, 183 mmol) is added and after one hour bromine (9.4 ml, 183 mmol) in 50 ml dichloromethane. Stirring is continued for one hour and the mixture is
warmed to -30°C. Morpholine (15.9 ml, 183 mmol) is added below -20°C. Workup is carried out as described above for compound 7 and gave compound 10. Step 2.2
Sodium bicarbonate (1.4 g, 16.8 mmol) is dissolved in 12 ml water;
dibromide 10 (2.4 g, 4.2 mmol) and boronic ester 11 (2.4 g, 8.8 mmol) are dissolved in 20 ml tetrahydrofuran and the two solutions are combined and degassed by bubbling a stream of nitrogen through it. Bis(tri-(tert-butyl)phos-phino)palladium(0) (11 mg, 0.021 mmol) is added and the mixture is heated to reflux for 3 hours. After the usual workup, 2.6 g 12 (N-UIP-QI-9-Q-PU-N) is obtained as a colorless powder.
1H NMR (400 MHz, Chloroform-d) δ 7.46 (d, J = 8.7 Hz), 7.25 (s), 7.21– 7.12 (m), 2.10 (tdd, J = 11.3, 8.0, 5.6 Hz), 1.64– 1.55 (m), 1.39– 1.26 (m).
A.3. Synthesis of BM-4 (21) Step 3.1
Sodium metaborate tetrahydrate (45.3 g, 322 mmol) is dissolved in 290 ml water and 300 ml tetrahydrofuran,
bis(triphenylphosphino)palladium(II)chloride (4.6 g, 6 mmol) and hydrazinium hydroxide (0.3 ml, 6 mmol) are added and the mixture is stirred for 5 min at room temperature.1-Bromo-3-fluoro-4-iodobenzene 13 (100 g, 322 mmol), boronic acid ester 14 (81.3 g, 355 mmol) and 330 ml tetrahydrofuran are added and the mixture is heated to reflux overnight. After the usual workup crude 15 is obtained. Step 3.2
15 (126 mmol), bis(triphenylphosphino)palladium(II)chloride (8.4 g, 12 mmol), copper(I)iodide (2.5 g, 13.2 mmol) and diisopropylamine (84.1 ml, 0.6 mol) are combined with 600 ml tetrahydrofuran and warmed to 60°C. Pent-4-in-1-ol 16 (15.2 ml, 151 mmol) is dissolved in 170 ml tetrahydrofuran and is added dropwise within 15 min and the mixture is then heated to reflux overnight. After the usual workup 17 is obtained as a yellow solid.
Step 3.3
Crude 17 (31.9 g) is dissolved in 100 ml tetrahydrofuran and
hydrogenated (2.2 kPa H2, 1 h) over platinum on carbon (5 %). Step 3.4
Pyridinium chlorochromate (12.1 g, 56.2 mmol) and Celite (30 g) are suspended in 100 ml dichloromethane and 18 (47 mmol) dissolved in 60 ml dichloromethane is added dropwise between 20 and 30°C. After filtration and the usual workup 19 is obtained as a colorless oil.
Step 3.5
2-Trimethylsilyl-1,3-dithiane (6.7 ml, 35.4 mmol) is dissolved in 40 ml tetrahydrofuran and cooled to -70°C. Butyllithium in hexanes (23.4 ml of a 15 % solution, 37.2 mmol) is added dropwise and the mixture is warmed to -20°C and stirred for 4 hours. It is then cooled again to -70°C and 19 (37.2 mmol) dissolved in 40 ml dichloromethane is added dropwise. After warming to room temperature followed by the usual workup, 20 is obtained as a yellow oil.
Step 3.6
20 (17.2 mmol) is suspended in 200 ml dichloromethane, cooled to -15°C and trifluoromethane sulfonic acid (1.7 ml, 18.9 mmol) is added. The mixture is allowed to warm to room temperature, stirred for 30 min and then cooled to -70°C.4‘-Hydroxy-4-cyano-1,1‘-biphenyl 5 (3.8 g,
18.9 mmol), triethylamine (4.3 ml, 31 mmol) and 100 ml dichloromethane are added dropwise and the mixture is stirred for 1 hour at -70°C.
Triethylamine trishydrofluoride (13.9 ml, 86 mmol) is added dropwise and after 1 hour 4.4 ml (86 mmol) bromine in 100 ml dichloromethane. The mixture is stirred for 1 hour at -70°C. After warming to -20°C, morpholine (7.5 ml, 86 mmol) is added and stirring is continued for 1h at 0°C. After the usual workup 21 (N-PP-QI-5-GP-N) is obtained as a white powder.
( ) 1H NMR (500 MHz, Chloroform-d) δ 7.72 (dd, J = 8.5, 2.4 Hz), 7.65 (d, J = 8.3 Hz), 7.58– 7.52 (m), 7.34 (t, J = 8.0 Hz), 7.28 (d, J = 8.5 Hz), 7.11 – 6.99 (m), 2.70 (t, J = 7.6 Hz), 2.24– 2.12 (m), 1.72 (dtd, J = 12.3, 8.0, 5.9 Hz), 1.53– 1.46 (m).
A.4. BM-5, BM-6 and BM-7 In an analogue manner to the synthesis as described under 3. Synthesis of BM-4 (21), the following compounds BM-5, BM-6 and BM-7 are obtained:
C H3
B. Test cells and methods Typically a 3 ^m thick cell, having an anti-parallel rubbed PI alignment layer, is filled on a hotplate at a temperature at which the flexoelectric mixture in the isotropic phase. After the cell has been filled, the phase transitions including clearing point and the crystallization behavior are determined using Differential Scanning Calorimetry (DSC) and verified by optical inspection. For optical phase transition measurements, a Mettler FP90 hot-stage controller connected to a FP82 hot-stage is used to control the
temperature of the cell. The temperature is increased from ambient temperature at a rate of 5 degrees C per minute, until the onset of the isotropic phase is observed. The texture change is observed through crossed polarizers using an Olympus BX51 microscope and the respective temperature noted. Wires are then attached to the ITO electrodes of the cell using indium metal. The cell is secured in a Linkam THMS600 hot-stage connected to a Linkam TMS93 hot-stage controller. The hot-stage is secured to a rotation stage in an Olympus BX51 microscope. The cell is heated until the liquid crystal is completely isotropic. The cell is then cooled under an applied electric field until the sample is
completely nematic. The driving waveform is supplied by a Tektronix AFG3021B arbitrary function generator, which is sent through a
Newtons4th LPA400 power amplifier before being applied to the cell. The cell response is monitored with a Thorlabs PDA55 photodiode. Both input waveforms and optical response are measured using a Tektronix TDS 2024B digital oscilloscope. In order to measure the flexoelectric response of the material, the change in the size of the tilt of the optic axis is measured as a function of increasing voltage at a temperature of 35°C, unless stated explicitly otherwise. This is achieved by using the equation:
wherein φ is the tilt in the optic axis from the original position (i.e. when E = 0), E is the applied field, K is the elastic constant (average of K1 and K3) and e is the flexoelectric coefficient (where e = e1 + e3). The applied field is monitored using a HP 34401A multimeter. The tilt angle is measured using the aforementioned microscope and oscilloscope. The undisturbed cholesteric pitch, P0, is measured using an Ocean Optics USB4000 spectrometer attached to a computer. The selective reflection band is obtained and the pitch determined from the spectral data.
The media shown in the following examples are well suitable for use in ULH-displays. To that end, an appropriate concentration of the chiral dopant or dopants used has to be applied in order to achieve a typical cholesteric pitch of 350 to 275 nm. C. Mixture examples Host Mixture H-1 The following mixture H1 is prepared.
15 % w/w of the compound BM-1,
are added to 85 % w/w of host mixture H-1. The resulting mixture is homogenized and filled into a test cell as described above. Measurements with respect to the switching performance, the clearing point, the flexo elastic constant and the NTB transition temperature are performed and the results are summarized in the table under C.1.4. C.1.2 Mixture example M-2
15 % w/w of the compound BM-3,
are added to 85 % w/w of host mixture H-1. The resulting mixture is homogenized and filled into a test cell as described above. Measurements with respect to the switching performance, the clearing point, the flexo elastic constant and the NTB transition temperature are performed and the results are summarized in the table under C.1.4. C.1.3 Comparative Mixture Example CM-1 15 % w/w of the compound CM*-1,
are added to 85 % w/w of host mixture H-1. The resulting mixture is homogenized and filled into a test cell as described above. Measurements with respect to the switching
performance, the clearing point, the flexo elastic constant and the NTB transition temperature are performed and the results are summarized in the table under C.1.4 C.1.4 Summary
It is clear from the above given results of the measurement that the materials M-1 and M-2 show an advantage both in terms of phase range and also switching speeds when compared to the material CM-1. At the same time, the flexo elastic constant stays at an acceptable level. In addition, the NTB transition temperature can be favourably lowered by utilizing compounds according to the present invention. Furthermore, it is particularly surprising that the TNI of the mixture M-2 is significantly higher (+8.7°C) than the TNI of the mixture CM-1.
C.2.1 Mixture example M-3 15 % w/w of the compound BM-4,
are added to 85 % w/w of host mixture H-1. The resulting mixture is homogenized and filled into a test cell as described above. Measurements with respect to the switching performance, the clearing point, the flexo elastic constant and the NTB transition temperature are performed and the results are summarized in the table under C.2.3. C.2.2 Comparative Mixture Example CM-2 15 % w/w of the compound CM*-2,
are added to 85 % w/w of host mixture H-1. The resulting mixture is homogenized and filled into a test cell as described above. Measurements with respect to the switching performance, the clearing point, the flexo elastic constant and the NTB transition temperature are performed and he results are summarized in the table under C.2.3.
C.2.3 Summary
From the results of the measurement, it is clear that the material containing BM-4 in accordance with the present has a significant advantage with respect to the switching speed when compared to material comprising a compound of the prior art (CM*-2). The TNI is also similar, something that is surprising when considering conventional liquid crystal materials with differing switching speeds when normally a strong inverse relationship between TNI and switching speeds is observed (i.e. higher TNI leads to reduced switching speeds).
C.3.1 Mixture example M-4 15 % w/w of the compound BM-4,
are added to 85 % w/w of host mixture H-1. The resulting mixture is homogenized and filled into a test cell as described above. Measurements with respect to the switching performance, the clearing point, the flexo elastic constant and the NTB transition temperature are performed and the results are summarized in the table under C.3.3 C.3.2 Comparative Mixture Example CM-3 15 % w/w of the compound CM*-3,
are added to 85 % w/w of host mixture H-1. The resulting mixture is homogenized and filled into a test cell as described above.
Measurements with respect to the switching performance, the clearing point, the flexo elastic constant and the NTB transition temperature are performed and the results are summarized in the table under C.3.3
C.3.3 Summary
From the results of the measurement, it is clear that the material containing BM-6 in accordance with the present has a significant advantage with respect to the switching speed when compared to material comprising a compound of the prior art (CM*-3). The TNI is also similar, something that is surprising when considering conventional liquid crystal materials with differing switching speeds when normally a strong inverse relationship between TNI and switching speeds is observed (i.e. higher TNI leads to reduced switching speeds).
C.4.1 Mixture example M-5 15 % w/w of the compound BM-7,
are added to 85 % w/w of host mixture H-1. The resulting mixture is homogenized and filled into a test cell as described above.
Measurements with respect to the switching performance, the clearing point, the flexo elastic constant and the NTB transition temperature are performed and the results are summarized in the table under C.4.3 C.4.2 Comparative Mixture Example CM-4 15 % w/w of the compound CM*-4,
are added to 85 % w/w of host mixture H-1. The resulting mixture is homogenized and filled into a test cell as described above.
Measurements with respect to the switching performance, the clearing point, the flexo elastic constant and the NTB transition temperature are performed and the results are summarized in the table under C.4.3
C.4.3 Summary
From the results of the measurement, it is clear that the material containing BM-7 in accordance with the present has a significant advantage with respect to the switching speed and the TNI when compared to material comprising a compound of the prior art (CM*-4).
C.5.1 Comparative Mixture Example CM-5
The following comparative mixture example is prepared CM-5
The mixture is homogenized and filled into a test cell. Measurements with respect to the switching performance, the clearing point, the flexo elastic constant and the NTB transition temperature are performed . The results are summarized in the table under C.5.3. C.5.1 Mixture Example M-6
The following mixture example is prepared CM-6
The mixture is homogenized and filled into a test cell. Measurements with respect to the switching performance, the clearing point, the flexo elastic constant and the NTB transition temperature are performed. The results are summarized in the table under C.5.3
C.5.3 Summary
It can be clearly seen from the data in the table that the addition of the compound BM-7 results in over a 20 % improvement in the switching speed. This is a considerable advantage for ULH mixtures, especially for applications such as field sequential colour driving. Only a small reduction in TNI and e/K are observed due to the addition of BM-7, which means that the overall benefit to the performance is still significant.
Claims
Patent Claims 1. Compound of formula I, R11-MG11-X11-Sp11-X12-MG12-R12 I wherein
R11 and R22 are each independently H, F, Cl, CN, NCS or a straight-chain or branched alkyl group, which may be unsubstituted, mono- or polysubstituted by halogen or CN, it being also possible for one or more non-adjacent CH2 groups to be replaced, in each occurrence independently from one another, by -O-, -S-, -NH-, -N(CH3)-, -CO-, -COO-, -OCO-, -O-CO-O-, -S-CO-, -CO-S-, -CH=CH-, -CH=CF-, -CF=CF- or -C≡C- in such a manner that oxygen atoms are not linked directly to one another, MG11 and MG12 are each independently a mesogenic group, Sp11 is a spacer group comprising 1, 3 or 5 to 40 C
atoms, wherein one or more non-adjacent and non- terminal CH2 groups may also be replaced by -O-, -S-, -NH-, -N(CH3)-, -CO-, -O-CO-, -S-CO-,
-O-COO-, -CO-S-, -CO-O-, -CF2-, -CF2O-, -OCF2-, -C(OH)-, -CH(R11)-, -CH=CH- or -C ^C-, however in such a way that no two O-atoms are adjacent to one another and no two groups selected from -O-CO-, -S-CO-, -O-COO-, -CO-S-, -CO-O- and -CH=CH- are adjacent to each other, X11 and X12 denote -CF2-O-, -O-CF2- or a single bond, whereby at least one of X11 or X12 denotes -CF2-O-, or -O-CF2-.
2. Compound according to claim 1 characterized in that it is selected from the group of compounds of formulae Ia-1 or Ib-1 R11-MG11-OCF2-(CH2)n-CF2O-MG12-R12 Ia-1 R11-MG11-(CH2)n-CF2O-MG12-R12 Ib-1 wherein R11, R22, MG11, MG12 have one of the meanings as given above in claim 1 and n denotes 1, 3 or an integer from 5 to 15.
3. Method of production of compounds of formula Ia-1, comprising at least the ste of reactin one compound of the following formula,
with one or more compounds of formulae R11-MG11-OH or
R12-MG12-OH, wherein the parameters have one of the meanings as given above in claim 2.
4. Method of production of compounds of formula Ib-1, comprising at least the step of reacting one compound of the formula:
with at least one compound of formula R12-MG12-OH,
wherein the parameters have one of the meanings as given above in claim 2.
5. Use of the compounds of formula I in a liquid crystalline medium.
6. LC medium comprising one or more compounds of formula I.
7. LC medium according to claim 6, comprising one or more
compounds of formula II, R21-A21-A22-(CH2)a-A23-A24-R22 II wherein
R21 and R22 denote each and independently H, F, Cl, CN, NCS or a straight-chain or branched alkyl group, which may be unsubstituted, mono- or polysubstituted by halogen or CN, it being also possible for one or more non- adjacent CH2 groups to be replaced, in each
occurrence independently from one another, by -O-, -S-, -NH-, -N(CH3)-, -CO-, -COO-, -OCO-, -O-CO-O-, -S-CO-, -CO-S-, -CH=CH-, -CH=CF-, -CF=CF- or -C≡C- in such a manner that oxygen atoms are not linked directly to one another, A21 to A24 denote each and independently in each occurrence a aryl-, heteroaryl-, alicyclic- and heterocyclic group and a denotes an integer from 1 to 15.
8. LC medium according to claim 6 or 7, comprising one or more
compounds of formula III, R31-A31-A32-(A33)b-Z31-(CH2)c-Z32-A34-A35-A36-R32 III wherein
R31 and R32 have each and independently from another one of the meanings as given for R21 under formula II, A31 to A36 have each and independently from another one of the meanings as given for A21 under formula II,
Z31 and Z32 denote each and independently in each occurrence, -COO-, -OCO-, -O-CO-O-, -OCH2-, -CH2O-,
-CH2CH2-, -(CH2)4-, -CF2CF2-, -CH=CH-, -CF=CF-, -CH=CH-COO-, -OCO-CH=CH- or -C ^C-, optionally substituted with one or more of F, S and/or Si c denotes an integer from 1 to 15 and
a denotes 0 or 1.
9. LC medium according to one or more of claims 6 to 8, comprising one or more compounds of formula IV, R41-A41-A42-Z41-(CH2)d-Z42-A43-A44-R42 IV wherein
R41 and R42 have each and independently from another one of the meanings as given for R21 under formula II,
A41 to A44 have each and independently from another one of the meanings as given for A21 under formula II, Z41 and Z42 are each independently in each occurrence,
-COO-, -OCO-, -O-CO-O-, -OCH2-, -CH2O-,
-CH2CH2-, -(CH2)4-, -CF2CF2-, -CH=CH-, -CF=CF-, -CH=CH-COO-, -OCO-CH=CH- or -C ^C-, optionally substituted with one or more of F, S and/or Si, d denotes an integer from 1 to 15,
10. LC medium according to one or more of claims 6 to 9, comprising one or more compounds of formula V, R51-A51-Z51-(CH2)e-Z52-A52-(A53)f-R52 V
wherein
R51 and R52 have each and independently from another one of the meanings as given for R21 under formula II, A51 to A53 have each and independently from another one of the meanings as given for A21 under formula II, Z51 and Z52 are each independently in each occurrence,
-COO-, -OCO-, -O-CO-O-, -OCH2-, -CH2O-, -CH2CH2-, -(CH2)4-, -CF2CF2-, -CH=CH-, -CF=CF-, -CH=CH-COO-, -OCO-CH=CH- or -C ^C-, optionally substituted with one or more of F, S and/or Si, f denotes 0 or 1, e denotes an integer from 1 to 15,
11. LC medium according to one or more of claims 6 to 10, comprising one or more compounds of formula VI, R61-A61-A62-(CH2)g-Z61-A63-A64-(A65)h-R62 VI wherein
R61 and R62 have each and independently from another one of the meanings as given for R21 and R22 under formula II, A61 to A64 have each and independently one of the meanings as given above for A21 under formula II, Z61 denotes -O-, -COO-, -OCO-, -O-CO-O-, -OCH2-,
-CH2O, -CH2CH2-, -(CH2)4-, -CF2CF2-, -CH=CH-,
-CF=CF-, -CH=CH-COO-, -OCO-CH=CH- or -C ^C-, optionally substituted with one or more of F, S and/or Si, h denotes 0 or 1 and g denotes an integer from 1 to 15.
12. LC medium according to one or more of claims 6 to 11, comprising one or more compounds of formula VII, R71-A71-Z71-A72-(Z72-A73)j-(CH2)k-(A74-Z73-)l-A75-Z74-A76-R72 VII wherein
R71 and R72 have each and independently one of the meanings as given above for R21 under formula II, A71 to A76 have each and independently one of the meanings as given above for A21 under formula II, Z71 to Z74 each and independently denotes -COO-, -OCO-,
-O-CO-O-, -OCH2-, -CH2O-, -OCF2-, -CF2O-, -CH2CH2-, -(CH2)4-,-CF2CF2-, -CH=CH-, -CF=CF-, -CH=CH-COO-, -OCO-CH=CH- or -C ^C-, optionally substituted with one or more of F, S and/or Si or a single bond, with the proviso that at least one of Z71 to Z74 is not a single bond, j denotes an integer from 1 to 15 and i and k denotes 0 or 1.
13. LC medium according to one or more of claims 6 to 12, comprising one or more chiral dopants.
14. LC medium according to one or more of claims 6 to 13, comprising one or more nematic LC compounds selected compounds selected from compounds of formula X-1 to X-4,
R2A denotes H, an alkyl, alkenyl or alkoxy radical
having 1 to 15 C atoms, where, in addition, one or more CH2 groups in these radicals may each be replaced, independently of one another, by -C ^C-, -CF2O-, -CH=CH-, , , -O- , -CO-O- or -O-CO- in such a way that O atoms are not linked directly to one another and in which, in addition, one or more H atoms may be replaced by halogen, L1 and L2 each, independently of one another, denote F, Cl,
CF3 or CHF2, preferably each denote F, Z2 and Z2’ each, independently of one another, denote a sin- gle bond, -CH2CH2-, -CH=CH-, -C≡C-
, -CF2O-, -OCF2-, -CH2O-, -OCH2-, -COO-, -OCO-, -C2F4-, -CF=CF- or -CH=CHCH2O-, p denotes 0, 1 or 2, q denotes 0 or 1, (O)CvH2v+1 denotes OCvH2v+1 or CvH2v+1 and v denotes 1 to 6.
15. Method for the production of an LC medium according to one or more of claims 6 to 14, comprising the step of mixing one or more compounds of formula I, with at least one compound selected from compounds of formulae II to X.
16. Use of a LC medium according to one or more of claims 6 to 14, in electro optic devices.
17. Electro optical device comprising a medium according to one or more of claims 6 to 14.
18. Electro optical device according to claim 17, characterized in that it is a flexoelectric device.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE112017006197.0T DE112017006197T5 (en) | 2016-12-08 | 2017-12-05 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DEVICE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16203024 | 2016-12-08 | ||
EP16203024.1 | 2016-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018104279A1 true WO2018104279A1 (en) | 2018-06-14 |
Family
ID=57794025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2017/081471 WO2018104279A1 (en) | 2016-12-08 | 2017-12-05 | Liquid crystal medium and liquid crystal device |
Country Status (3)
Country | Link |
---|---|
DE (1) | DE112017006197T5 (en) |
TW (1) | TW201833307A (en) |
WO (1) | WO2018104279A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112442380A (en) * | 2019-09-04 | 2021-03-05 | 江苏集萃智能液晶科技有限公司 | Liquid crystal composition and light modulation device thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998000428A1 (en) | 1996-07-01 | 1998-01-08 | Merck Patent Gmbh | Chiral dopants |
GB2328207A (en) | 1997-08-13 | 1999-02-17 | Merck Patent Gmbh | Chiral hydrobenzoin derivatives for use as dopants in liquid crystalline mixtures |
EP0971016A1 (en) | 1998-07-08 | 2000-01-12 | MERCK PATENT GmbH | Mesogenic estradiols |
GB2356629A (en) | 1999-10-04 | 2001-05-30 | Merck Patent Gmbh | Bimesogenic compounds and their use in flexoelectric liquid crystal devices |
WO2006066688A1 (en) * | 2004-12-23 | 2006-06-29 | Merck Patent Gmbh | Bimesogenic compounds and flexoelectric devices |
WO2013004333A1 (en) | 2011-07-05 | 2013-01-10 | Merck Patent Gmbh | Bimesogenic compounds |
WO2013174478A1 (en) | 2012-05-25 | 2013-11-28 | Merck Patent Gmbh | Bimesogenic compounds and mesogenic media |
WO2014005672A1 (en) | 2012-07-06 | 2014-01-09 | Merck Patent Gmbh | Bimesogenic compounds and mesogenic media |
WO2015036079A1 (en) | 2013-09-12 | 2015-03-19 | Merck Patent Gmbh | Mesogenic compounds and mesogenic media |
WO2016096112A1 (en) * | 2014-12-19 | 2016-06-23 | Merck Patent Gmbh | Bimesogenic compounds and mesogenic media |
-
2017
- 2017-12-05 WO PCT/EP2017/081471 patent/WO2018104279A1/en active Application Filing
- 2017-12-05 DE DE112017006197.0T patent/DE112017006197T5/en active Pending
- 2017-12-07 TW TW106142837A patent/TW201833307A/en unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998000428A1 (en) | 1996-07-01 | 1998-01-08 | Merck Patent Gmbh | Chiral dopants |
GB2328207A (en) | 1997-08-13 | 1999-02-17 | Merck Patent Gmbh | Chiral hydrobenzoin derivatives for use as dopants in liquid crystalline mixtures |
EP0971016A1 (en) | 1998-07-08 | 2000-01-12 | MERCK PATENT GmbH | Mesogenic estradiols |
GB2356629A (en) | 1999-10-04 | 2001-05-30 | Merck Patent Gmbh | Bimesogenic compounds and their use in flexoelectric liquid crystal devices |
WO2006066688A1 (en) * | 2004-12-23 | 2006-06-29 | Merck Patent Gmbh | Bimesogenic compounds and flexoelectric devices |
WO2013004333A1 (en) | 2011-07-05 | 2013-01-10 | Merck Patent Gmbh | Bimesogenic compounds |
WO2013174478A1 (en) | 2012-05-25 | 2013-11-28 | Merck Patent Gmbh | Bimesogenic compounds and mesogenic media |
WO2014005672A1 (en) | 2012-07-06 | 2014-01-09 | Merck Patent Gmbh | Bimesogenic compounds and mesogenic media |
WO2015036079A1 (en) | 2013-09-12 | 2015-03-19 | Merck Patent Gmbh | Mesogenic compounds and mesogenic media |
WO2016096112A1 (en) * | 2014-12-19 | 2016-06-23 | Merck Patent Gmbh | Bimesogenic compounds and mesogenic media |
Non-Patent Citations (5)
Title |
---|
C. TSCHIERSKE; G. PELZL; S. DIELE, ANGEW. CHEM., vol. 116, 2004, pages 6340 - 6368 |
CHANDRASEKHAR: "Liquid Crystals", 1992, CAMBRIDGE UNIVERSITY PRESS |
COLES, H.J.; MUSGRAVE, B.; COLES, M.J.; WILLMOTT, J., J. MATER. CHEM., vol. 11, 2001, pages 2709 - 2716 |
P. RUDQUIST ET AL., LIQ. CRYST., vol. 23, no. 4, 1997, pages 503 |
P.G. DEGENNES ET AL.: "The Physics of Liquid Crystals", 1995, OXFORD SCIENCE PUBLICATIONS |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112442380A (en) * | 2019-09-04 | 2021-03-05 | 江苏集萃智能液晶科技有限公司 | Liquid crystal composition and light modulation device thereof |
US11932799B2 (en) | 2019-09-04 | 2024-03-19 | Smart Liquid Crystal Technologies Co., Ltd. | Liquid crystal mixture and light modulating device |
Also Published As
Publication number | Publication date |
---|---|
TW201833307A (en) | 2018-09-16 |
DE112017006197T5 (en) | 2019-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3218446B1 (en) | Bimesogenic compounds and mesogenic media | |
WO2014005672A1 (en) | Bimesogenic compounds and mesogenic media | |
EP2870219A1 (en) | Bimesogenic compounds and mesogenic media | |
EP2870218A1 (en) | Bimesogenic compounds and mesogenic media | |
WO2014032772A1 (en) | Bimesogenic compounds and mesogenic media | |
WO2015036079A1 (en) | Mesogenic compounds and mesogenic media | |
WO2014090372A1 (en) | Bimesogenic compounds and mesogenic media | |
EP3234064B1 (en) | Bimesogenic compounds and mesogenic media | |
EP3169749B1 (en) | Bimesogenic compounds and mesogenic media | |
WO2015096879A1 (en) | Bimesogenic compounds and mesogenic media | |
WO2019121368A1 (en) | Liquid crystal medium and liquid crystal device | |
EP3049506A1 (en) | Compounds and mesogenic media | |
WO2018104279A1 (en) | Liquid crystal medium and liquid crystal device | |
CN110997870B (en) | Liquid crystal medium and liquid crystal device | |
EP3071668B1 (en) | Bimesogenic compounds and mesogenic media | |
WO2019030150A1 (en) | Liquid crystal medium and liquid crystal device | |
WO2019081561A1 (en) | Liquid crystal medium and liquid crystal device | |
EP3512920B1 (en) | Liquid crystal medium and liquid crystal device | |
WO2019081389A1 (en) | Liquid crystal medium and liquid crystal device | |
WO2019121438A1 (en) | Liquid crystal compound and liquid crystal medium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17808918 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17808918 Country of ref document: EP Kind code of ref document: A1 |